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Patients initiating highly emetic chemotherapy are at a 90% risk of chemotherapy-induced nausea 
and vomiting (CINV).  Antiemetic drugs are highly effective in preventing CINV and thus improve 
quality of life and generate cost savings by reducing the need for CINV-related health services. Despite 
guideline-concordant antiemetic prescribing preventing CINV in up to 80% of patients, evidence suggests 
that use of ASCO and NCCN guideline-concordant antiemetic regimens by patients initiating highly 
emetogenic chemotherapy is low.  Furthermore, of the multiple CINV preventative treatment regimens 
that are considered guideline concordant, there is no clear clinical preference and costs vary widely. The 
purposes of this dissertation were to characterize antiemetic use; identify predictors of antiemetic under-
use; and evaluate the trade-offs in cost, clinical, and quality of life outcomes across the guideline-
concordant recommendations in patients initiating intravenous highly emetogenic chemotherapy. Aim 1 
used descriptive statistics to describe antiemetic prescribing patterns, including antiemetic under-use, in 
patients with cancer initiating highly emetic chemotherapy using the IBM Watson’s/Truven’s MarketScan 
Commercial Claims and Encounters (CCAE) and Medicare Supplemental and Coordination of Benefits 
data.  Aim 2 used a modified Poisson regression to identify factors associated with antiemetic under-use 
(i.e., environmental, predisposing, enabling, and need) in these same data.  Aim 3 assessed the health and 
economic impacts of guideline-concordant antiemetic strategies through a cost-utility analysis in order to 
prioritize them.  Alarmingly, under-use of guideline-concordant antiemetic fills is high, at 49% and 68% 
in the commercial claims and Medicare supplement populations, respectively (Aim 1).  While more than 
75% of patients are filling 5HT3As and dexamethasone, NK1 product fills were low and olanzapine fills 
were negligible.   Site of chemotherapy setting was among the greatest predictors of antiemetic use, with 
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patients receiving chemotherapy in an outpatient hospital setting at a 1.28 (p<0.0001) and 1.48 
(p<0.0001) times higher risk of under-use compared to outpatient physician setting in the CCAE and 
Medicare Supplement populations, respectively (Aim 2).  Medical benefit generosity and prescription 
drug generosity has limited impact on under-use in both populations.   Olanzapine + fosaprepitant + 
5HT3A + dexamethasone dominates all other strategies; however, after excluding olanzapine-based 
strategies fosaprepitant + 5HT3A + dexamethasone was the most efficient strategy (Aim 3). Given the 
limited incremental benefits across strategies, treatment acquisition costs should be considered when 
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CHAPTER 1: INTRODUCTION 
1.1 Background 
Cancer is among the leading causes of mortality in the US, with incidence rates increasing in 
certain cancer types.(5) Managing cancer is challenging given the need to balance high costs and varied 
patient preferences regarding quality of life (e.g., side-effects) with survival. Furthermore, cancer 
treatment is highly heterogeneous even within cancer type. Chemotherapy is one type of cancer treatment 
that uses chemical anti-cancer drugs systemically. While chemotherapy can be life-saving and life-
prolonging, certain types include the risk of significant side-effects including severe nausea and vomiting.  
Uncontrolled, severe chemotherapy-induced nausea and vomiting (CINV) is among the most 
feared treatment side effects by patients and reduces patient quality of life.(6) CINV can occur in the 
acute (i.e., within 24 hours / day 1) or delayed (i.e., 24-120 hours / days 2-5) phases after chemotherapy 
administration.(1) Patients with breakthrough CINV are those that experience it despite receiving 
appropriate prophylactic antiemetics. Additionally, patients who experience CINV in anticipation of 
future chemotherapy cycles are defined as anticipatory, while those who experience CINV following 
future chemotherapy treatments are classified as refractory.(7) Figure 1.1 depicts CINV types.  




CINV leads to significant clinical issues including, but not limited to dehydration, fatigue, and 
slow wound healing, as well as utilizing significant healthcare resources, including additional hospital and 
physician visits.(3) Preventing CINV has been shown to reduce downstream costs and improve quality of 
life. Estimates on average CINV-related monthly costs range from $1,280 to $5,386.(8-10) CINV may 
also prevent patients from adhering to chemotherapy treatments.(1, 4, 11-13) In addition to patient 
history, evidence has overwhelmingly demonstrated that the type of chemotherapy initiated is the best 
predictor of CINV risk.(14)   
Antiemetic drugs are a highly effective prophylaxis to prevent CINV and the evidence base to 
support these products’ ability to prevent and reduce CINV, improve quality of life, and generate cost 
savings is robust. (1-4) Conventional antiemetic drugs used to prevent acute and delayed CINV, in order 
of least to most potent, are glucocorticoids (i.e., dexamethasone), 5-HT3 receptor antagonists (5HT3A) 
(e.g., ondansetron), and NK1 receptor antagonists (e.g., aprepitant and fosaprepitant).(15) Notably, these 
conventional antiemetics used to prevent CINV are generally not effective in treating CINV.(7, 16, 17) As 
such, non-traditional antiemetics may be used as rescue therapies to treat CINV in patients who failed 
conventional prophylactic therapy and experienced breakthrough CINV, as well as those experiencing 
anticipatory, or refractory CINV.(18-20) Specifically, non-traditional antiemetics for CINV-treatment 
include: antipsychotics (i.e., olanzapine), benzodiazepines (e.g., lorazepam), cannabinoids (e.g., 
nabilone), and phenothiazines (e.g., prochlorperazine), among others (e.g., haloperidol, metoclopramide, 
and scopolamine). (While they lack a strong evidence base, 5HT3As and corticosteroids are also used to 
treat breakthrough therapy.)  Leveraging rigorous evidence reviews, US-based guidelines developed by 
the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network 
(NCCN) offer recommendations on the appropriate use of antiemetic drugs to prevent acute and delayed 
CINV based on the classification of the likelihood of emesis of the chemotherapy regimen (i.e., 
emetogenicity), which include high, moderate, low, and minimal (Table 1.1).(15, 18-21) This 
dissertation focuses on patients with cancer who are newly initiating highly emetogenic chemotherapy, 
who are at a 90% risk of having a CINV event. For this population, both ASCO and NCCN guidelines 
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recommend that patients receive a triple therapy combination of an NK1, 5HT3A, and glucocorticoids for 
CINV prevention. Additionally, more recently, NCCN and ASCO guidelines recommend the use of 
olanzapine for CINV prevention, though they differ in the recommended olanzapine strategies (Table 
1.1). Notably, there are many prophylactic treatment regimens that are considered guideline-concordant 
for patients initiating highly emetogenic chemotherapy with varying costs, and there is no preferred 
option. Recommendations on treating breakthrough CINV are sparse given the limited evidence on 
treating CINV, but those that exist center on adding a product that is from a different drug class than the 
current treatment.  
Table 1.1 2017 ASCO and 2017 NCCN Prophylactic Antiemesis Guideline Recommendations in 
Patients Initiating Highly Emetogenic Chemotherapy Intravenously*(18, 20) 
 ASCO NCCN 
Day 1 
(Acute) 
• NK1, 5-HT3A, and corticosteroid 
• NEPA and corticosteroid 
• Olanzapine+aprepitant+5HT3A+ 
corticosteroid** 
• NK1, 5-HT3A, and corticosteroid 
• NEPA and corticosteroid 






• Aprepitant on days 2-3 
(if aprepitant on day 1) 
• Corticosteroid days 2-4 
• Olanzapine days 2-4 
(if olanzapine on day 1) 
• Aprepitant on days 2-3  
(if aprepitant on day 1) 
• Corticosteroid days 2-4 
• Olanzapine days 2-4  
(if olanzapine on day 1) 
*Corticosteroid: Dexamethasone; 5-HT3A: Granisetron, Ondansetron, Palonosetron, Dolasetron; NK1s: Aprepitant, 
Fosaprepitant, Rolapitant  
**This strategy is only recommended in NCCN guidelines 
***2017 NCCN and ASCO guidelines newly recommend olanzapine + aprepitant + 5HT3A + dexamethasone 
 
The purposes of this dissertation were to characterize antiemetic use; identify predictors of antiemetic 
under-use; and evaluate the trade-offs in cost, clinical, and quality of life outcomes across the guideline-
concordant recommendations in patients who initiate highly emetogenic chemotherapy.  
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1.2 Specific Aims 
1.2.1 Aim 1: To characterize antiemetic use (including types and regimens) in patients who were 
diagnosed with cancer and newly initiated highly emetogenic, intravenous chemotherapy for the 
first time from 2013-2015. 
Evidence demonstrates that antiemetic drugs are highly effective in preventing CINV, and thus 
improve quality of life, and generate cost savings. (1-4) However, use of antiemetics in the real world is 
suboptimal. (22, 23) In general, patients receive at least one type of antiemetic in the acute phase, but 
receipt of an antiemetic in the delayed phase is much lower. Understanding patterns of antiemetic 
prescribing in the United States (US) is important given the number of options that are considered 
guideline-concordant in patients initiating highly emetogenic chemotherapy. Of particular interest is the 
uptake of the highly promising and less expensive product, olanzapine, which is currently unknown.(1, 7, 
24-29) Notably, patterns of antiemetic prescribing among patients initiating highly emetogenic 
chemotherapy has not been well studied in the United States, especially in recent history or in a large, 
nationally representative study.(22, 23, 30-37) Studies that have examined prophylactic antiemetic 
prescribing were not only in different healthcare systems than the US, but also in countries where 
antiemetic product availability is dissimilar. There is also much within-country heterogeneity in 
prescribing patterns, highlighting the inability to generalize one country’s study findings to another.  
The rate of guideline-discordant CINV-related antiemetic prescribing is high in patients initiating 
highly emetogenic chemotherapy, especially in the delayed phase.(22, 38-44) The primary reason for 
guideline-discordance for patients initiating highly emetogenic chemotherapy is under-prescribing, which 
is defined as prescribing a product that is less potent (including lower doses) than recommended or 
excluding drugs that should be included. Under-prescribing of antiemetic drugs leads to the occurrence of 
preventable CINV-related events, their associated resource use and costs as well as reductions in quality 
of life.(4) The most common occurrence of under-prescribing in this population is not receiving an 
NK1.(45) In fact, a prior study found that only 40% of white women and 30% of black women in the 
Medicare population initiating highly emetogenic anthracycline and cyclophosphamide received 
NK1s.(45, 46). Over-prescribing is defined as prescribing: 1) a more potent drug or 2) more complex drug 
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regimens than recommended. In general, over-prescribing of antiemetics is an important issue to address, 
as those drugs that are intended to treat high-risk CINV are more expensive than low-risk CINV 
drugs.(47) However, for highly emetogenic products, over-prescribing centers on using NK1s or 5HT3As 
beyond the days recommended (if the patient is not experiencing symptoms). While three US-based 
guideline concordance studies were identified, there are several gaps in the literature that this dissertation 
will fill.(22, 38, 45) Two of the three prior studies focused on discordant prescribing in general. 
Additionally, these studies had limited generalizability given that one was a small southeast practice with 
an EMR-based automated prescription system and the other used two large claims data sets, but only 
focused on breast cancer. The third study assessed over-prescribing in a large claims data set, but under-
prescribing was not assessed.(38) 
The primary purpose of Aim 1 is to describe what types of antiemetic regimens are being used 
and to assess the proportion of antiemetic use in patients with cancer who are initiating highly 
emetogenic, intravenous chemotherapy. These results will help payers and providers identify 
opportunities to increase appropriate antiemetic uptake. While there is value in examining both under-use 
and over-use in patients initiating highly emetogenic chemotherapy because of their different implications 
on the healthcare system (disparity versus cost), this dissertation focuses on under-use because the narrow 
definition of over-prescribing presents outcomes measurement challenges.(22, 45) Our study population 
includes patients who were newly initiating single-day highly emetogenic intravenous chemotherapy for 
cancer, who were not pregnant, and who did not have comorbid schizophrenia or bipolar disorder. Data 
for Aim 1 came from IBM Watson’s/Truven’s MarketScan Commercial Claims and Encounters (CCAE) 
and Medicare Supplemental and Coordination of Benefits (MCOB) database from 2013-2015. The 
MarketScan CCAE database is composed of a nationally representative sample of people with employer-
sponsored insurance in the US consisting of over 200,000 new initiators of chemotherapy in this time 
period. The MarketScan Medicare Supplement database represents Medicare patients who purchase 
employer-paid supplemental insurance and are retired. Medicare serves as the primary source of insurance 
for those who are retired.(48)  
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Descriptive statistics will be used to assess patterns of antiemetic drug use as well as guideline-
concordance. Patterns that will be examined include types of antiemetics filled (i.e., product and class), 
number of antiemetic products filled, as well as regimens filled and their associated costs. To assess 
guideline concordance, the most recent antiemetic guidelines in 2015 were used given the time frame of 
interest. Antiemetics were identified using HCPCS codes for intravenously administered products and 
NDC codes for oral products. Analyses were run on the commercially insured and Medicare Supplement 
populations separately. 
1.2.2 Aim 2: To identify predictors of antiemetic under-use in patients diagnosed with cancer and 
newly initiating highly emetogenic, intravenous chemotherapy. 
 
In the US, the increased attention on value-based care, including advanced payment models and 
outcomes-based contracting are incentivizing stakeholders to emphasize high quality, value-based care, 
which includes guideline adherence.(49) Importantly, guideline adherence can lead to improved patient 
experiences and outcomes and reduce costs. (50, 51) As such, identifying factors that influence antiemetic 
discordance will help address gaps in antiemetic prescribing and promote high-quality and high-value 
care. While prior studies have examined predictors of concordance and discordance, many are in non-US 
healthcare systems or are limited in scope, highlighting the need to study predictors in the US system.(22, 
38, 45) Again, it is crucial to consider these predictors in the context of the healthcare delivery system in 
which they were assessed given the differences across systems.  
The purpose of Aim 2 is to identify predictors of antiemetic under-use as opposed to guideline-
concordant use in patients with cancer who are initiating highly emetogenic, intravenous chemotherapy. 
We focus on under-use in patients initiating highly emetogenic chemotherapy, because for these patients, 
the definition of over-use is limited to using more pills than recommended or more products (e.g., 
multiple NK1s) than necessary, as opposed to more potent products than recommended.  Additionally, 
under-use for this population presents a greater opportunity to improve patient outcomes for this 
population. Data for Aim 2 came from the MarketScan Commercial Claims and Encounters (CCAE) and 
Medicare Supplement database from 2013-2015. Categorization of patients as guideline-concordant or 
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under-use were based on the results of Aim 1. Potential predictors were identified based on Andersen’s 
Behavioral Model of Health Service Use and the availability of variables in the data set (Figure 1.2). 
Environmental factors (e.g., chemotherapy setting, urban/rural, and region), predisposing characteristics 
(e.g., gender and age), enabling resources (e.g., health insurance type, insurance generosity, in/out 
network chemotherapy administration, year of chemotherapy administration, and quarter of chemotherapy 
administration), and need factors (e.g., chemotherapy regimen, number of comorbid conditions, number 
concomitant medications, prior antiemetic use, prior chemotherapy (oral or IV), and prior radiation 
therapy) were assessed. Given the dichotomous nature of the outcome variable, a modified Poisson 
regression directly estimating the effect of covariates in terms of relative risks (while controlling for the 
influence of other factors in the model) was used. Predictors were assessed separately in the Commercial 
Claims and Medicare supplement data sets. 
Figure 1.2 Adapted Andersen’s Behavioral Model of Health Services Use to Examine Patterns of 




1.2.3 Aim 3: To assess the most cost-effective antiemetic regimen for patients diagnosed with cancer 
and newly initiating highly emetogenic, intravenous chemotherapy. 
 
In a value-driven environment, it is important to understand the trade-offs between the upfront 
costs of prophylactic antiemetic use compared to the occurrence of CINV events and the associated 
increases in healthcare resource use and costs as well as decreases in quality of life. There are many 
prophylactic treatment regimens that are considered guideline-concordant for patients initiating highly 
emetogenic chemotherapy, and there is no preferred option. Given the wide range of costs for these 
regimens, assessing cost-effectiveness across all of the regimens is one way to prioritize products, which 
has yet to be done. Notably, the 2016 ASCO guidelines (e-published in 2015) specifically highlight the 
need to evaluate the value of NEPA given its high costs and potential out-of-pocket patient costs as it is 
an oral product.(52) To date there have been two cost-effectiveness studies that examined the cost-
effectiveness of NEPA in patients initiating highly emetogenic chemotherapy from the United Kingdom 
and Italian payer perspectives.(53) Additionally, in five other studies comparing aprepitant-based 
regimens to 5HT3A regimens in patients initiating highly emetogenic chemotherapy, aprepitant was 
found to be either cost-effective at a $50,000/QALY or a dominated standard of care.(54-58) No studies 
have compared olanzapine in any setting or across all NK1s from a US commercial payer or societal 
perspective using cost effectiveness. 
The purpose of Aim 3 is to assess the health and economic impacts of guideline-concordant 
antiemetic regimens in patients initiating highly emetic, intravenous chemotherapy using a cost-utility 
analysis. The primary outcomes are cost (2016 USD), quality-adjusted life days (QALDs) and quality-
adjusted life years (QALYs). Regimens were ranked by cost and assessed for efficiency or dominance. 
Guideline recommendations include: (1) NK1 (aprepitant, fosaprepitant and rolapitant), 5HT3A (first 
generation: ondansetron, granisetron, and dolasetron and second generation: palonosetron), and a 
corticosteroid (dexamethasone); (2) Netupitant / palonosetron combination + dexamethasone; (3) 
Olanzapine + palonosetron + dexamethasone; (4) Olanzapine + aprepitant/fosaprepitant + 5HT3A + 
dexamethasone; and (5) Aprepitant/Fosaprepitant + 5HT3A + dexamethasone. These results will help 
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decision-makers prioritize and optimize antiemetic use in clinical practice. Based on the literature, the 
effectiveness of 5HT3As was assumed to be similar in the presence of NK1-based strategies, so only the 
NK1s were varied when the NK1 was not specified.(20, 56, 59) 
Aim 3 used a Markov model with both one-way and probabilistic sensitivity analyses to estimate 
the incremental costs and quality-adjusted life years from the perspectives of the US healthcare system 
and society. The time horizon was five days, including the acute phase (day 1) and delayed phase (days 2-
5), which aligns with clinical trials. Patients may have experienced incomplete response, complete 
response, or complete protection in both the acute and delayed phases. The hypothetical cohorts consisted 
of 100,000 adults aged 18-65 with cancer, being newly treated with single-day, highly emetogenic, 
intravenous chemotherapy. As the guidelines of interest are applicable to patients newly initiating highly 
emetogenic chemotherapy, the model encompassed a single chemotherapy cycle. Clinical inputs were 
based on randomized controlled trial evidence. Quality of life and cost inputs were based on a literature 
review. Costs were adjusted to US 2016 dollars using the medical component of the Consumer Price 
Index. Given the short time frame, cost and quality-of-life outcomes were not discounted. 
1.3 Significance  
The US healthcare system is under tremendous pressure to reduce costs. This has spurred the 
development of oncology pathways and guidelines that use rigorous evidence evaluation to create 
treatment algorithms that exploit value and encourage appropriate use. Additionally, the growing focus on 
patient engagement and value-based care will require consideration beyond treating disease to balancing 
patient preferences regarding quality of life (e.g., side-effects) with high costs. Preventing CINV events 
through guideline-concordant prescribing not only offers the US healthcare system and payers cost-
effective care, but also offers improved quality of life for patients.  
 This dissertation will contribute to understanding and optimizing antiemetic use in patients 
initiating highly emetogenic chemotherapy. Specifically, the results from Aim 1 characterize current 
patterns of antiemetic use in the US and assess guideline concordance. From Aim 2, predictors of 
antiemetic under-use are identified to develop targeted interventions to improve guideline concordance. 
 
10 
Finally, the results from Aim 3, which incorporate measures of patient quality-of-life, considering the 
trade-offs between cost and effectiveness of antiemetic treatment strategies, will help optimize antiemetic 
use to prevent CINV in this patient population. 
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CHAPTER 2: LITERATURE REVIEW 
Chapter 2 is presented in five sections and intended to contextualize the three aims of this 
dissertation. The first section (2.1) provides an overview on CINV including its incidence and associated 
clinical, economic, and quality of life outcomes. It also details CINV prevention and treatment options, 
and the evidence generated on these products to date. The second section (2.2) establishes what is known 
on antiemetic prescribing to date and its impact on clinical and healthcare resource use outcomes to 
support Aims 1 and 2. This third section (2.3) reviews cost-effectiveness (including cost-utility) studies 
conducted to date to help design and evaluate Aim 3. The fourth section (2.4) details the conceptual 
model that motivates this dissertation. The final section (2.5) concludes the literature review by 
summarizing key points. 
2.1 Overview Of Chemotherapy Induced Nausea And Vomiting 
Cancer is among the leading causes of mortality in the US, with cancer incidence rates increasing 
in certain cancer types.(5) In 2016, the National Cancer Institute anticipates over one 1.6 million new 
cancer diagnoses. Cancer is a particularly challenging disease area to manage given the need to balance 
high costs, varied patient preferences regarding quality of life (e.g., side-effects), and survival. In addition 
to being expensive, estimated at $125B in 2010 and projected to increase up to 40% by 2020, cancer 
treatment is highly heterogeneous even within cancer type.(60, 61) While chemotherapy can be life-
saving and life-prolonging, certain types include the risk of significant side-effects including severe 
nausea and vomiting, which are among the most feared by patients.(15) This section provides an 




2.1.1 Chemotherapy Induced Nausea and Vomiting: Definition 
Nausea is “characterized by a queasy sensation and /or the urge to vomit” and vomiting is 
“characterized by the reflexive act of ejecting the contents of the stomach through the mouth.”(62) The 
five types of CINV, detailed in Table 2.1, are classified by the following two factors: 1) when it occurs 
relative to initiating chemotherapy and 2) prior prophylactic experience.(1, 7, 63-66) Acute and delayed 
CINV refer to CINV events that occur within 0-24 and 25-120 hours of chemotherapy initiation. 
Breakthrough CINV is the occurrence of CINV-events despite appropriate prophylactic treatment. 
Anticipatory and refractory CINV apply to patients who have CINV events during prior chemotherapy 
cycles, and experience it either as a conditioned response prior to, or reoccurrence in, future cycles. 
Table 2.1 Types of CINV (Adapted from Navari 2016) (1, 7, 63-66) 
CINV Definition 
Acute Occurring within the first 24 hours (1 day) after initiation of chemotherapy 
Delayed Occurring days 2-5 after chemotherapy 
Breakthrough Occurring despite appropriate prophylactic treatment 
Anticipatory 
Occurring before a chemotherapy treatment as a conditioned response to the 
occurrence of CINV in previous cycles 
Refractory Recurring in subsequent cycles of therapy (excluding anticipatory) 
 
CINV can also lead to serious metabolic derangements, nutritional depletion and anorexia, deterioration 
of patients’ physical and mental status, esophageal tears, fractures, wound dehiscence, anti-cancer 
treatment discontinuation, and degeneration of self-care and functional ability.(17) 
2.1.1.1 Quality of Life 
CINV not only has significant clinical impacts, but also significantly reduces patients’ quality of 
life.(3, 11, 67, 68) This includes, but is not limited to daily functioning (affects 40% of patients and up to 
90% when CINV is poorly managed), leisure activities, and ability to eat and drink and thus impacting 
nutritional status.(3, 10, 69, 70) Quality of life is significantly worse in patients initiating highly 
emetogenic chemotherapy than those on moderately emetogenic chemotherapy.(3, 71)  Moreover, nausea 
influences quality of life more than vomiting.(6, 71, 72) CINV may also prevent patients from adhering to 
chemotherapy treatments.(1, 4, 11-13)  
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2.1.2 CINV Healthcare Resource Use and Cost 
Studies have consistently demonstrated that direct costs are higher in patients with uncontrolled 
CINV versus those who do not experience CINV.(2, 8-10, 58, 72) Additionally, indirect costs are higher 
not only in patients with uncontrolled CINV, but also patients experiencing more severe CINV.(8, 10) 
The following section will focus on the US-based CINV related cost studies.  
A retrospective cohort study by Burke et al, 2010 using the Premier Perspective TM Database, 
which includes hospital service data (2003-2007) from 600 hospitals in the United States, found that 
18.0% of highly emetogenic chemotherapy users experienced any CINV-related event.(9) These patients 
were prescribed one or more drugs commonly used for antiemetic prophylaxis, with 95.3% of highly 
emetogenic users being prescribed a 5HT3A. About 5% of patients were prescribed an NK1. Results 
based on antiemetic use were not provided. Visits for delayed CINV were more likely than acute CINV 
across patients (13.7% vs. 0.2%). The average cost of any CINV event in the highly emetogenic group 
was $5,386 (SD $6,425) in the 30 days following first chemotherapy initiation or 1 day before the next 
chemotherapy administration. Inpatient visits were most common and expensive ($7,678/patient (SD 
$6,875), followed by outpatient hospital ($1,461/patient (SD $2,551), and emergency room 
($1,007/patient (SD $1,453)). The authors conducted several sensitivity analyses to account for the fact 
that some of the costs being attributed to CINV may be due to other conditions, and found the average 
CINV costs to be much lower. Of note, in one sensitivity analysis where the study window was limited to 
the 6 days following chemotherapy administration, the average cost of a CINV event was $218 (SD 
1,393) across all patients translating to $1,210 among those experiencing CINV. (All costs were 
unadjusted and based on what was reported in the database) 
In another retrospective database study by Shih et al, using data from the Medstat MarketScan 
Health and Productivity management database (1997-2002), representing US large employers, nearly 
30% of patients initiating moderate or highly emetogenic chemotherapy experienced uncontrolled CINV 
despite over 85% of patients using a 5HT3A.(8) It was estimated that the direct medical costs in the 
uncontrolled CINV group was $1,383 higher than the controlled group. After adjusting for 
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sociodemographic, comorbidity, cancer type, metastasis, region, and year, the estimated adjusted direct 
cost of an uncontrolled CINV event was $1,280 per patient per month and $433 per patient per month for 
indirect costs over 6 months. These cost estimates are much lower than those estimated by Burke et al, 
2011 and may be the result of covariate adjustments as well as the inclusion of primary and secondary 
diagnoses of CINV according to Shih et al.(8, 9) However, even by limiting CINV event to primary 
diagnosis, Burke et. al’s average CINV cost was $4,043, despite the CINV incidence rate being less than 
Shih et. al’s and a shorter follow-up period. Additionally, on average, the cost associated with missed 
work and reduced productivity were $31.57 and $14.82, respectively. Notably, the costs increase to 
$112.40 and $67.70 for missed work and reduced productivity among those that were currently 
employed.(8) 
In 2011, Craver et al. used the same data source as the Burke study, but between 2007-2009, and 
studied CINV events across all types of CINV-risk chemotherapy initiators.(2) In this study, 
approximately 75% of patient received antiemetic prophylaxis, and the risk of CINV was 20%. 
Importantly, both studies likely underestimate CINV costs, as non-hospital rescue medications were not 
captured. Unlike Shih et al, outpatient visits were not only the most common type of hospital encounter, 
but also the least costly.(8) The average direct CINV costs were $1855 (inpatient: $2422/day, outpatient: 
$1365/day, emergency room: $1987/day). (2) (All costs were unadjusted and based on what was reported 
in the database) 
Haiderali et. al’s assessed CINV-related events in a small (N=178), prospective, multi-site 
observational study. CINV events were based on self-reporting by adult patients initiating moderately or 
highly emetogenic chemotherapy and their physicians, and costs were calculated using the Centers for 
Medicare & Medicaid Services Hospital Outpatient Perspective Payment System.(10) While most patients 
report receiving some type of antiemetic prophylaxis, 66% of patients experienced a CINV-related event 
with an average direct cost of $732.14/person (SD $734.00). After including indirect medical costs (i.e. 
missed work and productivity), the costs increase to $778.53/person (SD $782.61). For patients using 
highly emetogenic chemotherapy, the average costs were higher with direct costs of $836.70/person (SD 
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$836.00), direct + medical cost of $898.36/person (SD $898.36), and direct medical + missed work + 
productivity loss of $905.31/person (SD $863.25). 
2.1.3 CINV Risk Factors 
CINV-risk is classified as highly, moderately, low, or minimally emetogenic (Table 2.2). (63, 73)   
Notably most oral and targeted anticancer therapies have minimal and low CINV risk, and are not 
included in this analysis.(18, 20) Evidence has overwhelmingly demonstrated that the type of 
chemotherapy initiated is the best determinant of CINV-risk.(14) The types of chemotherapy associated 
with high CINV risk are detailed in Table 2.3.(18, 20)   
Table 2.2 Categories of CINV Risk(63, 73)    






Table 2.3 Types of Intravenous Chemotherapy with High Risk of CINV in 2017(18, 20) 
Chemotherapy and Targeted Therapy 
• AC combination defined as any chemotherapy 
regimen that contains anthracycline and 
cyclophosphamide 
• Carboplatin ≥ 4** 
• Carmustine ≥ 250 mg/m2 
• Cisplatin 
• Cyclophosphamide >1,500 mg/m2 
• Dacarbazine 
• Dactinomycin* 
• Doxorubicin ≥ 60mg/ m2** 
• Epirubicin ≥ 90 mg/m2** 
• Ifosfamide ≥ 2 g/m2 per dose** 
• Mechlorethamine 
• Streptozotocin 
Anthracycline therapies: Doxorubicin, Epirubicin, Idarubicin 
*Only in ASCO guidelines **Only in NCCN guidelines 
 
Other chemotherapy-related risk factors include shorter infusion time and administration of multiple 
cycles. Patient-level factors include being female, age<50, history of low alcohol intake (<1.5 oz/day), 
history of motion sickness, history of nausea and vomiting during pregnancy, history of prior CINV, and 
extreme anxiety.(4, 67, 73-78) 
2.1.4 CINV Prophylaxis  
Antiemetic drugs are a highly effective prophylaxis to prevent CINV in the acute and delayed 
phases and the evidence base to support these products’ ability to prevent and reduce CINV, improve 
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quality-of-life, and generate cost-savings is robust.(1, 4, 10, 79) Antiemetic efficacy is typically assessed 
using the response measures detailed below: 
• Incomplete Response: Having a CINV-related event; 
• Complete Response: No emesis, no use of rescue antiemetics; and 
• Complete Protection: Complete response and no significant nausea (VAS score of <25 
mm). 
Other measures of CINV may also assess the risk as well as the grade of nausea and vomiting. For 
example, nausea is frequently measured using a visual analogue scale in trials ranging from 0mm-100mm 
and “no nausea” to “nausea as bad as it could be (left to right),” respectively. A commonly used validated, 
questionnaire used to assess the impact of CINV on daily life in clinical trials is the Functional Living 
Index-Emesis (FLIE), which includes 9 questions in each of the nausea and vomiting domains.(3, 80) 
Other tools measuring CINV include, but are not limited to, the MASCC Antiemesis Tool (MAT) and the 
Rhodes Index for nausea, vomiting and retching (INVR).(81, 82) 
Conventional antiemetic drugs used to prevent acute and delayed CINV, in order of least to most 
potent, are corticosteroids, 5-HT3 receptor antagonists (5HT3A), and NK1 receptor antagonists.(15) 
Additionally, increasing trial evidence supporting the use of olanzapine for preventing CINV is emerging. 
(1, 19, 52, 83-86) Table 2.4 summarizes the dosing schedule and cost data for these products, and the 
below section further delves into these products’ evidence-base. Notably, antiemetic products have few 
safety concerns.(1) 
2.1.4.1 Early Antiemetic Prophylactic Therapies 
Dopamine-receptor antagonists (e.g., metoclopramide, prochlorperazine, and haloperidol) formed 
the basis of early antiemetic use.(1, 87) In 1978, the US Food and Drug Administration approved 
cisplatin, one of the most emetogenic chemotherapy products on the US market.(88) Low-dose 
metoclopramide was not found to be effective in preventing CINV in patients using cisplatin, spurring 
increased antiemetic research.(1, 63, 89) Subsequently, it was found that high-dose metoclopramide and 
glucocorticoids (i.e., dexamethasone) were effective compared to placebo in preventing CINV in patients 
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using cisplatin, and this was standard of antiemetic care through the 1980s.(1, 87, 90-92) Specifically, a 
meta-analysis by Ioannidis et. al in 2000 found that the odds of complete protection among 
dexamethasone users was 2.22 times higher than the odds of patients using placebo (95% CI: 1.89 to 
2.60) in the acute phase and 2.04 times higher in the delayed phase (95% CI: 1.63 to 2.56).(92) Today, 
dexamethasone is the backbone of antiemetic prophylaxis.(19, 52, 83)  
2.1.4.2 5HT3As 
First-generation 5HT3As have been on the US market since the early 1990s, and include 
ondansetron, granisetron, and dolasetron.(1) Ondansetron and granisetron are available as IV and oral 
formulations, while dolasetron is only available as an oral formulation today. Granisetron is also available 
as a trans-dermal patch.  
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Table 2.4 Summary of Antiemetic Products Used to as CINV Prophylaxis in the United States – 










5HT3A         
Ondansetron IV Zofran 
8mg / 
0.15mg/kg  Prechemotherapy, One Dose $1.10 
Ondansetron Oral - Generic Zofran 8mg Twice daily on days 1-3 $6.50 
Ondansetron Oral - Brand Zofran 8mg Twice daily on days 1-3 $268.28 
Ondansetron Oral Dissolving 
Tablet - Generic 
Zofran 
ODT 8mg Every 12 hours as needed days 1-3 $6.50 
Ondansetron Oral Dissolving 
Tablet - Brand 
Zofran 
ODT 8mg Every 12 hours as needed days 1-3 $253.14 
Ondansetron Oral Soluble Film - 
Brand Zuplenz 8mg Every 12 hours as needed days 1-3 $225.46 
Granisetron IV  Kytril 
1mg or 0.01 
mg/kg IV Prechemotherapy, One Dose $3.13 
Granisetron Oral Granisol 1mg 
Once (2MG) day 1, 1MG twice 
daily on days 2,3 $14.36 
Granisetron Transdermal Sancuso 3.1mg Prechemotherapy, Up to 7 Days $467.00 
Granisetron Subcutaneous*** Sustol 10mg Prechemotherapy, One Dose $518.7 
Dolasetron Oral Anzemet 100mg Once daily on days 1-3 $330.50 
Palonosetron IV Aloxi 0.25mg  Prechemotherapy, One Dose 228.80 
Palonosetron Oral** Aloxi 0.5mg Prechemotherapy, One Dose $521.95 
NK1 Antagonists         
Aprepitant Oral Emend 125mg Prechemotherapy, One Dose $284.01 
Aprepitant Oral Emend 80mg Once daily on days 2, 3 $364.28 
Fosaprepitant IV 
Emend 
IV 150mg  Prechemotherapy, One Dose $299.87 
Rolapitant Varubi 180mg Prechemotherapy, One Dose $610.50 
Combination Products         
NEPA (netupitant, palonosetron) Akynzeo 300mg/0.5mg Prechemotherapy, One Dose $632.35 
Atypical Antipsychotics         
Olanzapine - Generic Zyprexa 5mg Once daily on days 1-3 $6.50 
Olanzapine - Generic Zyprexa 10mg Once daily on days 1-3 $6.50 
Olanzapine - Brand Zyprexa 5mg Once daily on days 1-3 $43.22 
Olanzapine - Brand Zyprexa 10mg Once daily on days 1-3 $64.62 
Dopaminergic Antagonists         
Metoclopramide IV Reglan 1 to 2 mg/kg Prechemotherapy, One Dose $99.50 
Metoclopramide Oral - Generic Reglan 0.5mg/kg Every 6 hours days 2-4 $6.50 
Metoclopramide Oral - Brand Reglan 0.5mg/kg Every 6 hours days 2-4 $192.99 
Prochlorperazine IV 
Compazi
ne 5-10mg  
Prechemotherapy, every 6-8 
Hours, Max 40mg $11.93 
Prochlorperazine Oral 
Compazi
ne 10mg Every 6 to 8 hours as needed $6.50 
Cannabinoids         
Nabilone Oral Cesamet 1-2mg Twice daily days 1-3 $249.63 
Dronabinol Oral - Generic* Marinol 5mg/m2 Every 2-4 hours as needed $223.94 
Dronabinol Oral - Brand* Marinol 5mg/m2 Every 2-4 hours as needed $941.80 
*Assume 3 Days use, 12 pills per day **Palonosetron oral has been discontinued in the US  
*** 75% of AWP as ASP price not available. 
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A meta-analysis found that adding dexamethasone to a 5HT3A regimen offers incremental benefits.(83, 
92) The complete response effectiveness of first-generation 5HT3As + dexamethasone has ranged from 
68%-90% in the acute phase and 47%-64% in the delayed phase.(93-101) However, in 2007, a meta-
analysis of 44 studies found that the effectiveness of preventing CINV in the acute phase across these 
three products was comparable, suggesting that there is no need to prioritize one product over 
another.(59)   
In 2003, the Food and Drug Administration approved the second-generation 5HT3A, 
palonosetron.(102) Its longer half-life and higher binding affinity (estimated at 100-fold compared to the 
other 5-HT3As), which contribute to its longer inhibition of the 5-HT3 receptor, lead to palonosetron 
being more effective in preventing CINV in the delayed phase than first-generation 5HT3As in the 
moderately emetogenic chemotherapy group.(1, 20, 101, 103-105) Palonosetron + dexamethasone was 
more effective than ondansetron + dexamethasone (41% vs. 25%, p=.021), and granisetron + 
dexamethasone (57% vs. 44.5%, p=.0001) in preventing emesis in the delayed phase but rates of emesis 
in the acute phase were similar in patients on highly emetogenic chemotherapy.(20, 106, 107)It is 
important to note that neither of these studies evaluated the effectiveness of palonosetron in the presence 
of an NK1, which would be prescribed for highly emetogenic chemotherapy.(20) Additionally, 
palonosetron is much more expensive than first generation 5HT3As (Table 2.4). 
2.1.4.3 NK1s 
Since 2003, a new class of highly effective and more expensive (<$600/cycle) antiemetics, NK1s, 
has entered the marketplace with the introduction of oral aprepitant as well as IV fosaprepitant, an 
aprepitant prodrug, in 2008.(1) In particular NK1s conferred significant benefit in preventing vomiting in 
the delayed phase.(20) More recently FDA approved NEPA (netupitant and palonosetron combination) in 
2014, and rolapitant, in 2015.(108, 109) Both of these newer NK1s are oral products. Several trials and 
observational studies have assessed aprepitant regimens versus standard-of-care, which center on 
5HT3As.(19, 52, 83) Key aprepitant and fosaprepitant trial data are detailed in Table 3.7. 
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While an initial meta-analysis found that aprepitant regimens had higher rates of complete protection than 
5HT3A regimens in the delayed phase, there was no difference in the acute phase in patients initiating 
highly emetogenic chemotherapy.(110) However, authors recommend “cautiously interpreting” the acute 
phase results given trial inconsistency. Subsequently, a more robust meta-analysis, which includes 
patients receiving moderately and highly emetogenic chemotherapy, found that patients on aprepitant had 
higher rates of complete protection compared to those on standard-of- care (primarily consisting of a 
5HT3A+dexamethasone).(111) A pooled analysis also found that aprepitant regimen was even more 
effective in patients on concomitant emetogenic chemotherapy (doxorubicin or cyclophosphamide) than 
patients on an ondansetron regimen on day 1 than the general population.(112) Another trial found that 
the aprepitant-based regimen was also more effective than an ondansetron (5HT3A)-based regimen used 
on days 1-4, whereas in most trials patients received 5HT3A (ondansetron or another 5HT3A) only on 
day 1 in patients initiating highly emetogenic chemotherapy.(113)Non-inferiority trials support the use of 
infused fosaprepitant (day 1) as comparative with orally administered aprepitant (days 1-3).(114, 115)  
Trial data also supports that NEPA and rolapitant regimens are more effective in preventing CINV than 
5HT3As regimens than patients initiating highly emetogenic chemotherapy (Table 3.7).   
In 2016, a meta-analysis found that the NK1 regimens (as a group) offered a “clinically relevant 
benefit” over 5HT3A regimens (as a group) for no vomiting and nausea in patients initiating highly 
emetogenic chemotherapy. The risk difference for control was better than nausea for both cisplatin-based 
(risk difference: 21% vs. 8%) or AC-based highly emetogenic chemotherapy (risk difference 14% vs. 
4%).(116) Two indirect network analyses have also compared the effectiveness of the NK1s (aprepitant, 
fosaprepitant, netupitant (NEPA), and rolapitant), though a limitation of both studies is cross-trial 
comparisons and heterogeneity within studies included in the analysis.(117, 118) Both of these studies 
also included casopitant, which is no longer under clinical investigation so these results are not reviewed 
in this section. In general, both studies found that triple-regimens including NK1s were more effective 
than dual-regimens without an NK1. However, Zhang et. al found that NEPA in the acute phase, 
demonstrated non-significant superiority over dual-therapy regimens.(118) Furthermore, complete 
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response across triple therapy regimens containing NK1s were similar in the acute, delayed, and overall 
phases as were treatment-related adverse events, suggesting NK1s as interchangeable.(118) In contrast, 
Abdel-Rahman found that aprepitant-regimens are better than rolapitant-regimens in achieving complete 
response, though the confidence interval should be noted given that the lower bound is near the null (OR 
1.28, 95% CI 1.01–1.59).(117) Another point of difference is that Zhang found equivalent effects in triple 
regimens containing palonosetron versus a first-generation 5HT3A while Abdel-Rahman’s results 
suggested that patients on NK1 regimens containing palonosetron actually had worse complete response 
rates than those that did not.(117, 118)  Regardless, both studies support the use of less expensive, first-
generation 5HT3As over palonosetron. Zhang et al also found similar rates of complete response in NK1 
users regardless of dexamethasone dose suggesting that a lower dose of dexamethasone is appropriate 
(118) The difference in these two network meta-analyses results, which generally included the same trial 
data for patients initiating highly emetogenic chemotherapy highlights the need for more and more 
indirect analyses as new evidence is generated for newer NK1s and comparative effectiveness studies 
across NK1s. A network meta-analysis assessing NK1s in only patients initiating cisplatin-based 
chemotherapy suggested NEPA was the best with regards to complete response.(119)  
2.1.4.4 Olanzapine 
A potentially promising treatment to prevent CINV and treat breakthrough CINV is olanzapine, 
an atypical antipsychotic, which is inexpensive compared to the newer antiemetics (<$10.00/cycle). (1, 
19, 52, 83) Early evidence on the use of olanzapine to prevent CINV is limited to small phase II and 
phase III studies comparing the current standard of care to olanzapine monotherapy and olanzapine plus 
standard of care in previously chemotherapy naïve patients. These studies have consistently demonstrated 
that olanzapine regimens were as effective or better in preventing CINV during the acute and delayed 
phases in patients initiating highly emetogenic chemotherapy than standard regimens, which included 
various combinations of aprepitant, 5HT3A, and dexamethasone.(24, 25, 28, 29, 84-86, 120-122) A larger 
multi-center randomized controlled trial of olanzapine + standard of care (i.e., aprepitant+5HT3A+ 
dexamethasone) versus standard of care in patients initiating highly emetogenic chemotherapy supporting 
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these early findings (i.e., complete response rates of 85.7%, 66.9% and 63.6% respectively in the acute, 
delayed, overall phases versus 64.6%, 52.4%, and 40.6 % in the standard of care group (p<.001)) was 
published in 2016.(28) The evidence supporting olanzapine, which is also summarized in multiple meta-
analyses, is overwhelmingly positive for both olanzapine as a monotherapy, and combination therapy 
with standard of care in preventing CINV and treating breakthrough CINV compared to standard of 
care.(84, 85, 123, 124) Given that olanzapine is an antipsychotic, physicians are concerned about adverse 
events such as sedation and drowsiness. Additionally, some researchers and clinicians voiced concerns 
over the study design of some of the olanzapine studies.(28, 125) However, in Navari’s 2016 large 
clinical trial testing 10mg of olanzapine in combination with aprepitant or fosaprepitant, patient in the 
olanzapine-arm had significantly higher complete response rates in the acute, delayed and overall phases. 
Additionally, there were no major adverse events, and many patients who experienced drowsiness in the 
early phase, adapted to it in the delayed phase.(28) Notably, the 2016 meta-analysis by Chiu and 
colleagues found that the 5mg dose was as effective as the 10mg dose.(84)  Olanzapine studies are 
detailed in Table 3.8. 
2.1.5 Breakthrough CINV Treatment 
Patients with breakthrough CINV are those that experience it despite receiving appropriate 
prophylactic antiemetics. It is estimated that up to 40% of patients on moderately or highly emetogenic 
chemotherapy experience breakthrough CINV.(7) Notably, the conventional antiemetics described in 
section 2.1.3 used as CINV prophylaxis are generally not effective in treating CINV.(7, 16, 17) As such, 
non-traditional antiemetics may be used as rescue therapies to treat CINV in patients who failed 
conventional prophylactic therapy, and experienced breakthrough CINV. (19, 20, 52) Specifically, non-
traditional antiemetics for CINV-treatment include: antipsychotics (i.e., olanzapine), benzodiazepines 
(e.g., lorazepam), cannabinoids (e.g., nabilone and dronabinol), and phenothiazines (e.g., 
prochlorperazine), among others (Table 2.5). These products are also used to treat anticipatory and 
refractory CINV. There is sparse evidence on the treatment of breakthrough CINV using these products, 
which include a few phase II studies. Two small studies (each with less than 30 patients) that used self-
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reporting measures found that prochlorperazine, 5HT3As, and a topical product containing lorazepam 
might be effective in treating breakthrough CINV; but more rigorous studies that use objective measures 
are necessary to confirm these findings. (7, 126, 127) Notably, nabilone and dronabinol are approved by 
the Food and Drug Administration to treat breakthrough CINV in patients who have failed to respond to 
conventional antiemetic treatments.(128, 129) However, the widespread use of cannabinoids is 
controversial due to side-effects (i.e., disturbing psychotomimetic reactions).(83, 129-131) The most 
robust evidence for breakthrough CINV is for olanzapine, which is described below.(7, 29) Notably, there 
is no preferred treatment of breakthrough CINV.(7, 132) 
Table 2.5 Products Used to Treat Breakthrough CINV (15, 19, 52, 133) 
• Atypical antipsychotic (olanzapine) 
• Benzodiazepine (lorazepam) 
• Cannabinoid (dronabinol, nabilone) 
• Other (Haloperidol, metoclopramide, 
scopolamine) 
• Phenothiazine (prochlorperazine, 
promethazine),  
• 5HT3A (Dolasetron, granisetron, 
ondansetron)* 
• Corticosteroid (dexamethasone) 
*Anecdotal and limited trial evidence suggest switching 5HT3A may be effective 
2.1.5.1 Olanzapine 
In 2013, Navari et al, conducted the first phase III randomized controlled trial comparing 
olanzapine and metoclopramide in controlling nausea and vomiting outcomes among patients who 
initiated highly emetogenic chemotherapy and experienced breakthrough CINV.(24) In this study, 
olanzapine was statistically significantly better in preventing both nausea (70% vs. 31%, p<0.01) and 
vomiting (68% vs. 23%, p<0.01) compared to metoclopramide. Meta-analyses published in 2014 and 
2016 supported that olanzapine was more effective than prochlorperazine, metoclopramide, and 
dexamethasone in preventing emesis – the impact on preventing nausea could not be assessed as not 
enough studies reported on it.(84, 134) More recently, in an open label randomized controlled trial 
comparing olanzapine, palonosetron, and ondansetron among patients initiating hematopoietic stem cell 
transplantation found that olanzapine was significantly more effective in controlling CINV than 
palonosetron, which showed no difference compared to ondansetron.(121) In the only small retrospective 
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electronic medical record study, 88% experienced improved nausea, while 21% had improved vomiting 
among breakthrough CINV patients who used olanzapine.(84) 
2.1.6 Antiemetic Guidelines Recommendations 
The Multinational Association of Supportive Care in Cancer (MASCC) / European Society for 
Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO) and the National 
Comprehensive Cancer Network (NCCN) offer recommendations on the appropriate use of antiemetic 
drugs based on the likelihood of emesis of the chemotherapy regimen.(19, 52, 83, 135) These 
recommendations are based on rigorous, systematic evidence reviews. The 2017 ASCO and NCCN 
recommendations are detailed below in Table 2.6, though MASCC and ESMO recommendations are 
similar.(135) While ASCO and NCCN both utilize rigorous evidence-reviews to inform their guideline 
recommendations, NCCN also leverages consensus-driven physician opinion, which may offer more 
rapid uptake of certain products. Additionally, NCCN updates their guidelines yearly, while ASCO that 
has not conducted a major update in five years. 
2.1.7 NCCN and ASCO Guideline Recommendations for CINV Prophylaxis in Patients Initiating 
Highly Emetogenic Chemotherapy 
NCCN and ASCO guidelines include similar recommendations on the use of antiemetics for 
CINV prophylaxis (Table 2.6). (15, 18-21) Both, the 2017 NCCN and 2017 ASCO guidelines recommend 
that patients receive a triple therapy combination of an NK1, 5HT3A, and glucocorticoids on day 1.(18, 
20) Additionally, in 2017 both ASCO and NCCN guidelines recommended olanzapine + 
aprepitant/fosaprepitant + 5HT3A+ dexamethasone as an effective CINV-prevention strategy. This is the 
first time, ASCO recommended olanzapine, an atypical antipsychotic, as a strategy for CINV prevention 
despite not having FDA approval. The key difference between the ASCO and NCCN guidelines is that 
NCCN also recommends the use of olanzapine in conjunction with palonosetron, while ASCO does not. 
Notably, all highly emetogenic chemotherapy antiemetic recommendations are now category 1, the 
highest level recommendation (meaning the evidence level is high and there was uniform NCCN 
consensus). From a maintenance perspective, both guidelines recommend that patients who initiate 
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aprepitant on day 1 continue it on days 2 and 3, patients who initiate olanzapine continue it on days 2-4, 
and all patients, regardless antiemetic regimen strategy, continue corticosteroids on days 2-4.   
Table 2.6 2017 ASCO and 2017 NCCN Prophylactic Antiemesis Guideline Recommendations in 
Patients Initiating Highly Emetogenic Chemotherapy Intravenously * (15, 19, 52, 133)  
 ASCO NCCN* 
Day 1 
(Acute) 
• NK1, 5-HT3A, and corticosteroid 
• NEPA and corticosteroid 
• Olanzapine+aprepitant+5HT3A+ 
corticosteroid** 
• NK1, 5-HT3A, and corticosteroid 
• NEPA and corticosteroid 





• Aprepitant on days 2-3 
(if aprepitant on day 1) 
• Corticosteroid days 2-4 
• Olanzapine days 2-4 
(if olanzapine on day 1) 
• Aprepitant on days 2-3  
(if aprepitant on day 1) 
• Corticosteroid days 2-4 
• Olanzapine days 2-4  
(if olanzapine on day 1) 
*Corticosteroid: Dexamethasone; 5-HT3A: Granisetron, Ondansetron, Palonosetron, Dolasetron; NK1s: Aprepitant, 
Fosaprepitant, Rolapitant  
**This strategy is only recommended in NCCN guidelines 
***2017 NCCN and ASCO guidelines newly recommend olanzapine + aprepitant + 5HT3A + dexamethasone 
 
2.1.8 Guideline Recommendations for Breakthrough CINV Treatment 
Recommendations on treating breakthrough CINV are sparse given the limited evidence on 
treating CINV and the lack of a superior product class demonstration, but generally center on adding a 
product that is from a different drug class from the current treatment regardless of chemotherapy risk.(19, 
52, 83)  ASCO’s recommendation is as follows: 
Clinicians should re-evaluate emetic risk, disease status, concurrent illnesses, and medications; 
ascertain that the best regimen is being administered for the emetic risk; consider adding 
lorazepam or alprazolam to the regimen; and consider adding olanzapine to the regimen or 
substituting high-dose intravenous metoclopramide for the 5-HT3 antagonist or adding a 
dopamine antagonist to the regimen. (19, 52) 
 
NCCN’s recommendations to treat breakthrough CINV (organized alphabetically) are as detailed in 
Figure 2.1. NCCN also states that it is easier to prevent breakthrough CINV than to treat it.(133) 
Consequently, NCCN suggests guideline concordant-prescribing and that prescribers “strongly consider 
routine around-the-clock administration rather than PRN [as the situation arises] dosing.” Physicians are 
also debating what antiemetics to send patients home with following chemotherapy in anticipation of 
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breakthrough CINV in days 2-5 (as opposed to patients filling products as they develop CINV 
symptoms).  
Figure 2.1 NCCN Breakthrough Treatment Options (organized alphabetically)(64) 
• Atypical Antipsychotic 
− Olanzapine 10 mg PO daily for 3 days 
• Benzodiazepine 
− Lorazepam 0.5-2 mg PO/SL/IV every 
6h 
• Cannabinoid 
− Dronabinol 5-10 mg PO every 3-6 h 
− Nabilone 1-2 mg PO BID 
• Other 
• Haloperidol 0.5-2 mg PO/IV every 4-6 h 
• Metoclopramide 10-40 mg PO/IV every 
4-6 h 
• Scopolamine transdermal patch 1 patch 
every 72 h 
• Phenothiazine 
− Prochlorperazine 25 mg sup pr every 12 
h or 10 mg PO/IV every 6 h 
− Promethazine 25 mg sup pr every 6 h or 
12.5-25 mg PO/IV (central line only) 4-
6h 
• Serotonin 5HT3A 
− Dolasetron 100 mg PO daily 
− Granisetron 1-2 mg PO daily or 1 mg PO 
BID or 0.01 mg/kig (maximum 1 mg) IV 
daily 
− Ondansetron 16 mg PO/IV daily 
• Steroid 
− Dexamethasone 12 mg PO/IV daily 
 
2.2 Antiemetic Prescribing 
Antiemetic drugs are a highly effective prophylaxis to prevent CINV and thus improve quality-
of-life, and generate cost-savings. (1-4) However, use of antiemetics is suboptimal. In general, patients 
are receiving at least one type of antiemetic in the acute phase, but receipt of an antiemetic in the delayed 
phase is much lower. (22, 31, 34, 39, 136) This section will describe general patterns of prophylactic 
antiemetic prescribing with a focus on patients initiating highly emetogenic chemotherapy organized by 
region as well as summarize breakthrough-prescribing patterns. Notably, many of these studies take place 
in Asia and Europe where both the healthcare systems and antiemetic product availability differ from the 
U.S.  Asian and European studies are detailed in Appendix 2. Unsurprisingly there is much country-level 
heterogeneity in prescribing patterns highlighting the inability to generalize one country’s study findings 
to another. Furthermore, patterns of antiemetic prescribing among patients initiating highly emetogenic 
chemotherapy has not been well studied in the United States, especially in recent history or in a large, 
nationally representative study. 
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2.2.1 United States Studies 
One small US-based study examining patterns of antiemetic use was identified supporting the 
need to assess prescribing patterns in a larger, generalizable dataset. This prospective observational study 
used electronic health data from practices in Georgia, Tennessee and Florida and includes 460 patients 
using highly emetogenic, single-day chemotherapy.(22) The primary objective of this study was to assess 
guideline concordance and its associated outcomes, which are discussed in the next section (2.2.4), but 
characterizing antiemetic products’ used was part of the authors’ process for assessing guideline 
concordance (Table 2.7). Notably all patients received an antiemetic in the acute phase and only 1.1% did 
not receive a product in the delayed phase. (22) In another US-based study, using IntrinsiQ clinical 
warehouse data between July 2006-April 2008, again a high proportion of patients initiating highly 
emetogenic chemotherapy received an antiemetic (>80%), but NK1 use was only 11%.(30) The authors 
suggest that the low uptake of NK1s is a result of poor clinical understanding by prescribers as aprepitant 
was FDA-approved in 2003, and guidelines incorporated NK1s into recommendations in 2006 and 2009 
respectively for ASCO for NCCN.(30) 
Table 2.7 Summary of Antiemetic Regimens Administered or Prescribed on Day 1 (N=460) (22) 
Phase and Regimen No. % 
Acute Phase 
Corticosteroid+NK1+5HT3A 417 90.7 
Corticosteroid+5HT3A 36 7.8 
Other regimen 7 1.5 
Delayed phase 
NK1-RA + 5HT3A 284 61.7 
Corticosteroid+NK1+5HT3A 131 28.5 
5HT3-RA 29 6.3 
No primary antiemetic 5 1.1 
NK1-RA 5 1.1 
Corticosteroid + 5HT3A 2 0.4 
Corticosteroid +NK1 2 0.4 




2.2.2 Guideline-based Prescribing Patterns 
Clinical trial data suggest that guideline-concordant antiemetic prescribing is estimated to prevent 
CINV in 80% of patients.(137) Most studies demonstrate that patients who receive guideline-concordant 
prescribing have fewer CINV-events and less healthcare resource use (Table 2.8). (The exception were 
two studies – 1) a retrospective claims data analysis, that may have unmeasured confounding due to a lack 
of being able to measure patient/provider engagement as well as being unable to capture non-hospital 
related CINV events and healthcare resource use and 2) a small study (n=102) that found no association 
(Table 2.8).)  
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Table 2.8 The Effect of Guideline Concordance on CINV-events and Healthcare Resource Use 




Size Results  









800 • Complete response, no nausea, no 
vomiting, and no nausea and vomiting 
was higher in concordant patients 
(AOR 1.43 p<.05) 
• Higher proportion of patients using 
HCRU with specialist visits and ER 
being statistically significant among 
discordant patients 




Singapore ProObs Interview 361 • Significantly higher proportion of 
adherent than non-adherent patients 
achieved delayed complete control 
(26.8% vs. 16.4%, P = 0.020) 







ProObs Electronic  648 • Patients who were prescribed an 
antiemetic regimen adhering to quality 
guidelines had significantly higher 
odds of no emesis in cycle 1 (adjusted 




Multi Turkey ProObs  Daily 
Diary 
100 • Complete control for both nausea and 
vomiting was higher in GAG; the 
difference was highly significant in 
the first cycle for both the acute and 
delayed phase of the CINV (p<0.05) 
Check et al. 
2016(139) 
HEC (AC) US Retro Claims 
Data 
1130 • Unexpectedly, compared to women 
who did not receive an NK1 for the 
prevention of CINV, women who did 
experienced higher CINV-related 
utilization as measured through post-
chemotherapy inpatient or outpatient 
visits for nausea and vomiting, volume 
depletion, dehydration, or 
hypovolemia (aRR = 1.34, 95 % CI = 






US ProObs EHR Data 1295 • Over 5 days post-chemotherapy, the 
incidence of no CINV was 
significantly higher in the concordant 
cohort than the non-concordant cohort 
(53.4% v 43.8%; P .001). The aOR of 
no CINV with concordance was 1.31 
(P< .037) 
• Concordant use resulted in 
significantly higher adjusted odds of 
no CINV and no clinically significant 









102 • No statistically significant difference 
between adherence to the protocols 
and complete response in any of the 
groups 
HEC: Highly Emetogenic Chemotherapy  MEC: Moderately Emetogenic Chemotherapy  
HER: Electronic Health Record   ProObs: Prospective Observational  
Retro: Retrospective    F-BC-AC: Female, Breast Cancer, AC-based Therapy 






Table 2.9 Guideline Concordance Across Multiple Types of CINV-Risk 
Authors Study Population Study 
Size 






Common Reasons for Discordance  
DeTursi et. al 
2015(140) 
Patients receiving 











Franca et al. 
2015(40) 
Adults initiating 














• Higher CSC, 5HT3A, and NK1 dose 
Double Discordance: 
• Higher CSC dose 







CT naive patients 
initiating CT 
100 Daily Diary Turkey 5/2015-
9/2015 




• Over-prescription: 55% 
• Inappropriate Dose: 70% 
• Under prescription: 35% 
• Inappropriate Prescription: 0% 
Delayed: 
• Over-prescription: 33% 
• Inappropriate Dose: 4% 
• Under prescription: 25% 
• Inappropriate Prescription: 65% 
Caracuel et al. 
2014(43) 
Adults patients 















day MEC and 
HEC for cancer 



























• Incorrect use of aprepitant 
Delayed: 
• Over-prescribing of 5HT3A 
• CSC dose not reduced 
CT: Chemotherapy    MEC: Moderately Emetogenic Chemotherapy HEC: Highly emetogenic Chemotherapy  
LER: Low Emetogenic Risk  ProObs: Prospective Observational   Retro: Retrospective  
Dex: Dexamethasone   CSC: Corticosteroid    IV: Intravenous     
Acute: Day 1    Delayed: Days 2-5    Overall: Day 1-5
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Despite this, it is suggested that the rate of guideline-discordant CINV-related antiemetic prescribing is 
high across CINV-risk ranging from 20%-80%, and higher in the delayed phase than the acute phase 
(Table 2.9). Guideline-discordant prescribing includes both under and over-prescribing. Under 
prescribing is prescribing a product that is less potent (including lower doses) than recommended or 
excluding drugs that should be included.  Furthermore, under-prescribing of antiemetic drugs leads to the 
occurrence of preventable CINV-related events and their associated resource use and costs.(1-4) Over-
prescribing is prescribing: 1) a more potent drug or 2) more complex drug regimens than recommended, 
while under-prescribing is prescribing a product that is less potent than recommended or excluding drugs 
that should be included. Over-prescribing of antiemetics is an important issue to address, as those drugs 
that are intended to treat high-risk CINV are more expensive than low-risk CINV drugs. For example, 
NK1 combinations can cost as much as $650/chemotherapy regimen, while olanzapine costs <$10.00. 
Notably, in 2013, the Choosing Wisely Campaign partnered with several US professional societies to 
identify and communicate ineffective and inefficient healthcare practices in their specialty.(47) Under the 
Campaign, ASCO identified antiemetic over-use in cancer patients treated with chemotherapy 
(specifically the use of the products that are intended to prevent CINV in patients initiating highly 
emetogenic chemotherapy in patients initiating lower CINV risk) as a potentially wasteful oncology 
practice. Additionally, prescribing more complex antiemetic regimens than necessary raises questions of 
excess costs. Section 2.2.5 will describe the antiemetic guideline-concordant literature related to patients 
initiating highly emetogenic chemotherapy with an emphasis on US-based studies. 
2.2.3 Breakthrough Prescribing 
Breakthrough antiemetic prescribing has been studied less than prophylactic antiemetic 
prescribing. Notably, prescribing of breakthrough products is more common in patients receiving highly 
emetogenic chemotherapies versus other types of chemotherapy and was more likely to be prescribed in 
the acute phase.(23, 34) A retrospective claims study in commercially insured US patients estimated that 
32.5% of patients initiating highly or moderately emetogenic chemotherapy received breakthrough 
products on day one. Similarly, breakthrough product prescribing in European based studies was lower 
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ranging from 29-39%. (23, 31) Breakthrough product use among patients initiating highly emetogenic 
chemotherapy in Asian based studies was higher ranges from 31% - 62% with the most common products 
being metoclopramide and chlorpheniramine, which have a different mechanism of action than 
preventative antiemetics.(34-37)  
2.2.4 Guideline-Concordant Prescribing in Patients Initiating Highly Emetogenic Chemotherapy 
Remarkably, while patients on highly emetogenic chemotherapy are more likely to receive 
antiemetics and guideline concordant care compared to chemotherapy with lower CINV risk, the 
concordance rate is still poor (Table 2.10). Studies examining general guideline concordance in patients 
initiating highly emetogenic chemotherapy spanned US, Asia, and Europe and used both prospective and 
retrospective study designs. Data sources include claims data, daily diaries, patient interviews, and 
clinical systems, which offer advantages and disadvantages. Clinical systems include data on what was 
prescribed, while claims data offers data on what was filled. Patient interviews and daily diaries can 
capture what the patient actually took, though this is subject to respondent bias. The studies detailed 
below are listed in Table 2.10. 
Studies that do not specify whether the acute or delayed phase of prescribing was examined 
estimate discordance rates ranging from 26%-99%.(37, 45, 141) The proportion of patients receiving 
guideline-discordant antiemetic in the delayed phase (60%-90%) was typically much higher than in the 
acute phase (10%-70%), mirroring trends across multiple types of CINV-risk.(22, 31, 34, 39, 136) 
Discordance rates across the five day acute and delayed periods (i.e., overall period) range from 60%-
90%; notably female patients on doxorubicin (AC) therapy had higher proportion of concordance 
compared to patients on other types of highly emetogenic chemotherapy.(22, 31, 34, 36) Specifically in 
the US, a prospective observational study using practice data from southeastern states estimated the 
proportion of patients receiving guideline-concordant antiemetics at 90.7%, 28.9%, and 28.7% in the 
acute, delayed, and overall phases.(22) While these results suggest that guideline discordance may be 
lower in the US than other countries, the authors note the implementation of a standardized antiemetic 
electronic medical record protocol by prescribers, which automates the prescribing process. Additionally, 
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it is important to consider that product availability and guidelines vary by country. However, another US-
based study assessing guideline concordance in patients with breast cancer initiating highly emetogenic 
chemotherapy using claims representing 1) the US commercial insured and supplemental Medicare 
(MarketScan) and 2) the Medicare populations (SEER Medicare), 22.4% and 22.8% of patients were 
respectively adherent on day 1 throughout the study period.(45) Notably, adherence was over 80% in both 
populations in 2005 prior to the release of the updated ASCO guidelines incorporating NK1s as a 
recommended antiemetic for patients initiating highly emetogenic chemotherapy in 2006, while 
adherence was less than 3% in 2007, suggesting that new product uptake and guideline dissemination 
contributed to this drastic drop. Adherence in both populations increased over time, and reached as high 
as 56.4% in 2013 for the MarketScan population, which also had a more rapid increase compared to the 
SEER Medicare population.(45) This study focuses only on breast cancer, and did not breakdown under 
versus over prescribing in detail. 
Studies examining over and under-prescribing are detailed in the next two sections. While three 
US-based guideline concordance studies were identified. (22, 38, 45) Two of the three focused on 
discordant prescribing in general – it is crucial to discriminate between under and over prescribing rates 
because of their different implications on the healthcare system (disparity versus cost).(22, 45) 
Additionally, these studies had limited generalizability given that one was a small southeast practice with 
an EMR-based antiemetic prescription system and the other used two large claims data sets, but only 
focused on breast cancer. The third study assessed overprescribing in a large claims data set, but under-
prescribing was not assessed.(38) 
2.2.4.1 Under-prescribing in Patients Initiating Highly Emetogenic Chemotherapy 
Under-prescribing specifically is not well researched, especially in the US. In regards to patients 
initiating highly emetogenic chemotherapy, a UK-based study estimates that 58.8% of patients are under-
prescribed antiemetics while a Swiss-based study found that 19% of patients were undertreated in the 
acute phase.(39, 141) Under prescribing in patients initiating highly emetogenic chemotherapy primarily 
centers on non-prescribing of an NK1 which comprises 51%-80% of the reasons for discordances. (22, 
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31, 39, 45, 46) However, in the delayed phase, discordances commonly resulted from the non-prescribing 
of corticosteroids and 5HT3As or lack of dose reduction in corticosteroids. (31, 39) 
2.2.4.2 Over-prescribing in Patients Initiating Highly Emetogenic Chemotherapy 
Over-prescribing in patients initiating highly emetogenic chemotherapy is characterized by 
receiving higher dose or more products than recommended with estimates ranging from 5.9%-10%. (39, 
141) In particular, prior studies have found that unnecessary 5HT3As and higher dosing of corticosteroids 
than recommended are prescribed.(23, 32, 34) Encinosa and Davidoff estimate that over-prescribing in 
patients initiating moderately or highly emetogenic chemotherapy at 34.1% on day 1 using US 
commercially insured and supplemental Medicare claims data (MarketScan) between a class level and not 
by the number of products of received.(38) A British study estimated overprescribing at 5.9%, based on 
prescribing of cyclizine in the delayed phase. However, cyclizine is again, typically used for breakthrough 
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*In studies where multiple types of risk were studied; only HEC-specific results are included in this table
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2.3 Cost Effectiveness 
As discussed in (section 2.1.7), guideline recommendations for preventing CINV in patients 
initiating highly emetogenic chemotherapy center on triple-regimens containing an NK1 (aprepitant, 
fosaprepitant, netupitant, and rolapitant), 5HT3A (first generation: ondansetron, granisetron, and 
dolasetron and second generation: palonosetron), and a corticosteroid (dexamethasone) as well as newer 
recommendations for using triple regimens containing olanzapine + palonosetron + dexamethasone or 
quadruple regimens consisting of olanzapine + aprepitant/fosaprepitant + 5HT3A + dexamethasone. As 
outlined in section 2.1.4.3, clinical trials, meta-analyses, and network meta-analyses have found similar 
effectiveness across the NK1s. However, differences in 5HT3As in combination with NK1s has not been 
previously studied. Additionally, while studies to date support that regimens containing olanzapine are 
more effective than ones that do not (including ones with aprepitant), this evidence-base is still being 
developed. As such, there is no preferred antiemetic regimen for preventing CINV in patients initiating 
high CINV risk chemotherapy based on effectiveness.  However, given the varied cost of available 
treatment strategies, identifying the most cost-effective strategy can help inform value-driven prescribing 
in this clinical context. Notably, the 2015 ASCO guidelines specifically highlight the need to evaluate the 
value of NEPA given its high costs to payers and potential out-of-pocket spending implications for 
patients.(142) 
To date there have been two studies that examined the cost effectiveness of NEPA in patients 
initiating highly emetogenic chemotherapy.(53, 143, 144) These two cost-utility studies, conducted from 
the perspectives of the UK National Health Services and Italian National Health Services, found that 
NEPA was dominant (i.e., was more effective and less costly) strategy over aprepitant and fosaprepitant-
based strategies (no olanzapine-based strategies were studied). It is important to note that the cost of 
NEPA and all antiemetics are cheaper in both the UK and Italy.(18, 143, 144) Additionally, in five other 
studies comparing aprepitant-based regimens to 5HT3A-regimens in patients initiating highly emetogenic 
chemotherapy, aprepitant was either found to be cost-effective at a willingness-to-pay threshold of 
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The use of apr-containing regimens is associated with an 
improvement in QALYs compared with non-apr regimens. For 
cisplatin-based chemotherapy, the incremental cost/QALY gained 
is HKD 239,644 /when ondansetron is administered on day 1 only. 
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In HEC patients, the NEPA strategy was more effective than apr 
(QALDs of 4.263 versus 4.053; incremental emesis and CINV free 
days of +0.354 and +0.237 respectively) and was less costly (£80 
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Studies included perspectives from payers and patients, ranged from 5-28 day cycles, had 1-5 cycles, and 
used decision-tree and Markov model study designs. Two other cost models were identified, but one was 
used to calculate the optimal price of NK1s from the perspective of the Canadian payer and the other was 
a cost-minimization model comparing NEPA and aprepitant for the Scottish Medicines Consortium. (145, 
146) No studies have compared olanzapine in any setting or all NK1s from a US commercial payer 
perspective. 
2.4 Theoretical Framework 
Aday and Andersen’s Behavioral Model of Health Services Use will serve as the theoretical 
foundation for this dissertation (Figure 2.2).(147) Aday and Andersen’s Behavioral Model of Health 
Services Use stipulates that environmental, population characteristics, and behavior are predictors of the 
use of health services by patients.(148) Environmental factors include the healthcare system and the 
external environment. Population characteristics include predisposing characteristics that may affect 
antiemetic use, enabling resources that affect access to antiemetics, and need for antiemetics. Health 
behavior factors include personal health practices and use of health services. Finally, outcome measures 
include perceived health status and evaluated health status. Because antiemetic use is multifaceted and 
factors associated with its use span guideline-adherence, cancer care, and preventive care, all three bodies 
of evidence were assessed to build this conceptual model. Notably, Table 2.12 summarizes predictors 
identified in the studies looking at both antiemetic prescribing and guideline-concordance discussed 
earlier in section 2.2. However, the variables included in this dissertation, and ultimately in the model, are 
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While this section focuses on patient, treatment, and external predictors of antiemetic concordance, it is 
crucial to remember that the role of the physician (e.g., knowledge and belief of antiemetics) and 
healthcare system factors (e.g., automated prescribing in an EMR system) are arguably among the most 
important factors in predicting guideline adherence as they are the one prescribing the antiemetic 
regimen.(42, 137) (Though the onus is on the patient to fill and take the medication.) Reasons for low 
guideline adherence result from: 1) physician (and institution) awareness and knowledge of guidelines 
that have not only many antiemetic options (over 400 antiemetic regimens are estimated to exist across 
CINV-risk categories), but also guideline-concordant options and 2) healthcare stakeholders’ historical 
emphasis on eliminating care efficiencies to maximize revenue versus high-quality outcomes.(23, 42, 137, 
149) Prescriber characteristics and healthcare system factors cannot be measured in the proposed data 
source, but they highlight opportunities for future research. 
However, especially in the US, the increased focus on value-based care, including advanced 
payment models and outcomes-based contracting are incentivizing patients to focus on high quality, 
value-based care, which includes guideline adherence. As such, identifying patient-level factors that 
influence both antiemetic guideline concordance and discordance will help address guideline discordance. 
(22, 38, 45) Again, it is crucial to consider these predictors in the context of the healthcare delivery 
system in which they were assessed given the differences across systems limiting the generalizability of 
one system’s findings to another.  
2.4.1 Conceptual Model: Environment 
2.4.1.1 Environment: Healthcare System 
The healthcare system includes whether the patient received the highly emetogenic chemotherapy 
in an inpatient our outpatient setting as well as whether the outpatient setting was affiliated with a hospital 
or a physician office. Prior studies have shown that patients who receive care in an inpatient setting are 
more likely to receive guideline-concordant antiemetics, especially in the acute setting. (34, 39) This may 
be because providers can ensure that patients take their antiemetic medication in an inpatient setting if all 
medications were received in the inpatient setting (versus picking up antiemetics at a community 
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pharmacy). However, inpatient chemotherapy is associated with lower patient satisfaction and higher 
costs.(150-153) Furthermore, cancer care in an outpatient setting affiliated with a physician’s office is 
associated with lower costs than with a hospital, which may be due to hospitalizations and billing 
practices; however, no other differences in chemotherapy care patterns exist.(154-156) Please note that 
because we are unable to discern the type of chemotherapy administered in an inpatient setting in this data 
set, whether the chemotherapy was administered in a physician-affiliated or hospital-affiliated outpatient 
setting will be examined. Notably, supportive cancer care including antiemetic use was not examined. 
Another factor associated with treatment and guideline concordance, but not measured in this research 
project include whether the institution where care was provided had participated in antiemetic 
research.23) 
2.4.1.2 Environment: External Environment 
The external environment includes geographic region as well as whether care is delivered in a rural or 
urban setting. Many studies have shown that there is large regional variation in terms of the availability of 
cancer care including National Cancer Institute (NCI) designated comprehensive cancer centers, 
Commission on Cancer (CoC) Accredited Hospitals, academic-medical centers, and any specialized 
cancer care.(157) Travel time to a NCI designated comprehensive cancer center, which includes access to 
a full range of diagnostic and treatment services as well as cutting-edge novel treatments that may not be 
available elsewhere, was 5 times, 3 times, and 2 times longer in the south, west, and Midwest respectively 
compared to the Northeast. The Northeast also had the highest per capita number of oncologists.(157) The 
2003 Institute of Medicine Report on “Unequal treatment: Confronting Racial And Ethnic Disparities In 
Health Care” stated that quality of care at rural hospitals is lower than urban teaching hospitals 
highlighting the gap between rural and urban care.(158) Patients who received care in a rural setting were 
more likely to receive over-prescribing compared to those in an urban setting.(38) Furthermore, increased 
rurality was associated with increased risk of cancer-related death.(159) Additionally, gaining access to 
cancer care in a rural setting is challenging given the limited availability of care professionals and 






Figure 2.2 Adapted Andersen’s Behavior Model Used to Examine Patterns of Antiemetic Prescribing, Predictors of Guideline-Concordant 
Antiemetic Prescribing, and Cost-Effectiveness of CINV Strategies in Cancer Patients Initiating Highly Emetogenic Chemotherapy 
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2.4.2 Conceptual Model: Population Characteristics 
2.4.2.1 Population Characteristics: Pre-disposing Characteristics 
Studies have identified the pre-disposing characteristics gender, age, and employment status as 
predictors of guideline-concordant antiemetic use. (32, 34, 38, 39) In general, female patients are more 
likely to receive guideline concordant antiemetic products and breakthrough therapy compared to men 
across CINV-risk as well as in high CINV-risk chemotherapy. Only one study found that male patients 
were more likely to receive prophylactic antiemetics than women in the delayed phase. (32, 34, 39) 
Additionally, women are more likely to be over-prescribed antiemetics compared to men.(38) Two 
potential reasons for this are 1) women are more likely to use preventative care services and cancer care 
and 2) women are known to be at higher risk for CINV.(4, 162) While conflicting results exist, generally, 
younger patients were more likely to receive the guideline-concordant antiemetics compared to older 
patients, likely because being under 50 is associated with higher risk of CINV. (4, 32, 34, 39, 43, 74) 
Across cancer care and guideline-concordance studies, it has been shown that black patients receive 
worse care than white patients and patients with a lower deprivation index (based on educational 
opportunities, labor force skills, economic, and housing conditions) had higher cancer-related 
mortality.(45, 46, 159) Unfortunately, the data used for the proposed study does not include race or 
socioeconomic status. Other patient-level predictors of guideline-concordance that are not measurable in 
this dataset include lower educational levels and lower consumption of alcohol.(38, 136)  
2.4.2.2 Population Characteristics: Enabling Resources 
Prior studies have demonstrated that the health insurance type and whether the chemotherapy was 
administered in/out of network influence guideline concordant antiemetic-use. Related to health 
insurance, patients on a health maintenance organization plan or a high-deductible health plan were more 
likely to receive over-prescribing of antiemetics compared to a fee-for-service plan.(38) These are 
surprising findings given that 1) enrolling in a high deductible health plan generally results in lower 
healthcare utilization including prescription drug use and 2) by definition, managed care organizations 
aim to prevent unnecessary healthcare resource use.(163, 164) Patients who receive chemotherapy out-of-
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network are less likely to receive over-prescribing of antiemetics, possibly due to higher out-of-pocket 
expenses associated with out-of-network care.(165) Studies have also shown that as out-of-pocket costs 
increase, medication adherence generally decreases.  
Finally, because we only have co-pay and deductible data on drugs filled, we aim to use insurance 
generosity as a surrogate of the effect of co-pay and/or deductibles on antiemetic use, as it hypothesized 
these out-of-pocket costs could impact guideline adherence.(166) We are distinguishing creating separate 
measures for prescription drug versus medical benefit insurance generosity as antiemetics can be 
administered orally and covered through the prescription drug benefit or intravenously and covered 
through the medical benefit. 
2.4.2.3 Population Characteristics: Need 
Prior studies have shown that need variables such number of concomitant medication use, number 
of comorbid conditions, cancer type, year of chemotherapy administration, quarter of chemotherapy 
administration, and prior antiemetic use are associated with guideline concordance. Antiemetic overuse 
decreased with an increased number of concomitant medications.(38) Interestingly, studies have also 
shown that patients with cancer and other comorbidities are less likely to receive treatment, but among 
those that do, they are over-treated, though this does not include supportive care.(167) Furthermore, it is 
known that patients with multiple chronic conditions and more concomitant therapies have lower 
medication adherence due to treatment burden.(168, 169) Prior studies have shown that chemotherapy 
type is associated with guideline-concordance. Specifically, studies have found that patients on 
anthracycline (epirubicin or doxorubicin) and cyclophosphamide combination were more likely to receive 
guideline-concordant care compared with cisplatin-based chemotherapy.(34) Studies have also shown that 
certain types of cancer are associated with higher rate of antiemetic guideline concordance including solid 
tumor, kidney cancer, myeloma and cervical cancer.(32, 39) While cancer type is available in the dataset, 
we anticipate it being collinear with chemotherapy type, and are not including it in the model. 




Year of chemotherapy administration is also associated with guideline-concordance – this may be 
the result of new guideline diffusion and/or new product entrance.(45) While not specifically examined in 
relation to antiemetics in prior research, we hypothesize that the quarter in which chemotherapy is 
administered may be a predictor of concordance. Specifically, patients may have reached annual out-of-
pocket costs in later quarters, and more likely to fill guideline-concordant antiemetic treatments.  Prior 
antiemetic use should also be included in the conceptual model. Specifically, antiemetics used to prevent 
chemotherapy induced nausea and vomiting can also be used to prevent nausea and vomiting in other 
conditions such as gastroenteritis, as well as nausea and vomiting that is the side-effect of other drugs 
such opioids.(170, 171) Notably, patients on opioids were more likely to receive guideline-concordant 
antiemetics than those that are not, because opioids have their own risk of nausea and vomiting.(34) 
Additionally, prior chemotherapy or radiation induced nausea and vomiting is a risk factor for future 
CINV.(4, 74) Studies have shown that patients with prior nausea and vomiting are less likely to receive 
guideline-concordant antiemetic regimens, but patients undergoing later cycles of chemotherapy are more 
likely to receive guideline-concordant antiemetic regimens, likely responding to prior experience.(34, 36, 
43) While this data set does not reliable capture prior nausea and vomiting related to the chemotherapy or 
radiation, we will use prior chemotherapy (oral or IV) as well as prior or radiation therapy exposure as a 
proxy. Additionally, we hypothesize that physicians might be more diligent in prescribing guideline-
concordant antiemetics to patients who are undergoing concomitant radiation therapy and chemotherapy. 
Notably, guidelines recommend that when radiation and chemotherapy are combined, the chemotherapy 
regimen dictates the prophylactic antiemetic regimen.(20) Time to chemotherapy initiation following 
diagnosis has also shown to be a predictor of guideline-concordant, but is not measured in this 
dataset.(45)  
2.4.3 Conceptual Model: Behavior 
The primary behavior measured is use of health services or, specifically, appropriate antiemetic 
use. Antiemetic use will be stratified by whether products were filled in the acute (day 1) or delayed 
phase (days 2-5) as well as whether products were guideline-concordant. 
 
49 
2.4.4 Conceptual Model: Outcomes 
The outcomes of this model are based on evaluated and perceived health status. Specifically, the 
evaluated health status is the cost associated with CINV-related healthcare utilization. This includes 
rescue antiemetic use, emergency department visits, inpatient visits, outpatient visits, and ordered labs.  
Perceived health status will be measured using quality-adjusted life years, based on utilities.  
2.5 Conclusion 
In conclusion, chapter 2 provides a history of antiemetic availability and use in the United States 
and summarizes the literature associated with antiemetic prescribing, antiemetic guideline-concordance, 
and antiemetic cost-effectiveness. First, with regard to prescribing and assessing guideline-concordance, 
most studies take place in Europe or Asia, which have different availability of products and healthcare 
systems. As such these studies have limited generalizability to the United States. Furthermore, studies in 
the US that have examined prescribing and concordance in the US have limitations in that they only 
examine over-prescribing, do not distinguish between over and under-prescribing, or use targeted sub-
populations (i.e., breast cancer and a southeast practice). (22, 38, 45) The proposed project aims to fill 
these gaps by assessing antiemetic use and concordance (including over prescribing and under 
prescribing) among patients initiating highly emetogenic chemotherapy. Second, there are several 
guideline-concordant antiemetic regimens for patients initiating highly emetogenic chemotherapy. While 
the cost-effectiveness of aprepitant-based strategies versus 5HT3A-based strategies is established, no 
studies have compared the cost-effectiveness of all NK1s. As such, it is important to compare the cost 
effectiveness across these regimens. (53-58)  
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CHAPTER 3: METHODS 
Chapter 3 outlines the methods used in this dissertation including the data source, study design, 
variables, and statistical analysis by aim.  
3.1 Aim 1: To characterize antiemetic use (including types, regimens, and concordance) in patients 
diagnosed with cancer who newly initiated highly emetogenic, intravenous chemotherapy from 
2013-2015. 
3.1.1 Data Source 
We used the IBM Watson’s/Truven’s MarketScan Commercial Claims and Encounters Database 
(Commercial Claims Database) and Medicare Supplemental and Coordination of Benefits (MCOB) for 
patients initiating highly emetogenic chemotherapy between January 2013 through December 2015. The 
Commercial Claims Database includes a nationally representative sample of patients with employer-
sponsored insurance in the US.(172) The Medicare Supplement data represents retirees on Medicare with 
employer-sponsored supplemental plans and largely includes fee-for-service plan data. The specific 
research files used were enrollment, inpatient services, outpatient services, and prescription drugs, which 
include patient-level data on enrollment, clinical utilization, and expenditures.(172) Files were linked 
based on unique enrollee ID.  
The study aims were reviewed by the University of North Carolina at Chapel Hill’s Institutional 
Review Board (IRB) and are exempt. 
3.1.2 Study Design – Aim 1 
This aim used a prospective cohort study design using retrospective data.  
3.1.3 Study Cohort – Aim 1 
The study population was adult patients (age 18-64) with cancer who newly initiated highly 
emetogenic chemotherapy between January 2013 and December 2015 (Figure 3.1). We applied several 
inclusion/exclusion criteria. First, we identified adult patients’ first use of a highly emetogenic 
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intravenous chemotherapy using the J-Codes listed in Table 3.1 in the outpatient files between 2013 and 
2015.(173, 174) Highly emetogenic chemotherapies were identified using NCCN and ASCO 
guidelines.(19, 20, 52) Because we do not have data on body surface area, we assigned chemotherapies 
that are assigned risk based on quantity per body surface area to the highly emetogenic group when 
relevant.(38)  
Figure 3.1 Identification of First Highly Emetogenic Chemotherapy Use 
  
 
Second, we required patients to have at least six months of continuous health plan enrollment prior to the 
index chemotherapy treatment date (first observed chemotherapy treatment in the study period) to ensure 
they were newly initiating highly emetogenic chemotherapy, and to have a follow-up of at least one 
month after chemotherapy initiation to ensure adequate follow-up time (Figure 3.1). Highly emetogenic 
IV chemotherapy codes were identified using the October 2017 ASP files and the National Cancer 
Institute Chemotherapy Lookup Tables.(175, 176) For patients starting chemotherapy between January 
2013 and March 2013, we required access to data from 2012 to ensure appropriate look-back. Third, we 
required that patients have a primary diagnosis of cancer recorded on the claim with the chemotherapy 
infusion. Cancer diagnosis codes were identified using the Agency for Healthcare Research and Quality 
International Classification of Diseases (ICD)-9 and ICD 10 Clinical Classification Software (CCS)) for 
“neoplasm.” Cancer diagnosis was required, as some chemotherapies may be used off-label for other 
diseases (e.g., bevacizumab for wet age-related macular degeneration (AMD)).(177) Fourth, we excluded 
patients who were pregnant using AHRQ CCS codes (i.e., “Certain conditions originating in the perinatal 
period,” “Complications of pregnancy; childbirth; and the puerperium,” “congenital abnormalities”) in 
patients aged 45 or younger. Fifth, we excluded patients with conditions for which olanzapine is used to 
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treat, including schizophrenia and bipolar disorder using AHRQ CCS codes (i.e., “Mental Illness”). This 
is because we would have been unable to distinguish whether olanzapine was used to treat one of these 
conditions or to prevent CINV, leading to potential exposure misclassification. Finally, we required that 
MarketScan included the patients’ prescription drug file to ensure that “no fills” were in fact due to a lack 
of filling and not missing data. 
Table 3.1 J-Codes for Intravenous Chemotherapy Administration with Risk of Highly Emetogenic 
Chemotherapy in 2015(19, 133, 175, 176)**  
IV Chemotherapy  JCode1 




































Ifosfamide ≥ 2 g/m2per dose * C9427 J9208 
Mechlorethamine J9230 
Streptozocin J9320 
AC combination defined as either doxorubicin, 
idarubicin or epirubicin with cyclophosphamide 
See Above 
*Denotes highly emetogenic chemotherapy classification only in NCCN 
**While 2011 ASCO Guidelines include dactinomycin as highly emetogenic, 2015 NCCN guidelines classify it as 
highly emetogenic in certain patients, but do not specify the characteristics of those patients. Furthermore, 2017 
ASCO guidelines not only exclude dactinomycin from the highly emetogenic category, but also from the guideline 
altogether. As such, dactinomycin is not included in this analysis given the ambiguity related to when it is 




3.1.4 Measures – Aim 1 
This aim describes type of antiemetic (i.e., product, class, and administration route) filled, 
number of antiemetic products filled, as well as regimens filled and their associated costs by 
commercially insured and Medicare insured individuals who received highly emetogenic chemotherapy in 
the United States between 2013 and 2015. Guideline concordance was also assessed.  
3.1.4.1 Antiemetic Identification 
To identify antiemetics filled, we created person-level binary indicators for each antiemetic 
product (0=no/1=yes), including prophylactic and breakthrough.(38) Antiemetics were identified using J-
codes for intravenously administered products and National Drug Codes (NDC) codes for oral products in 
the outpatient file as well as prescription drug files (Table 3.2).(38) NDC codes were identified using the 
Red Book in IBM Watson’s / Truven’s MarketScan by conducting text string searches for each product’s 
generic name. While orally administered products should be included in the prescription drug files and 
intravenous products should be listed in the outpatient medical files, we checked all files for both 
prescription and intravenous claims to ensure complete capture of products filled.  
Intravenously (IV) administered products were assessed on the day of HEC administration. Post-
hoc boundary identification was necessary to determine the look-back period for oral antiemetic use, as 
physicians often prescribe antiemetics and chemotherapy simultaneously, well in advance of the 
chemotherapy administration date. Often the antiemetic regimen is filled immediately, while the use of 
payer management tools, such as prior authorization, delay chemotherapy regimen filling. To identify the 
boundaries, we created a histogram of preventative antiemetic fills during the study period (six months 
prior to highly emetogenic IV chemotherapy administration) for both study populations (Appendix Table 
A.1 and Appendix Table A.2). Subsequently, the number of days at which 75% of antiemetics were filled 
before the date of highly emetogenic intravenous chemotherapy administration was used as the fill date 
boundary (Figure 3.2). This was -32 days and -53 days prior to first IV HEC administration for the CCAE 
and Medicare Supplement populations.  
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J1100 Dexamethasone IV 
J7312 Dexamethasone intra implant 
J8540 Dexamethasone oral 
5HT3A**  
J2405 Ondansetron IV 
Q0162 Ondansetron oral 
J1626 Granisetron IV 
Q0166 Granisetron Oral 
J1260 Dolasetron IV* 
Q0180 Dolasetron Oral 
J2469 Palonosetron IV 
NK1 
J8501 Aprepitant Oral 
J1453 Fosaprepitant IV 
J8670 Rolapitant 
Q9981 Rolapitant 
J8655 Netupitant / Palonosetron Combination 
Q9978 Netupitant / Palonosetron Combination 
Q0181 Unspecified oral form of an IV antiemetic substitute 
Atypical Antipsychotic 
J2358 Olanzapine** 
Typically Used as Rescue Products for Breakthrough CINV 
Dopaminergic Antagonists 
J2765 Metoclopramide IV 
J0780 Prochlorperazine IV 
Q0164 Prochlorperazine Oral 
Q0165 Prochlorperazine Oral 
J2550 Promethazine IV 
Q0169 Promethazine Oral 
Q0170 Promethazine Oral 
J1630 Haloperidol IV 
J1631 Haloperidol Decanoate IV 
Cannabinoids 
Q0167 Dronabinol Oral 
Q0168 Dronabinol Oral 
Benzodiazepine 
J2060 Lorazepam IV 
*No longer used for CINV as of 2011(179) 







Figure 3.2 Antiemetic Look-back Period  
 
 
 Primary Characterization Analysis: Antiemetics Filled for CINV Prophylaxis or in 
Anticipation of Rescue Therapy Necessity 
Characterization (i.e., product, class, administration route, and patterns) of antiemetics filled for 
CINV prophylaxis or in anticipation of needing rescue therapy ranged from the beginning of the look-
back period through day 1 for oral products and day 1 for IV products. We also calculated the associated 
total and out-of-pocket costs (i.e., deductible + copay + coinsurance) based on the transactional prices 
available in the data.  All costs were inflation-adjusted to 2016 USD using the medical component of the 
Consumer Price Index.  Claims with “zero-dollar” total costs or negative copay, deductible, coinsurance, 
or net pay costs were excluded.  
 Secondary Characterization Analysis: NK1 Use in the Post Period 
Guidelines recommend that NK1 only be used as prophylaxis and not as rescue medication. In 
this secondary analysis, we assessed the use of NK1 in the five days following IV chemotherapy 
administration to assess potential over-use. We assumed products filled during this post-period are likely 
used as rescue medication. 
3.1.4.2 Guideline Concordance 
To assess guideline concordance for preventing CINV in patients initiating highly emetogenic 
chemotherapy, we compared the combination of antiemetic products identified in Section 
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3.1.4.1.1(Antiemetics Filled for CINV Prophylaxis or in Anticipation of Rescue Therapy Necessity) 
against the most recent ASCO and NCCN antiemetic guidelines in 2015 (Table 3.3).(19, 133)  These 
guidelines were used as the reference given that our study period ranges from 2013 to 2015. We also 
examined the frequency of products used by class to determine which products are most and least 
frequently used among guideline-concordant users. Some chemotherapy regimens (i.e., 
cyclophosphamide only and anthracycline only regimens) are considered highly emetogenic based on a 
surface area doing threshold level, which was not available in the claims data. As a result, we also 
assessed under-use by type of chemotherapy received (i.e., anthracycline + cyclophosphamide on the 
same day, cyclophosphamide only, anthracycline only, and other).  
3.1.5 Data Analysis – Aim 1 
Descriptive statistics were used to assess patterns of use as well as guideline-concordant 
antiemetic drug use in newly diagnosed adult patients with cancer who initiated highly emetogenic 
chemotherapy. Mean/standard deviation and median/interquartile ranges were provided for cost variables. 
Analyses were run on the commercially insured and Medicare Supplement data sets separately. The two 
data sets are representative of two very different populations, which may result in different factors 
influencing their antiemetic prescribing. In fact, a prior study found that patients enrolled in Medicare 
were less likely to receive over-prescribing of antiemetics compared to commercially insured 
patients.(38)  
3.1.5.1 Power Calculation 






Table 3.3 NCCN and ASCO Guideline-Concordant Strategies*(19, 133) 
Strategy Number # 1 2 3 4 5 6 7 
Acute Day 1 
Aprepitant               
Fosaprepitant               
Rolapitant               
NEPA               
Olanzapine               
Palonosetron               
Any 5HT3A               
Dexamethasone               
Delayed 
Day 2 
Aprepitant               
Fosaprepitant               
Rolapitant               
NEPA               
Olanzapine               
Palonosetron               
Any 5HT3A               
Dexamethasone               
Day 3 
Aprepitant               
Fosaprepitant               
Rolapitant               
NEPA               
Olanzapine               
Palonosetron               
Any 5HT3A               
Dexamethasone     `         
Day 4 
Aprepitant               
Fosaprepitant               
Rolapitant               
NEPA               
Olanzapine               
Palonosetron               
Any 5HT3A               
Dexamethasone               
Day 5 
Aprepitant               
Fosaprepitant               
Rolapitant               
NEPA               
Olanzapine               
Palonosetron               
Any 5HT3A               
Dexamethasone               




3.2 Aim 2: To identify predictors of antiemetic under-use in patients diagnosed with cancer and 
newly initiating highly emetogenic, intravenous chemotherapy. 
3.2.1 Data Source – Aim 2 
Aim 2 used the same data sources as Aim 1. This data source is described in section 3.1.1.  
 
3.2.2 Study Design – Aim 2 
This aim used the same design outlined in section 3.1.2 to assess predictors of guideline under-
use (Table 3.6). We calculated frequencies for each covariate to assess variation and missing data. How 
we handled missing data for each variable is described in section 3.2.4.1. 
3.2.3 Study Cohort – Aim 2 
Aim 2 used the same study cohort as Aim 2 except that patients had to initiate highly emetogenic 
chemotherapy on or before October 2015 (as opposed to on or before December 2015). This is because 
one of the covariates described in section 3.1.4.2 uses an algorithm using ICD-9 codes that has not yet 
been translated for use in ICD-10 codes, and ICD-10 went into effect in October 2010. 
3.2.4 Measures – Aim 2 
The variables measured for this aim are described in Table 3.6. The justification for the 
dependent and independent variables are described in section 3.2.3.1 and 3.2.3.2, respectively.  
3.2.4.1 Dependent Variable 
Aim 1 has one outcome variable, guideline concordance, with two categories: antiemetic under-
use and guideline-concordant antiemetic use. Identification of antiemetics and their level of concordance 
are detailed earlier, in sections 3.1.4.1 and 3.1.4.2, respectively.  
3.2.4.2 Independent Variables 
The independent variables in Table 3.5 were considered for model inclusion as potential 
predictors of antiemetic under-use. Specifically, these variables are organized as environmental factors 
(healthcare system and external environment) and population characteristics (pre-disposing, enabling, or 
need characteristics) and described below. This categorization aligns with Andersen’s Behavioral Model 
of Health Services Use as described in Section 2.4 
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Table 3.4 Definition and Characteristics of Dependent and Independent Variables 




















Geographical Setting Binary Enroll 
Urban (Municipal Statistical Area > 0) / 
Rural (Municipal Statistical Area = 0) 
Region Categ Enroll 






Age Binary Enroll 18-50, 50-64, 65-75, 75-85, 85+ 
Gender Binary Enroll Male / Female 
Enabling 
Resources 
Health Insurance Type Categ Enroll 
Point of Service, Health Maintenance 
Organization, Preferred Provider 
Organization, Consumer-driven Health 
Plan / High Deductible Health Plan, 
Other 
Insurance Generosity – 
Intravenous Medication 
Categ IP/OP No/Poor/Fair Coverage, Good Coverage 
Insurance Generosity – 
Prescription Drug 
Categ PD No/Poor/Fair Coverage, Good Coverage 
Chemotherapy Network Binary OP In-Network / Out-of-network 
Year of Chemotherapy Categ OP 2013, 2014, 2015 
Chemotherapy Quarter Categ OP Quarter 1 / 2 / 3 / 4 
Need 
Chemotherapy Type Categ OP 
Anthracycline Only, Cyclophosphamide 
Only Anthracycline + 
Cyclophosphamide, Carmustine, 
Cisplatin and Other 
Prior Antiemetic Use Binary PD Yes/No 
Chronic Condition 
Number 
Count IP/OP NCI Comorbidity Index 
Concomitant Medication 
Number 
Count PD ≥ 0 
Prior IV Chemotherapy  Binary OP Yes/No 
 
Prior or Concomitant 
Radiation Therapy 
Binary IP/OP Yes/No 




3.2.4.3 Environment: Healthcare System 
Healthcare system variables were coded using MarketScan data as follows: 
• Chemotherapy setting is a categorical variable that describes the setting in which 
chemotherapy was received. While 46 settings exist in MarketScan, the main categories 
used were hospital-affiliated outpatient, physician-affiliated outpatient, and other. 
3.2.4.4 Environment: External Environment 
External environment variables were coded using MarketScan data as follows: 
• Geographic setting was assessed as a binary variable (0=urban, 1=rural). Urban areas 
were those that are assigned a metropolitan statistical area (MSA) while rural areas were 
those that do not have an MSA. Assigning urban/rural status was based on the 2010 US 
Census Rural/Urban Classification. Metropolitan statistical area was derived in the 
dataset based on 5-digit employee ZIP code. 
• Region was defined as a categorical variable (0=northeast, 1=north central, 2=south, 
3=west, 4= north central, and 5=unknown). It is derived in the data set based on 5-digit 
employee ZIP code, to which we do not have access. 
3.2.4.5 Population Characteristics Predisposing Characteristics 
Predisposing characteristics were coded using MarketScan data as follows: 
• Age was defined as the patient’s age, in years, on the first day of newly initiating highly 
emetogenic, intravenous chemotherapy. Younger patients tend to be more adherent, 
likely because being under age 50 is a known risk factor for CINV. (4, 32, 34, 39, 43, 74) 
As a result, we dichotomized age in the CCAE population as younger commercial adults 
(18-49) and older commercial adults (50-64). In the Medicare Supplement population, 
patients were categorized as younger Medicare adult (65-74), middle aged Medicare adult 
(75-85), and older Medicare adult (85+). 
• Sex was measured as a binary variable (0=male, 1=female). 
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3.2.4.6 Population Characteristics: Enabling Characteristics 
Enabling characteristics were coded using MarketScan data as follows: 
• Health insurance type was a categorical variable based on the plan type in which the 
patient is enrolled on the first day of newly initiating highly emetogenic, intravenous 
chemotherapy. This variable was coded the same in both CCAE and MCOB raw data and 
was coded as follows: 1 = basic/major medical, 2 = comprehensive, 3 = exclusive 
provider organization (EPO), 4 = health management organization (HMO), 5 = point of 
service (POS), 6 = preferred provider organization (PPO), 7 = POS with capitation, 8 = 
consumer-driven health plan (CDHP), and 9 = high deductible health plan (HDHP). Due 
to similarities in plan structure and administration and limited patient frequencies across 
some categories, we combined the CDHP and HDHP into a single category and created 
an “other” category consisting of basic/major medical, comprehensive, EPO, and POS 
with capitation. As some patients were missing health insurance type, a “missing” 
category was created. 
• Insurance generosity was assessed both for medical benefit and prescription drug benefit. 
Insurance generosity-medical benefit was used as a proxy for copay / deductible for 
intravenously administered antiemetics. (166) Insurance generosity-prescription drugs 
was used as a proxy for copay / deductible for oral antiemetics. Insurance generosity was 
defined as the average proportion of patient cost sharing for all intravenous drugs in the 
inpatient and outpatient setting for medical benefit and all prescription drugs for 
prescription drug benefit in the six months prior to initiating highly emetogenic 
chemotherapy. Claims with “zero-dollar” total costs or negative copay, deductible, 
coinsurance, or net pay costs were dropped. The following thresholds were initially used: 
>0.8 = no / poor coverage, 0.20-0.80 = fair coverage, <0.20 = good coverage. However, 
after assessing category distributions, modifications were necessary. First, there were a 
limited number of patients in the Medicare Supplement population with “no/poor” 
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prescription drug coverage, so it was combined with “fair” in both populations and 
benefits for consistency. Second, we were unable to calculate insurance generosity for the 
prescription drug benefit for some patents in both populations because of a lack of prior 
drug fills. Because this was the case for over 1,000 CCAE patients, a “missing” category 
across both populations in both the medical and prescription drug benefit was created to 
maintain consistency.  However, the frequency of the “missing” category was extremely 
small in the Medicare Supplement population, so it was combined with the “no/poor/fair” 
category in both populations for consistency. We combined “missing” with 
“no/poor/fair” as opposed to “good” because “missing” meant a lack of insurance usage, 
and thus any out-of-pocket cost maximums had likely not been met.  
• Whether chemotherapy was administered in or out of network was coded as a binary 
variable (0=out of network, 1=in network). This was based on whether the network 
provider indicator associated with the new initiation of highly emetogenic chemotherapy 
claim was “yes” or “no” in the data set. A “missing” category was also included for 
patients for whom the network status was unknown. Because out-of-network 
chemotherapy administration is extremely expensive, it was also a proxy for financial 
toxicity. Ultimately, this variable was dropped from the model due to the lack of variation 
(more than 95% of patients were in-network). 
• Year of Chemotherapy Administration was categorical and based on the year of the date 
of the chemotherapy administration claim (0=2013, 1=2014, 2=2015). 
• Quarter of Chemotherapy Administration was coded as a categorical variable based on 
the month of the date of the chemotherapy administration claim (1=Quarter 1 (Jan-Mar), 
2=Quarter 2 (Apr-Jun), 3=Quarter 3 (Jul-Sep), 4=Quarter 4 (Oct-Dec)).  
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3.2.4.7 Population Characteristics: Need Characteristics 
Need characteristics were coded using MarketScan data as follows: 
• Chemotherapy type was categorized based on whether the chemotherapy was 
anthracycline (doxorubicin, epirubicin, idarubicin) and cyclophosphamide–based (i.e., 
administered on the same day), cyclophosphamide only, anthracycline only, carmustine 
or other. These categories reflect chemotherapies that are considered highly emetogenic 
at certain surface area thresholds or in certain combinations (0=Anthracycline + 
Cyclophosphamide, 1=Anthracycline Only, 2=Cyclophosphamide Only, 3=Carmustine, 
4=Other).  Anthracycline only, cyclophosphamide only, and carmustine are surface-area-
based dosing highly emetogenic chemotherapies. 
• Prior antiemetic use was classified as any preventative or breakthrough antiemetic fills 
between the six months prior to the chemotherapy initiation date and the start of the 
antiemetic look-back period (Figure 3.3).  It was denoted using an indicator variable 
(0=No, 1=Yes). Oral products were assessed in the prescription drug file and intravenous 
products were assessed in the outpatient file.  




• The number of chronic conditions was coded as a count variable based on the National 
Cancer Institute Comorbidity Index, which combines the Klabunde comorbidity index, a 
validated algorithm for physician claims data specifically for patients with cancer, and 
the Charleson Comorbidity Index.(180-182) We used a look-back period of six months in 
both the inpatient and outpatient services files. 
• Number of unique concomitant medications was calculated based on the number of 
prescription drugs filled in the 30 days prior to initiating highly emetogenic 
chemotherapy. Preventative and rescue treatment drugs were excluded. Number of 
unique concomitant medications was identified by NDC codes in the prescription drug 
file and mapped back to the Red Book. 
• Prior chemotherapy use (IV) was coded as a binary variable (0=no, 1=yes). It was 
defined as any type of IV chemotherapy within the six months prior to initiating highly 
emetogenic chemotherapy. IV chemotherapy claims were identified in the outpatient 
services file using “J9XX” codes. 
• Prior or concomitant radiation therapy was coded as a binary variable (0=no, 1=yes). It 
was defined as any exposure to radiation therapy six months prior to initiating highly 
emetogenic chemotherapy. Radiation J-codes in the outpatient services files and CPT 
codes in the inpatient services file were identified using the National Cancer Institute 
Radiation Therapy Lookup Tables.  
3.2.5 Data Analysis – Aim 2 
Analyses were conducted in the Commercially Insured and Medicare Supplement populations 
separately. First, we calculated descriptive statistics for each variable in the model. T-tests were used to 
assess differences in continuous outcome variables, and chi-squared tests were used to assess differences 
in categorical variables across antiemetic under-use and guideline-concordant use. Next, we assessed the 
effect of each variable on predicting antiemetic under-use versus guideline-concordant use while all other 
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covariates were held constant. As the outcome is binary, we used a modified Poisson regression. 
Exponentiation of the coefficients provides the relative risk. Though a Poisson distribution is traditionally 
used for count data, it may also be applied to binomial data, though the error term is over-estimated.(183) 
However, this can be corrected if the standard errors are calculated using sandwich estimates or Huber-
White standard errors, and subsequently can directly estimate risks and relative risks. The general 
estimating equation used an independent correlation structure and log link function.  
3.2.5.1 Sensitivity Analysis 
To account for the fact that cheaper generic drugs might have a higher co-pay and/or deductible, 
we ran a sensitivity analysis excluding all oral drugs with a total cost of $50 when calculating the 
prescription drug insurance generosity measure. 
3.2.5.2 Power Calculation 
Based on existing studies, the difference in guideline-concordant use across types of CINV-risk 
ranged from 5 to 25%. Using cancer epidemiology in the US and rates of chemotherapy use, we estimated 
that approximately 5,000 patients will be at risk of CINV in the MarketScan® database. The number of 
patients in the study provided adequate power for calculating effect sizes of at least 5%.  
3.3 Aim 3: To assess the most cost-effective antiemetic regimen for patients diagnosed with cancer 
and who are newly initiating highly emetogenic, intravenous chemotherapy.  
3.3.1 Study Design and Comparators – Aim 3 
Our aim was to prioritize ASCO and NCCN antiemetic guideline recommendations in patients 
initiating highly emetogenic chemotherapy by assessing the health and economic impact through 
conducting a cost-utility analysis. We used a Markov model built in MS Excel to evaluate the following 
antiemetic treatment comparators: 
• NK1 (aprepitant), 5HT3A (first generation: ondansetron, granisetron, and dolasetron and 
second generation: palonosetron), and a corticosteroid (dexamethasone); 
• NK1 (fosaprepitant), 5HT3A (first generation: ondansetron, granisetron, and dolasetron 
and second generation: palonosetron), and a corticosteroid (dexamethasone); 
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• NK1 (rolapitant), 5HT3A (first generation: ondansetron, granisetron, and dolasetron and 
second generation: palonosetron), and a corticosteroid (dexamethasone); 
• Netupitant + palonosetron combination + dexamethasone; 
• Olanzapine + palonosetron + dexamethasone;  
• Olanzapine + aprepitant + 5HT3A + dexamethasone; and 
• Olanzapine + fosaprepitant + 5HT3A + dexamethasone. 
This model reflects only the first chemotherapy cycle because the guidelines of interest are only 
applicable to patients newly initiating highly emetogenic chemotherapy. Prescribers should use patients’ 
experience from their first cycle to inform future antiemetic use.(19, 20, 52). 
3.3.2 Time Horizon and Cycle - Aim 3 
The time horizon for analysis was five days, including the acute phase (day 1) and delayed phase 
(days 2-5), which aligns with the timing of outcomes measured in clinical trials and guideline 
recommendations. Patients transitioned once a day, for a total of five cycles.  
3.3.3 Perspective - Aim 3 
The recommendations from the Panel on Cost-Effectiveness in Health and Medicine are 
considered the gold standard in cost-effectiveness methods in the US. In the 2016 update, the panel 
recommended that models should include both the healthcare perspective and societal perspective.(184) 
As such, we modeled from the 1) US healthcare perspective, which includes direct costs of medical care 
(reimbursed by payer or paid out-of-pocket by patient) and the 2) societal perspective, which includes all 
medical costs (direct and indirect) regardless of who is responsible for the cost or receives the benefit.  
Per the Panel’s recommendations, we included an impact inventory, which lists the formal health care, 
informal health care, and non-health care sector consequences included for each perspective for this 
model (Table 3.5).  Notably, indirect costs were limited to productivity because that was only estimate we 
could find for indirect costs for this population in the literature. 
Because patients with cancer who are commercially insured often reach their out-of-pocket 
maximums, the results from the US healthcare perspective may be applicable to the US commercial payer 
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perspective. This is further supported by the fact that the main difference between the healthcare and 
commercial payer perspectives is the cost of the healthcare resource use associated with each health state, 
which would be modeled by reducing the total costs by a standardized percentage. This would not alter 
the ICER. In addition to having no out-of-pocket maximums, the reimbursement of the medical benefit 
and prescription drug benefit for patients covered by Medicare is different. Exploring the cost-
effectiveness across guideline-concordant antiemetic options for patients initiating highly emetogenic 
chemotherapy in the Medicare population is an important area of future research.  
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Table 3.5 Impact Inventory*(184) 
Sector Type of Impact 
Perspective 
Healthcare Sector Societal 
Formal Health Care Sector 
Health 
Health Outcomes (Effects) 
CINV Events X X 
HRQoL X X 
Medical Costs 
Paid by third-party payer X X 




Cost of unpaid lost productivity 
due to illness 
 X 
*No inputs available on informal health care sector costs 
3.3.4 Hypothetical Cohort, and Patient Flow - Aim 3 
The hypothetical cohorts consist of 100,000 adults aged 18-65 with cancer who are being newly 
treated with single-day, highly emetogenic chemotherapy. The Markov model and how patients flow 
through it are described in Figure 3.4.(143, 144) In the acute phase (day 1), a patient may experience 
incomplete response (having emesis and/or using rescue medication), complete response (no emesis + no 
use of rescue medications), or complete protection (no emesis + no use of rescue medication + no 
significant nausea (Visual Analogue Scale score of <25 mm)). Notably, complete response and complete 
protection are modeled as two distinct, mutually exclusive health states with the difference being whether 
significant nausea is experienced.  Subsequently, in the delayed phase (days 2-5), patients may remain in 
the same health state or transition to a worse health state (i.e., complete protection to complete response, 
complete protection to incomplete response, or complete response to incomplete response). This patient 
flow model and assumptions regarding phases of protection were utilized to provide consistency between 




Figure 3.4 Patient Flow for Patients Who Initiate High-CINV Risk Chemotherapy in A Markov 
Model(143, 144) 
 
3.3.5 Clinical Inputs - Aim 3 
3.3.5.1 Clinical Inputs - Source 
As mentioned, efficacy measures for guideline-concordant antiemetic prescribing include the 
probability of having one of three response options: complete response, complete protection, or 
incomplete response. These transition probabilities, in addition to dosing and administration schedules 
(Table 3.6), were obtained from randomized clinical trials (Table 3.7 and 3.8).  Many of the studies were 
used to seek Food and Drug Administration approval and supported “high quality of evidence” guideline 
recommendations by ASCO and/or NCCN. Trials were identified based on existing meta-analyses that 
were supplemented by a literature review. ((84, 85, 117, 118, 123, 124) The meta-analysis results were 
ultimately not used as inputs because the baseline effectiveness was not specified, involved several 
indirect comparisons, had inconsistent results across NK1 comparisons, combined various olanzapine 





Table 3.6 Highly Emetogenic Chemotherapy – Acute and Delayed Emesis Prevention (Adapted 
from NCCN Guidelines)(19, 20, 52) 
Acute (Day 1) Delayed (Days 2-4) 
• Aprepitant 125 mg PO once 
• 5HT3RA (Choose one) 
− Palonosetron .25 mg IV once 
− Granisetron 10 mg SQ once, or 2mg PO once, or 0.01 mg/kg (max 1 mg) IV 
once, or 3.1 mg/24-h transdermal patch applied 24-48 h prior to first CT dose 
Ondansetron 16-24 mg PO once, or 8-16 mg IV once 
− Dolasetron 100 mg PO once 
• Dexamethasone 12 mg PO/IV once 
• Aprepitant 80 mg PO 
daily on days 2,3 
• Dexamethasone 8 mg 
PO/IV daily on days 
2,3,4 
• Fosaprepitant 150 mg IV once 
• 5HT3RA (Choose one) 
− Palonosetron .25 mg IV once 
− Granisetron 10 mg SQ once, or 2mg PO once, or 0.01 mg/kg (max 1 mg) IV 
once, or 3.1 mg/24-h transdermal patch applied 24-48 h prior to first CT dose 
Ondansetron 16-24 mg PO once, or 8-16 mg IV once 
− Dolasetron 100 mg PO once 
• Dexamethasone 12 mg PO/IV once 
• Dexamethasone 8 mg 
PO/IV daily on day 2, 
then dexamethasone 8 
mg twice daily on days 
2,3,4 
• Rolapitant 180 mg PO once 
• 5HT3RA (Choose one) 
− Palonosetron .25 mg IV once 
− Granisetron 10 mg SQ once, or 2mg PO once, or 0.01 mg/kg (max 1 mg) IV 
once, or 3.1 mg/24-h transdermal patch applied 24-48 h prior to first CT dose  
− Ondansetron 16-24 mg PO once, or 8-16 mg IV once 
− Dolasetron 100 mg PO once 
• Dexamethasone 12 mg PO/IV once 
• Dexamethasone 8 mg 
PO/IV twice daily on 
days 2,3,4 
• Netupitant 300 mg/palonosetron 0.5 mg PO once 
• Dexamethasone 12 mg PO/IV once 
• Dexamethasone 8 mg 
PO daily on days 2,3,4 
• Olanzapine 10 mg PO once 
• Palonosetron .25 mg IV once 
• Dexamethasone 20 IV once 
• Olanzapine 10 mg PO 
daily on days 2,3,4 
• Aprepitant 125 mg PO  
• 5HT3RA (Choose one) 
− Palonosetron .25 mg IV once 
− Granisetron 10 mg SQ once, or 2mg PO once, or 0.01 mg/kg (max 1 mg) IV 
once, or 3.1 mg/24-h transdermal patch applied 24-48 h prior to first CT dose 
Ondansetron 16-24 mg PO once, or 8-16 mg IV once 
− Dolasetron 100 mg PO once 
• Dexamethasone 12 mg PO/IV once 
• Olanzapine 10 mg PO once 
• Aprepitant 80 mg PO 
daily on days 2,3 (if 
aprepitant on day 1) 
• Dexamethasone 8 mg 
PO/IV daily on days 
2,3,4 
• Olanzapine 10 mg PO 
daily on days 2,3,4 
• Fosaprepitant 150 mg IV once 
• 5HT3RA (Choose one) 
− Palonosetron .25 mg IV once 
− Granisetron 10 mg SQ once, or 2mg PO once, or 0.01 mg/kg (max 1 mg) IV 
once, or 3.1 mg/24-h transdermal patch applied 24-48 h prior to first CT dose 
Ondansetron 16-24 mg PO once, or 8-16 mg IV once 
− Dolasetron 100 mg PO once 
• Dexamethasone 12 mg PO/IV once 
• Olanzapine 10 mg PO once 
• Aprepitant 80 mg PO 
daily on days 2,3 (if 
aprepitant on day 1) 
• Dexamethasone 8 mg 
PO/IV daily on days 
2,3,4 
• Olanzapine 10 mg PO 







Table 3.7 NK1 Randomized Clinical Trial Results in Adult Patients Initiating Highly Emetogenic Chemotherapy 
   Complete Response Complete Protection 
Trial  Pt Number Regimens* Acute % Delayed % Overall % Acute% Delayed % Overall % 
2003 Chawla(185) 131 A+D+O  82% 73% 71% 79% 67% 64% 
126 D+O  71% 44% 44% 67% 41% 40% 
2003 de Wit(186) 80 A+D+O  NA  NA  64% NA  NA  NA  
84 D+O  NA  NA  49% NA  NA  NA  
2003 Hesketh (187) 260 A+D+O  89% 75% 73% 85% 66% 63% 
260 D+O  78% 56% 52% 75% 52% 49% 
2003 Poli-Bigelli(188)  261 A+D+O  83% 68% 63% 80% 61% 56% 
263 D+O  68% 47% 43% 65% 40% 41% 
2005 Warr(189)  433 A+D+O  76% 55% 51% NA NA NA 
424 D+O  69% 49% 42% NA NA NA 
2006 Schmoll (113) 243 A+D+O  88% 74% 72% NA NA NA 
241 D+O  79% 63% 61% NA NA NA 
2008 Herrington(190)  27 A+D+P  70% 59% 52% NA NA NA 
16 D+P  56% 31% 31% NA NA NA 
2009 Roila(191)  327 C+D+O  92% 78% 78% NA NA NA 
82 A+D+O  90% 76% 76% NA NA NA 
2009 Yeo(192)  62 A+O+D  72% 64% 47% 67% 56% 39% 
62 O+D  73% 58% 42% 73% 58% 42% 
2010 Takahashi(193)  146 A+G+D  87% 73% 71% 84% 65% 62% 
150 G+D  83% 52% 50% 82% 44% 43% 
2011 Grunberg  (115) 1109 F+O+D  89% 74% 72% NA NA NA 
1138 A+O+D  88% 74% 72% NA NA NA 
2013 Saito(194)  173 F+G+D  94% 65% 64% 90% 58% 58% 
167 G+D  81% 49% 47% 77% 46% 44% 
2014 Aapro(195)  724 N+P+D  88% 77% 74% 82% 67% 64% 
725 P+D  85% 70% 67% 81% 60% 58% 
2014 Hesketh(196)  135 N+P+D  99% 90% 90% 97% 84% 83% 
134 A+O+D  95% 89% 87% 90% 82% 78% 
2014 Hu(197)  204 A+G+D  79% 74% 70% NA NA NA 
207 G+D  79% 59% 57% NA NA NA 
2015 Rapoport (HEC)(198)  90 R+D+O  88% 64% 63% 52% 33% 30% 
91 D+O  67% 49% 47% 49% 24% 23% 
2015 Rapoport 
(HEC1)(199)  264 R+G+D  84% 73% 70% 80% 66% 63% 






   Complete Response Complete Protection 
Trial  Pt Number Regimens* Acute % Delayed % Overall % Acute% Delayed % Overall % 
2015 Rapoport 
(HEC2) (199)  271 R+G+D  83% 70% 68% 82% 65% 63% 
273 G+D  79% 62% 60% 78% 58% 57% 
2016 Ando(200)  48 
A+D+P/G/ 
AZ  98% 88% 85% NA NA NA 
45 
F+D+P/G/AZ
  98% 84% 82% NA NA NA 
2013 Wenzell(201) 20 A+P+D 75% 65% 65% NA NA NA 
20 A+O+D 55% 45% 40% NA NA NA 
Incomplete Response = 1- Complete Response 
A: Aprepitant F: Fosaprepitant R: Rolapitant N: Netupitant / Palonosetron Combination D: Dexamethasone G: Granisetron O: Ondansetron D: Dolasetron P: Palonosetron Dual: 







Table 3.8 Olanzapine Randomized Clinical Trial Results in Adult Patients Initiating Highly Emetogenic Chemotherapy (Adapted from 
Yang 2017)(124) 
  Complete Response 
Trial Pt Number Regimens*  Acute % Delayed % Overall % 
Tan et al. 2009*(122) 121 O+Aza+D 94% 84% 84% 
108 Aza+D 94% 68% 68% 
Navari et al.,2011(27) 121 O+P+D 97% 77% 77% 
120 A+P+D 87% 73% 73% 
Mizukami et al., 2014(202) 22 O+D+5HT3A+A 100% 100% 100% 
22 D+5HT3A+ A 86% 16% 68% 
Mukhopadhyay et al., 2015(86) 50 O+P+D 98% 96% 94% 
50 P+D 94% 42% 40% 
Shumway et al., 2009(203) 8 O+P+D 75% 63% 44% 
9 A+P+D 44% 56% 20% 
Babu et al., 2016 (120) 50 O+P+D 84% 77% 78% 
50 A+P+D 86% 73% 80% 
Navari et al., 2016(28) 192 O+5HT3A+D+NK1 86% 67% 64% 
188 5HT3A+D+NK1 65% 52% 41% 










-BC LCI UCI 
Acute -
BC LCI UCI 
Delayed 
-BC LCI UCI 
Fos+5HT3A+Dex 0.712 0.640 0.820 0.899 0.890 0.980 0.734 0.650 0.840 
NEPA+Dex 0.767 0.740 0.900 0.900 0.880 0.990 0.790 0.770 0.900 
Rol+5HT3A+Dex 0.678 0.630 0.700 0.842 0.830 0.880 0.702 0.640 0.730 
Olanz+Palo+Dex 0.796 0.440 0.940 0.930 0.670 0.980 0.830 0.770 0.960 
Fos/Apr+5HT3A+Dex+Olz* 0.900 0.641 1.000 0.950 0.859 1.000 0.917 0.672 1.000 
Apr+5HT3A+Dex 0.681 0.400 0.870 0.849 0.550 0.980 0.712 0.450 0.890 
Complete Protection 
Overall 
-BC LCI UCI 
Acute -
BC LCI UCI 
Delayed 
-BC LCI UCI 
Fos+5HT3A+Dex* 0.578 0.520 0.636 0.896 0.806 0.986 0.664 0.520 0.730 
NEPA+Dex 0.668 0.640 0.830 0.846 0.820 0.970 0.584 0.670 0.840 
Rol++5HT3A+Dex 0.582 0.300 0.630 0.768 0.520 0.820 0.700 0.330 0.650 
Olanz+Palo+Dex 0.612 0.300 0.830 0.833 0.520 0.970 0.653 0.330 0.840 
Fos/Apr+5HT3A+Dex+Olz* 0.612 0.300 0.830 0.833 0.520 0.970 0.653 0.330 0.840 
Apr+5HT3A+Dex 0.618 0.390 0.780 0.822 0.670 0.850 0.664 0.560 0.820 
*Unless denoted, confidence intervals are based on the literature. Because complete protection rates for Fos+5HT3A+Dex only had one study, we calculated a 
range using +/-10% of the base case. There was only one study assessing the effectiveness of Apr+5HT3A+Dex+Olz, and we used the relative risk data versus 
the actual complete response probability to calculate the base-case input value. The actual complete response probability was used as the lower confidence 
interval. 
**Incomplete response = 1- Complete Response 







The following search strategy was used: (“generic name of drug”) AND ((“chemotherapy induced nausea 
and vomiting”) OR (“CINV”)).”  Studies where results of patients initiating moderately emetogenic and 
highly emetogenic chemotherapy were combined unless there were no other studies examining the drug 
combination of interest.  Because most strategies’ evidence base included multiple randomized controlled 
studies, effect estimates for antiemetic efficacy were pooled and averaged for the base case clinical inputs 
(Table 3.9).  The ranges of trial-specific estimates were used in the sensitivity analyses. 
3.3.5.2 Clinical Inputs - Assumptions and Manipulations 
The effectiveness of 5HT3As was assumed to be similar in the presence of NK1-based strategies. 
(59, 117, 118) This is because meta-analyses have demonstrated that the effectiveness of 5HT3As is 
similar across first-generation 5HT3As.(59) Furthermore, no study has directly compared the 
effectiveness of NK1s in the presence of palonosetron versus first-generation 5HT3A in a superiority 
trial, though meta-analyses have suggested that the effect is similar if not better in 5HT3As compared to 
palonosetron.(117, 118)  We did not include adverse events in the model because they are minimal and 
similar across strategies.(18, 20)  
The probabilities of entering each of the health states in the acute phase and overall phase were 
used as the transition probabilities for day 1 and day 5, respectively.(143, 144) Because trials typically do 
not report day-specific outcomes, we used linear interpolation between the acute and overall phase to 
calculate event probabilities for days 2-4. Additionally, olanzapine trials did not capture complete 
protection rates. We estimated olanzapine complete protection transition probabilities by averaging the 
pooled complete protection rates of each of the NK1-based strategies. Finally, there is only one study 
comparing the effectiveness of an NK1-based strategy with an olanzapine and NK1-based strategy, 
specifically aprepitant/fosaprepitant. While this study that found that the strategy with olanzapine 
(apr/fos+olz+5HT3A+dex) had statistically significant higher complete response and complete protection 
rates, the NK1-only strategy (apr/fos+5HT3A+dex) had much lower acute and overall complete response 
and complete protection rates than in other studies. To reflect the rest of the evidence base, we used the 
average pooled results of the aprepitant- and fosaprepitant-based strategies and the relative risk from this 
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trial to estimate the complete response and complete protection rates for the olanzapine-based strategy in 
the base case. The actual complete response value of the olanzapine-based strategy was used as the lower 
bound of the range of values in the probabilistic sensitivity analysis. 
3.3.6 Cost Inputs - Aim 3 
3.3.6.1 Cost Inputs - Source 
Input costs were based on healthcare resource use associated with each health state and include 
the direct and indirect costs depending on the perspective. Input costs were identified through a literature 
review and listed in Table 3.10. Direct costs are the costs associated with any healthcare resource use 
including prophylactic antiemetics, rescue antiemetics, inpatient visits, outpatient visits, emergency 
department visits, and laboratory use. While there are many indirect costs (e.g., unpaid care-giver costs, 
transportation costs, social services costs, legal/criminal costs, education costs, etc.), we focused on 
productivity loss, as it is the only source of indirect costs we were able to identify in patients experiencing 
chemotherapy induced nausea and vomiting.(8, 10, 184, 204) 
3.3.6.2 Cost - Assumptions and Manipulations 
All costs were inflation-adjusted to 2016 dollars using the medical component of the Consumer 
Price Index. Given the short time horizon of this study (i.e., five days in the base-case), costs were not 
discounted. It was assumed that resource use among patients with complete response and complete 
protection was the same, as neither outcome had vomiting or used a rescue antiemetic. Because 5HT3As 
have multiple options with a wide range of costs, we used the median product cost (ondansetron generic) 
for the base case unless a 5HT3A is specified. We used the full range of 5HT3A product costs in the 
probabilistic sensitivity analysis. The cost of 10 mg of generic olanzapine was used for the base case, but 
+25% of the brand costs was used as the confidence interval.  Rescue medications also have a wide range 
of options and costs, so we assumed that generic olanzapine and generic ondansetron were used for the 
base case. Again, the full range of product costs was used in the probabilistic sensitivity analysis. For 
other antiemetic products, +/-25% of the base case cost was used for the range. A full list of all antiemetic 
products and their associated costs are listed in Table 2.4.  
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Table 3.10 Direct and Indirect Costs Associated with Antiemetics and CINV (Inflation Adjusted to 
2016 USD) 
Direct Costs Base Case Range  
Preventative Antiemetic Use(15, 18) 
Aprepitant  $649.00  $486.75 $811.25 
Fosaprepitant  $300.00  $225.00 $375.00 
Netupitant  $632.00  $474.00 $790.00 
Rolapitant  $610.50  $457.88 $763.13 
Olanzapine  $10.00  $4.88 $80.78 
All 5HT3A  $6.50  $1.10 $468.16 
Dexamethasone  $3.59  $2.69 $4.49 
Palonosetron  $228.80  $171.60 $286.00 
CINV Event 
HCRU*(2, 8-10)  $1754.60 $1297.55 $2355.41 
Rescue Medication Cost**(18)  $13.00  $6.50 $941.00 
Indirect Costs 
Productivity(8, 10)  $332.74 $72.26 $593.21 
*Inpatient and outpatient services **Olanzapine and ondansetron 
5HT3A: Ondansetron, Dolasetron, Granisetron, Palonosetron 
 
3.3.7 Utilities - Aim 3 
3.3.7.1 Utility Inputs – Source 
Utilities for complete protection, complete response, and incomplete response were obtained from 
previous studies involving patients whose clinical characteristics align with the hypothetical cohort used 
in this model, which is described in 3.3.1 (Table 3.11). Specifically, our cohort and the studies from 
which utilities were derived represent patients initiating chemotherapy for any cancer and assess utilities 
for our specific outcomes of interest.  
3.3.7.2 Utility Inputs - Assumptions and Manipulations 
Given that the model uses day lengths as a cycle, the outcome quality adjusted life days (QALD) was 
used in the model. However, results are presented in both QALYs and QALDs. QALDs are a variation of 
a common measure, QALYs. It was assumed that utility values for a QALY would be the same for a 
quality-adjusted life day, and as such, QALDs were calculated by multiplying the number of days spent in 
each health state by the utility value. QALDs were converted into QALYs by dividing QALD by 365 
days. Utilities were not discounted given the five-day time horizon.  While utility values established in 
 
78 
prior cost-effectiveness studies were used for the base-case, probabilistic sensitivity analysis used the full 
range of potential utility values (Table 3.11).  
Table 3.11 Proposed Utility Values 
State Base Case(58, 144) Range (145, 205-207)* 
Complete Protection 0.90 (.79-1.0) 
Complete Response 0.70 (.60-.76) 
Incomplete Response 0.20 (.18-0.50) 
*Studies used to establish the range of utility values for the base-case. 
3.3.8 Analysis –Aim 3 
The primary outcomes include the costs (US dollars in 2016), Quality Adjusted Life Day, and 
Quality Adjusted Life Years (QALYs) for all guideline-concordant treatment strategies over the analytic 
horizon. These metrics allow us to compare the economic and health impact of both strategies and, if 
indicated (i.e., in the absence of strong dominance), to identify which is more efficient via an incremental 
cost effectiveness ratio (ICER) (i.e., cost/QALY). Because we compared multiple treatment strategies, we 
could not simply calculate the ICER and compare it to a predetermined willingness-to-pay threshold (i.e., 
the traditional $50,000/QALY for the base-case).(208) Instead, we used the following process: 
• Rank alternatives by costs from lowest to highest; 
• Calculate incremental cost-effectiveness ratios; 
• Drop dominated strategy(ies); 
• Drop extended dominated strategy(ies); and 
• Re-rank and re-calculate ICERs.(209, 210) 
3.3.8.1 Sensitivity Analyses - Aim 3 
We conducted three types of sensitivity analyses from the perspective of the US Healthcare 
System. First, we conducted a probabilistic sensitivity analysis using Oracle’s Crystal Ball Excel plugin 
to assess the impact of uncertainty of all clinical, cost, and utility inputs using the minimum and 
maximum values. Specifically, a Monte Carlo simulation with 1000 trials was conducted across the 
ranges of all input variables. Beta distributions were used for clinical inputs and gamma distributions 
were used for cost and utility inputs. Because willingness-to-pay is a fluid concept, we assessed cost-
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effectiveness at a variety of thresholds ranging from $0-$250,000.(184) Higher willingness-to-pay 
thresholds may be acceptable for life-saving treatments such as chemotherapy or immunotherapies.  
These results were displayed using cost effectiveness acceptability curves, which show different 
probabilities of cost effectiveness at differing willingness-to-pay levels. Second, we conducted one-way 
sensitivity analyses for each input variable to identify which variables have the largest impact on cost 
effectiveness, holding all other variables at their base case values. Finally, we conducted scenario 
analyses by removing the olanzapine strategies due to clinicians’ hesitancy toward using olanzapine given 
its safety concerns as well as the limited evidence base supporting this strategy. 
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CHAPTER 4: RESULTS 
4.1 Aim 1 Results 
4.1.1 Aim 1 Results-CCAE Population 
4.1.1.1 Aim 1 – CCAE Population: Cohort Selection 
The inclusion / exclusion criteria used to develop our CCAE study cohort is described in Figure 
4.1. We identified 56,744 adult patients (age 18-64) initiating highly emetogenic chemotherapy between 
2013 and 2015. Of these patients, 43,112 had the required six months of continuous enrollment prior to 
initiating chemotherapy and one-month follow-up. Subsequently, 41,072 patients had a cancer diagnosis 
on the claim associated with the highly emetogenic chemotherapy administration. We then excluded 
1,591 patients for being pregnant and 473 for having a diagnosis of either schizophrenia or bipolar 
disorder. Finally, 7,055 patients who lacked prescription drug data were excluded. The final study 








4.1.1.2 Aim 1 – CCAE Population: Primary Characterization: Antiemetic Fills in the Pre-period 
Approximately 97% of patients (N=31,047) receiving highly emetogenic intravenous 
chemotherapy filled at least one antiemetic drug, with a median of three unique products (Figure 4.2); 
number of antiemetic filled by class by patient is presented in the Appendix 3. Dexamethasone, 5HT3A, 
NK1, and rescue therapies had at least one fill for 85%, 88%, 58%, and 68% of patients (Figure 4.3). The 
number of patients with at least one olanzapine fill in the pre-period was negligible at <1%.  
Of the 119,728 antiemetic claims, aprepitant and fosaprepitant were the primary NK1s filled 
(12% and 88%, respectively), with 0.2% NEPA fills and no rolapitant fills. Among 5HT3As, there were a 
higher proportion of second-generation 5HT3A, palonosetron (67%) versus first-generation 5HT3As 
(33%) fills, and there were limited dolasetron fills (<1%) (Figure 4.4). Preventative products were more 
likely to be intravenously administered (61%) as opposed to orally administered (39%) (not displayed). 
Out-of-pocket costs were generally low across preventative antiemetics, with IV products having $0 
median out-of-pocket costs (Table 4.1). Notably, the oral NK1, NEPA, had a median out-of-pocket cost 
of $52.11. 



























Figure 4.3	Percent of Patients Using At Least One Antiemetic Among All Patients Initiating Highly 
Emetogenic Chemotherapy 
 
First Generation 5HT3A: Ond, Gran, Dol Second Generation 5HT3A: Palo 
NK1: Aprep, Fos, Rol, NEPA (NK1+5HT3A Combo) 
 












































Table 4.1 Total and Out-of-Pocket Costs for Preventative and Rescue Antiemetics* 
    Transactional Cost (2016 USD$) Out-of Pockets (2016 USD$) 
Admin Antiemetic Mean Std Median IQR Ranger Mean STD Median IQR 
Corticosteroid 
IV Dex 20.71 316.03 2.47 5.10 0.71 26.15 0.00 0.00 
Oral Dex 10.50 52.83 6.33 8.57 5.07 6.57 4.36 6.87 
NK1 
Oral Apr 538.93 360.10 447.66 146.10 53.22 74.93 39.24 47.70 
IV Fos 489.57 409.78 330.27 273.02 13.30 55.64 0.00 0.00 
Oral NEPA 604.37 302.47 519.84 17.55 84.34 108.65 52.11 92.47 
5HT3A - First Generation 
IV Dol 46.07 31.91 51.01 63.23 3.99 6.92 0.00 11.98 
Oral Dol 598.10 847.49 314.57 242.11 48.90 16.76 49.05 21.80 
IV Gran 58.57 171.58 14.73 51.50 2.56 21.70 0.00 0.00 
Oral Gran 499.82 582.21 290.92 759.84 35.11 54.02 10.90 53.00 
IV Ond 51.64 158.10 9.40 44.86 1.04 9.79 0.00 0.00 
Oral Ond 51.83 343.34 5.00 37.98 0.95 6.89 0.00 0.00 
5HT3A-Second Generation 
IV Pal 467.51 606.12 319.81 274.97 12.88 51.11 0.00 0.00 
Oral Pal 692.98 486.23 428.45 718.97 91.42 113.35 54.50 80.25 
Atypical Antipsychotic 
Oral Olanz 37.11 56.24 12.09 33.52 5.52 5.96 4.98 8.40 
Rescue Medications (Dopaminergic Antagonists, Cannabinoids, Benzodiazepines, Other) 
Oral Dron 397.83 340.89 293.93 270.43 20.90 64.70 10.60 7.06 
IV Halo 16.30 0.70 16.30 0.99 0.00 0.00 0.00 0.00 
Oral Halo 8.20 6.57 5.37 9.49 5.07 4.28 5.36 5.68 
IV Loraz 11.67 165.90 1.24 3.39 0.17 1.28 0.00 0.00 
Oral Loraz 8.35 21.40 3.86 7.01 4.46 4.50 2.99 4.38 
IV Meto 11.82 19.38 3.37 17.35 0.13 0.52 0.00 0.00 
Oral Meto 5.88 4.44 4.57 3.75 4.16 3.24 4.12 3.78 
IV Proch 27.29 31.68 13.12 40.17 1.76 10.75 0.00 0.00 
Oral Proch 9.53 18.20 6.28 5.55 5.30 4.16 4.82 4.85 
IV Prom 15.05 23.93 3.64 11.98 0.51 1.93 0.00 0.00 
Oral Prom 15.07 33.73 7.43 8.62 6.39 16.73 5.33 6.34 
Oral Scop 100.14 66.45 74.87 131.51 35.16 29.13 31.80 28.85 
*We identified some “fosaprepitant” claims in the prescription drug file even though fosaprepitant is administered 
intravenously. We excluded these claims from the cost analysis.  
Apr: Aprepitant, Dex: Dexamethasone, Dol: Dolasetron, Dron: Dronabinol, Fos: Fosaprepitant, Gran: Granisetron, 
Hal: Haloperidol, Loraz: Lorazepam, Meto: Metoclopramide, NEPA: Netupitant/Palonosetron Como, Olanz: 
Olanzapine, Ond: Ondansetron, Palo: Palonosetron, Proch: Prochlorperazine, Prom: Promethazine, Scop: 
Scopolamine 




4.1.1.3 Aim 1 - CCAE Population: Secondary Characterization: NK1 Fills in the Post-period 
NK1 fills in the five days following first intravenous highly emetogenic chemotherapy 
administration (i.e., excluding day of intravenous highly emetogenic chemotherapy administration) was 
minimal. Of the 18,863 fills in the post-period, only 717 were for NK1 (3.8%). This translated to less than 
2% of patients filling an NK1 in the period. 
4.1.1.4 Aim 1 - CCAE Population: Guideline Concordance 
Approximately 49% of patients filled antiemetic regimens that are considered under-use by 
guidelines (Figure 4.5). Of concordant strategies, 0.19% consisted of olanzapine+ palonosetron+ 
dexamethasone (Not Displayed). The most common reason for under-use was not filling an NK1 
(N=85%). Interestingly, among the 58% of patients filling an NK1, 87% were concordant. The most 
common reason for discordance among patients who filled an NK1 was lacking a dexamethasone fill. 
Among those who filled at least one, second-generation 5HT3A, the concordance rate was 65% versus 
41% among those who filled at least one first-generation 5HT3A. 
Among patients initiating anthracycline + cyclophosphamide regimens and non-surface-area-
based IV HEC, guideline under-use decreased to 35% and 39%, respectively (Figure 4.6). For surface-
area-based chemotherapies, under-use was high at 69% for anthracycline only regimens and 78% for 
cyclophosphamide therapies. 




Figure 4.6	Chemotherapy Type Concordance Versus Under-use of Antiemetic Strategies by 
Chemotherapy Type 
 
AC = Cyclophosphamide + Anthracycline (doxorubicin, epirubicin, idarubicin) ON THE SAME DAY 
Surface Area Chemotherapies = Anthracycline and Cyclophosphamide 
Other HEC: Given the limited frequencies (<1%) of carmustine, dacarbazine, mechlorethamine, streptozocin, and 
ifosfamide, we grouped them together with cisplatin (76%). 
 
4.1.2 Aim 1 Results-Medicare Supplement Population 
4.1.2.1 Aim 1 – Medicare Supplement Population: Cohort Selection 
The inclusion / exclusion criteria used to develop our Medicare Supplement study cohort is 
described in Figure 4.7. We identified 15,639 adult patients (aged 65 and older) initiating highly 
emetogenic chemotherapy between 2013 and 2015. Of these patients, 11,856 had the required six months 
of continuous enrollment prior to initiating chemotherapy and one-month follow-up. Subsequently, 
11,316 patients had a cancer diagnosis on the claim associated with the highly emetogenic chemotherapy 
administration. After excluding 81 patients with a diagnosis of either schizophrenia or bipolar disorder 
































































































4.1.2.2 Aim 1 – Medicare Supplement Population: Primary Characterization: Antiemetic Fills in 
the Pre-period 
Approximately 93% of patients (N=31,047) receiving highly emetogenic intravenous 
chemotherapy filled at least one antiemetic drug, with a median of three unique products (Figure 4.8); 
number of antiemetic filled by class per patient is presented in Appendix 3. Dexamethasone, 5HT3A, 
NK1, and rescue therapies had at least one fill for 72%, 72%, 39%, and 59% of patients (Figure 4.9). Less 
than 1% of patients had at least one olanzapine fill.  
Of the 25,801 antiemetic claims, aprepitant and fosaprepitant were the only types of NK1s filled 
(14.58% and 85.42% of NK1 use, respectively); there were no NEPA and rolapitant fills. 5HT3As, there 
were a higher proportion of second-generation 5HT3A, palonosetron (72%) versus first-generation 
5HT3As (28%) fills, and there were limited dolasetron fills (<1%) (Figure 4.10). Preventative products 
were more likely to be intravenously administered (60%) as opposed to orally administered (40%) (not 
displayed). Out-of-pocket costs were generally low across preventative antiemetics, with IV products 
having $0 median out-of-pocket costs (Table 4.2). While proportion of out-of-pocket costs for oral 
dexamethasone and oral olanzapine is high (>50%), their total transactional median costs are nominal at 
less than $15.00. 


























Figure 4.9	Percent of Patients Using At Least One Antiemetic Among All Patients (N=8,991) 
 
First Generation 5HT3A: Ond, Gran, Dol Second Generation 5HT3A: Palo 
NK1: Aprep, Fos, Rol, Palo (NK1+5HT3A Combo 
 
Figure 4.10	Percent of Patients Using At Least One Antiemetic Among All Patients Initiating 

































Table 4.2 Total and Out-of-Pocket Costs for Preventative and Rescue Antiemetics* 
Transactional Cost (2016 USD$) Out-of-Pocket (2016 USD$) 
Admin Antiemetic Mean Std Median 
IQR 
Ranger 
Mean STD Median IQR 
Corticosteroid 
IV Dex 64.13 743.69 1.65 1.82 1.75 33.21 0.00 0.05 
Oral Dex 11.73 110.27 5.58 6.74 4.45 5.40 3.52 4.87 
NK1 
Oral Apr 512.43 283.27 445.34 90.52 43.95 51.15 35.97 32.70 
IV Fos 424.52 718.83 276.40 50.35 11.52 42.57 0.00 5.62 
5HT3A - First Generation 
IV Dol 11.91 . 11.91 0.00 0.00 . 0.00 0.00 
IV Gran 50.75 103.50 6.48 25.37 1.24 5.41 0.00 0.19 
Oral Gran 576.04 576.37 410.33 793.44 45.95 95.59 11.99 47.63 
IV Ond 85.60 788.04 2.66 15.17 0.74 10.43 0.00 0.03 
Oral Ond 108.57 652.78 4.33 11.52 1.20 4.61 0.00 0.06 
5HT3A - Second Generation 
IV Palo 365.36 1015.13 208.56 71.89 8.91 23.60 0.00 4.24 
Oral Palo 812.58 483.37 840.75 842.56 63.97 43.12 64.34 74.20 
Atypical Antipsychotic 
Oral Olanz 89.52 188.63 14.35 46.89 12.34 14.05 9.09 7.66 
Rescue Medications (Dopaminergic Antagonists, Cannabinoids, Benzodiazepines, Other) 
Oral Dron 349.52 197.23 301.70 205.25 28.18 78.99 10.60 12.23 
Oral Halo 12.54 12.04 6.97 4.96 7.71 4.90 6.97 0.97 
IV Loraz 4.39 16.59 0.77 0.59 0.04 0.13 0.00 0.01 
Oral Loraz 6.52 9.38 3.64 4.44 3.90 4.10 2.84 3.74 
IV Meto 10.36 13.35 1.20 22.52 0.76 2.21 0.00 0.02 
Oral Meto 6.90 6.36 5.19 4.07 4.26 3.21 4.12 4.00 
IV Proch 6.96 4.50 5.47 8.22 0.75 1.63 0.00 1.09 
Oral Proch 8.63 12.80 5.67 4.78 4.56 3.77 4.25 4.20 
IV Prom 8.72 13.33 2.62 10.58 0.01 0.04 0.00 0.00 
Oral Prom 15.84 39.40 7.34 7.45 6.30 6.88 5.45 5.64 
Oral Scop 114.84 113.53 68.29 110.74 22.49 20.71 18.80 24.03 
*We identified some “fosaprepitant” claims in the prescription drug file even though fosaprepitant is administered 
intravenously. We excluded these claims from the cost analysis.  
Apr: Aprepitant, Dex: Dexamethasone, Dol: Dolasetron, Dron: Dronabinol, Fos: Fosaprepitant, Gran: Granisetron, 
Hal: Haloperidol, Loraz: Lorazepam, Meto: Metoclopramide, NEPA: Netupitant/Palonosetron Como, Olanz: 
Olanzapine, Ond: Ondansetron, Palo: Palonosetron, Proch: Prochlorperazine, Prom: Promethazine, Scop: 
Scopolamine 




4.1.2.3 Aim 1 - Medicare Supplement Population: Secondary Characterization: NK1 Fills in the 
Post-period 
NK1 fills in the five days following first intravenous highly emetogenic chemotherapy 
administration (i.e., excluding day of intravenous highly emetogenic chemotherapy administration) was 
minimal. Of the 3,211 fills in the post-period, only 125 were for NK1 (3.9%). This translated to less than 
2% of patients filling an NK1 in the period. 
4.1.2.4 Aim 1 - Medicare Supplement Population: Guideline Concordance 
Approximately 68% of patients filled antiemetic regimens that are considered under-use by 
guidelines (Figure 4.11). The most common reason for under-use was not filling an NK1 (N=89%). 
Interestingly, among the 39% of new chemotherapy users who filled an NK1, 80% were concordant. Of 
concordant strategies, 0.25% consisted of olanzapine+ palonosetron+ dexamethasone (not displayed). The 
most common reason for discordance among patients who filled an NK1 was lacking a dexamethasone 
fill. Among those who filled at least one, second-generation 5HT3A, the concordance rate was 50% 
versus 29% among those who filled at least one first-generation 5HT3A. 
Among patients initiating anthracycline + cyclophosphamide regimens and non-surface-area-
based IV HEC, guideline under-use decreased to 61% and 54%, respectively (Figure 4.12). For surface-




Figure 4.11	Percentage of Patients Filling Guideline Concordant Preventative Antiemetic Strategies 
 
 
Figure 4.12 Chemotherapy Type Concordance Versus Under-use of Antiemetic Strategies by 
Chemotherapy Type 
 
AC = Cyclophosphamide + Anthracycline (doxorubicin, epirubicin, idarubicin) ON THE SAME DAY 
Surface Area Chemotherapies = Anthracycline and Cyclophosphamide 
Other HEC: Given the limited frequencies (<1%) of carmustine, dacarbazine, mechlorethamine, streptozocin, and 
























































































4.2 Aim 2 Results 
4.2.1 Aim 2 Results - CCAE Population 
4.2.1.1 Aim 2 – CCAE Population: Cohort Selection 
Aim 2 used the same study cohort as Aim 1 except that patients had to initiate highly emetogenic 
chemotherapy on or before October 2015 (as opposed to on or before December 2015). The inclusion / 
exclusion criteria used to develop our CCAE study cohort is described in Figure 4.13. We identified 
55,096 adult patients (age 18-64) initiating highly emetogenic chemotherapy between 2013 and 2015. Of 
these patients, 41,464 had the required six months of continuous enrollment prior to initiating 
chemotherapy and one-month follow-up. Subsequently, 39,424 patients had a cancer diagnosis on the 
claim associated with the highly emetogenic chemotherapy administration. We then excluded 1,591 
patients for being pregnant. Finally, 7,055 patients who lacked prescription drug data were excluded. The 




Figure 4.13	Consort Diagram for CCAE Study Cohort Creation 
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4.2.1.2 Aim 2 – CCAE Population: Descriptive Statistics 
We identified 30,275 patients newly initiating highly emetogenic intravenous chemotherapy 
between 2013 and 2015 in the commercial insurance claims. Baseline characteristics are detailed in Table 
4.3. Most patients were female (69.9%) and were between the ages of 50-64 (68.3%). Among patients in 
the cohort 44.4% had breast cancer and 34.9% used a chemotherapy regimen consisting of an 
anthracycline and cyclophosphamide. Prior use of antiemetics, prior or concomitant use of IV 
chemotherapy, or prior or concomitant use of radiation therapy, was used by 43.1%, 15.9%, and 16.8% of 
the population, respectively. The average number of comorbid conditions, excluding cancer, was 0.2 
(SD=0.7), with patients taking on average, 3.6 (SD=2.9) concomitant medications, excluding antiemetics, 
in the past 30 days. Approximately 85% of patients resided in an urban setting, with the highest 
proportion of patients in the southern United States (40.4%). These regional differences are expected 
based on the distribution of data contributors providing claims to MarketScan in the study period. Over 
half of patients had a PPO plan and 90.9% and 38.0% of patients had good medical benefit and 
prescription drug generosity, respectively (i.e., the proportion of out-of-pocket costs is less than 20% of 
the total healthcare cost). Chemotherapy was primarily administered in the physician office (53.6%) and 
outpatient hospital settings (45.2%).  
4.2.1.3 Aim 2 – CCAE Population: Modified Poisson Regression Multivariate, Adjusted Results 
Both bivariate, unadjusted and multivariable, adjusted results are found in Table 4.4; however, 
multivariable results are discussed in this section. Among patients initiating highly emetogenic 
chemotherapy in the commercial claims population, 49.6% of patients filled antiemetic regimens that did 
not meet guideline recommendations to prevent chemotherapy induced nausea and vomiting. Type of 
chemotherapy initiated was the greatest predictor of antiemetic under-use. In fact, anthracycline only, 
cyclophosphamide only, and carmustine regimens were at a 1.78 (95% confidence interval [CI]: 1.73-
1.84, P<0.0001), 2.01 (CI: 1.73-1.84, P<0.0001), and 2.19 (CI: 2.12-2.25, P<0.0001) times the risk of 
underusing antiemetic regimens compared to combination anthracycline and cyclophosphamide regimens.  
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Table 4.3 Descriptive Statistics for the CCAE Populations (N=30,275) 




Physician Office 53.6% 












Younger Adult (Age 18-50)  31.7% 
Older Adult (Age 51-64)  68.3% 
  
Gender 
Female  69.9% 
Male  30.1% 







Prescription Drug Generosity   
Good Coverage (<0.2 OOP costs) 38.0% 
Fair / Poor / No Coverage / Missing (>0.19 OOP costs) 62.0% 
Medical Benefit Generosity   
Good Coverage (<0.2 OOP costs) 91.0% 
Fair / Poor / No Coverage / Missing (>0.19 OOP costs) 9.1% 









Prior Antiemetic Use^   
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Prior / Concomitant IV Chemotherapy**   
Yes 15.9% 
No 84.1% 
Prior / Concomitant Radiation Therapy   
Yes 16.7% 
No 83.3% 
Number of Comorbid Conditions   
Klabunde Comorbidity Index 0.2 (0.7) 
Concomitant Medication Number   
Number of unique medications, excluding antiemetics 3.6 (2.9) 
Chemotherapy Type   
Anthracycline + Cyclophosphamide 34.9% 
Anthracycline Only*** 13.9% 
Cyclophosphamide Only*** 20.5% 
Carmustine*** 0.2% 
Cisplatin and Other 30.5% 
Cancer Type   
Breast 44.4% 
Lymphatic 15.5% 
Bronchus / Lung  7.3% 
Ovary, Uterus, and Other Female Reproduction 7.8% 
Urinary 2.2% 
Male Genital and Other Reproduction  2.1% 
Colorectal and Other GI  5.3% 
Other  15.4% 
Chemotherapy Setting Network   




*Partial year – January 1, 2015-October 1, 2015 
**Prior chemotherapy consists of exposure to any intravenously administered, non-highly emetogenic chemotherapy 
***Denotes chemotherapies classified as highly emetogenic based on surface area thresholds 
^Prior antiemetic use was assessed as any preventative antiemetic use between 6 months prior to IV HEC and the 
beginning of the look back period (i.e., 32 days)
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Receiving chemotherapy in an outpatient hospital setting compared to a physician office (RR=1.44, CI: 
1.33-1.55, P<0.0001) and having prior/concomitant chemotherapy therapy versus not having it (RR=1.22, 
CI: 1.18-1.25, P<0.0001) were the other largest predictors of antiemetic under-use.  
Within the cohort of commercially insured patients, older adults compared to younger adults were 
at a higher risk for under-use (RR=1.07, CI: 1.05-1.10, P<0.0001), while female patients were at a lower 
risk (RR=0.92, CI: 0.89-0.94, P<0.0001). Additionally, patients with prior or concomitant radiation use 
had 1.07 (CI: 1.04-1.11, P<0.0001) times the risk of under-use compared to those without radiation 
exposure, while patients with prior antiemetic use were at slightly lower risk for under-use (RR: 0.97 (CI: 
0.95-0.99, P=0.0057) compared to those who did not have prior antiemetic use. While the risk of 
underusing antiemetics increased with the number of comorbid conditions (P<0.0001), it decreased with 
the number of concomitant medications (P<0.0005). 
The risk of under-use was 3% and 4% higher among those having more than 20% out-of-pocket 
costs versus having less than 20% out-of-pocket costs (RR: 1.03, CI: 1.01-1.05, P=0.0091 and RR: 1.04, 
CI: 1.00-1.09, P=0.0314) in the prescription drug benefit and medical benefit, respectively. There were no 
statistically significant differences in under-use comparing patients with CDHP/HDHP plans with those 
with PPO plans at alpha = 0.05; however, patients with an HMO plan were at 1.11 times the risk of 
antiemetic under-use (CI: 1.08-1.15, P<0.0001). Compared to 2013, under-use decreased in 2014 
(P<0.0095) and 2015 (P<0.0001).  Additionally, under-use was significantly lower in quarter four 
compared to quarter one (RR=0.95, CI: 0.92-0.98, P<0.0001). 
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Table 4.4 Modified Poisson Unadjusted and Adjusted Results – CCAE 
    Bivariate, Unadjusted Multivariable, Adjusted 
 Variable Category Estimate CI P-Value Estimate CI P-Value 
Intercept   - -   0.31 (0.29,0.33) <.0001 
Chemotherapy  
Setting 
Other 1.52 (1.41,1.64) <.0001 1.44 (1.33,1.55) <.0001 
Hospital Outpatient 1.28 (1.25,1.31) <.0001 1.28 (1.25,1.30) <.0001 
Physician Office 1 REF . 1.00 REF . 
Geographical  
Setting 
Rural 1.01 (0.98,1.04) 0.57 1.02 (0.99,1.05) 0.27 
Urban 1 REF . 1 (1,1) . 
Region 
North Central 0.97 (0.93,1) 0.09 0.99 (0.95,1.02) 0.49 
South 1.03 (1,1.06) 0.09 1.08 (1.05,1.12) <.0001 
Unknown 0.80 (0.72,0.88) <.0001 0.84 (0.76,0.93) 0.0004 
West 1.15 (1.11,1.19) <.0001 1.15 (1.12,1.20) <.0001 
Northeast 1 REF . 1 REF . 
Age 
Older Adult 1.09 (1.06,1.12) <.0001 1.07 (1.05,1.10) <.0001 
Younger Adult 1 REF . 1 REF . 
Gender 
Female 0.97 (0.94,0.99) 0.0083 0.92 (0.89,0.94) <.0001 
Male 1 REF . 1 REF . 
Health Plan 
CDHP/HDHP 0.98 (0.95,1.01) 0.24 0.99 (0.96,1.02) 0.56 
HMO 1.12 (1.08,1.16) <.0001 1.11 (1.08,1.15) <.0001 
Missing 1.06 (0.99,1.13) 0.11 1.06 (0.99,1.13) 0.0924 
Other 0.98 (0.93,1.03) 0.46 1 (0.95,1.05) 0.93 
POS 0.95 (0.91,1) 0.045 0.96 (0.92,1) 0.0414 
PPO 1 REF . 1 REF . 
Medical Benefit Generosity
Fair / Poor / No / Missing 
Coverage 
0.96 (0.92,1) 0.06 1.04 (1.00,1.09) 0.0314 
Good Coverage 1 REF . 1 REF . 
Prescription Drug 
Generosity 
Fair / Poor / No / Missing 
Coverage 
0.97 (0.94,0.99) 0.003 1.03 (1.01,1.05) 0.0091 
Good Coverage 1 REF . 1 REF . 
Chemotherapy  
Year 
2014 0.97 (0.94,0.99) 0.0095 0.97 (0.95,0.99) 0.0095 
2015 0.94 (0.92,0.97) 0.0002 0.92 (0.89,0.95) <.0001 
2013 1 REF . 1 REF . 
Chemotherapy 
Quarter 
2 0.97 (0.94,1) 0.03 0.99 (0.96,1.02) 0.41 
3 0.98 (0.95,1.01) 0.16 0.99 (0.97,1.02) 0.58 
4 0.96 (0.93,0.99) 0.02 0.95 (0.92,0.98) 0.0026 
1 1 REF . 1 REF . 
Prior/Concomitant 
Chemotherapy 
1 1.28 (1.25,1.32) <.0001 1.22 (1.18,1.25) <.0001 
0 1 REF . 1 REF . 
Prior / Concomitant 
Radiation 
1 0.91 (0.88,0.94) <.0001 1.07 (1.04,1.11) <.0001 
0 1 REF . 1 REF . 
Prior Antiemetics 
1 1.11 (1.08,1.13) <.0001 0.97 (0.95,0.99) 0.0057 
0 1 REF . 1 REF . 
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  Bivariate, Unadjusted Multivariable, Adjusted 
 Variable Category Estimate CI P-Value Estimate CI P-Value 
Chemotherapy Type 
Anthracycline Only* 2 (1.93,2.06) <.0001 1.78 (1.73,1.84) <.0001 
Carmustine* 2.39 (2.13,2.69) <.0001 2.01 (1.79,2.26) <.0001 
Cyclo Only* 2.24 (2.17,2.3) <.0001 2.19 (2.12,2.25) <.0001 
Cisplatin and Other 1.1 (1.06,1.14) <.0001 0.99 (0.95,1.03) 0.63 
Anthracycline + Cyclo 1 REF . 1 REF . 
Comorbid Condition Klabunde Index 1.09 (1.08,1.1) <.0001 1.06 (1.04,1.07) <.0001 
Concomitant  
Medication 
Unique medication number 
excluding antiemetics 
0.99 (0.99,1) 0.0093 0.99 (0.99,1.00) 0.0005 
*Denotes chemotherapies classified as highly emetogenic based on surface area thresholds 
 
Patients living in the south and west,had a higher risk of antiemetic under-use compared to those 
living in the northeast (p<0.0001). There were no significant differences in risk of antiemetic under-use 
between patients living in rural and urban settings.  
4.2.1.4 Aim 2 – CCAE Population: Sensitivity Analysis 
Excluding prescription drugs that cost less than $50 increased the percent of people with good 
prescription drug coverage to 50%. It also increased the number patients with missing prescription drug 
coverage from 4 to 29%. Changes in the multivariate modified poisson results using the modified 
prescription drug generosity measure, were minimal (not displayed).  
4.2.2 Aim 2 Results – Medicare Supplement Population 
4.2.2.1 Aim 2 – Medicare Supplement Population: Cohort Selection 
Aim 2 used the same study cohort as Aim 1 except that patients had to initiate highly emetogenic 
chemotherapy on or before October 2015 (as opposed to on or before December 2015). The inclusion / 
exclusion criteria used to develop our Medicare Supplement study cohort is described in Figure 4.14. We 
identified 15,213 adult patients (aged 65 and older) initiating highly emetogenic chemotherapy between 
2013 and 2015. Of these patients, 11,430 had the required six months of continuous enrollment prior to 
initiating chemotherapy and one-month follow-up. Subsequently, 10,890 patients had a cancer diagnosis 
on the claim associated with the highly emetogenic chemotherapy administration. After excluding 81 
patients with a diagnosis of either schizophrenia or bipolar disorder and 2,244 patients who lacked 
prescription drug data the final study population consisted of 8,565 patients. 
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4.2.2.2 Aim 2 – Medicare Supplement Population: Descriptive Statistics 
We identified 8,565 patients newly initiating highly emetogenic intravenous chemotherapy 
between 2013 and 2015 in the Medicare Supplement cohort. Baseline characteristics are detailed in Table 
4.5. More than half of patients were female (58.0%) and 68.0% of patients were between the ages of 65-
74, with less than 5% over the age of 85. The most common type of cancer was lymphatic cancer (28.1%) 
and breast cancer (24.0%), and 25.1% of patients used a chemotherapy regimen consisting of 
anthracycline and cyclophosphamide. Prior use of antiemetics, concomitant chemotherapy, or radiation 
therapy was used by 39.7%, 22.7%, and 16.3%, respectively. The average number of comorbid 
conditions, excluding cancer, was 0.5 (SD=0.86), with patients taking on average, 3.9 (SD=3.03) 
concomitant medications, excluding antiemetics, in the past 30 days. Approximately 85% of patients 
resided in an urban setting, with the highest proportion of patients in the north central United States 
(35.5%). The most common plans were PPO (41.7%) and comprehensive (40.9%), and 97.0% and 44.9% 
patients had good medical benefit and prescription drug generosity (i.e., the proportion of out-of-pocket 
costs is less than 20% of the total healthcare cost), respectively. Chemotherapy was primarily 




Table 4.5 Descriptive Statistics for the Medicare Supplement Populations (N=8,565) 




Physician Office 57.0% 












Younger Medicare Adult (65-74) 68.0% 
Middle Aged Medicare Adult (75-85) 28.5% 
Older Medicare Adult (85+) 3.5% 
Gender 
Female  58.0% 
Male  42.0% 







Prescription Drug Generosity   
Good Coverage (<0.2 OOP costs) 44.9% 
Fair / Poor / No Coverage / Missing (>0.19 OOP costs) 55.1% 
Medical Benefit Generosity   
Good Coverage (<0.2 OOP costs) 97.0% 
Fair / Poor / No Coverage / Missing (>0.19 OOP costs) 3.1% 









Prior Antiemetic Use   
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Prior / Concomitant Chemotherapy**   
Yes 22.7% 
No 77.3% 
Prior / Concomitant Radiation Therapy   
Yes 16.3% 
No 83.7% 
Number of Comorbid Conditions   
Klabunde Comorbidity Index 0.5 (0.9) 
Concomitant Medication Number   
Number of unique medications, excluding antiemetics 3.91(3.0) 
Chemotherapy Type   
Anthracycline + Cyclophosphamide 25.1% 
Anthracycline Only*** 17.7% 
Cyclophosphamide Only*** 23.4% 
Carmustine*** 0.1% 
Cisplatin and Other 33.7% 
Cancer Type   
Breast 24.0% 
Lymphatic 28.2% 
Bronchus / Lung  11.4% 
Ovary, Uterus, and Other Female Reproduction 9.3% 
Urinary 6.3% 
Male Genital and Other Reproduction  0.6% 
Colorectal and Other GI  8.1% 
Other  12.2% 
Chemotherapy Setting Network   
In Network 65.8% 
Out-of-Network 31.1% 
Missing 3.1% 
*Partial year – January 1, 2015-October 1, 2015 
**Prior chemotherapy consists of exposure to any intravenously administered, non-highly emetogenic chemotherapy 
***Denotes chemotherapies classified as highly emetogenic based on surface area thresholds 
^Prior antiemetic use was assessed as any preventative antiemetic use between 6 months prior to IV HEC and the 




4.2.2.3 Aim 2 – Medicare Supplement Population: Modified Poisson Regression Multivariate, 
Adjusted Results 
Both bivariate, unadjusted and multivariable, adjusted results are found in Table 4.6; however, 
multivariable results are discussed in this section. Among patients initiating highly emetogenic 
chemotherapy in the Medicare Supplement population, 68.4% of patients filled antiemetic regimens that 
did not meet guideline recommendations to prevent chemotherapy induced nausea and vomiting. 
Receiving chemotherapy in an outpatient hospital setting compared to a physician office (RR=1.47, CI: 
1.43-1.51, P<0.0001) was the greatest predictor of antiemetic under-use in this population. Patients 
initiating anthracycline only as well as cyclophosphamide only regimens were at 29% (RR: 1.29, CI: 
1.24-1.35, P<0.0001) and 41% (RR: 1.41, CI: 1.36-1.46, P<0.0001) higher risk of underusing antiemetic 
regimens compared to patients initiating a combined anthracycline and cyclophosphamide regimen. 
However, patients initiating cisplatin and other chemotherapy regimens were 18% less likely to under-use 
antiemetics compared to patients initiating an anthracycline and cyclophosphamide chemotherapy 
regimens (CI: 0.78-0.86, P<0.0001). Additionally, adults aged 75-84 (RR=1.08, CI: 1.05-1.11, P<0.001) 
and over 85 (RR=1.15, CI: 1.10-1.21, P<0.0001) were at higher risk for under-use compared to Medicare 
beneficiaries aged 65-74.  
There were no significant differences in under-use by gender as well as prior antiemetic use at 
alpha=0.05; though statistically significant differences occurred prior to adjustment. Patients with prior or 
concomitant radiation (RR=1.09, CI: 1.04-1.14, P<0.0001) as well as patients with prior/concomitant 
chemotherapy (RR=1.12, CI: 1.09-1.16, P<0.0001) were at increased risk of under-use compared to those 
without prior or concomitant radiation or chemotherapy, respectively. An increase in the number of 
comorbid conditions, excluding cancer, or concomitant medications, excluding antiemetics, did not 




Table 4.6 Modified Poisson Unadjusted and Adjusted Results – Medicare Supplement 
    Bivariate, Unadjusted Multivariable, Adjusted 
Variable Category Estimate CI P-Val Estimate CI P-Val 
Intercept   - -   0.48 (0.44,0.51) <.0001 
Chemotherapy 
Setting 
Other 1.39 (1.29,1.5) <.0001 1.23 (1.15,1.33) <.0001 
Outpatient 1.47 (1.43,1.51) <.0001 1.47 (1.43,1.51) <.0001 
Physician Office 1 REF . 1 REF . 
Geographical 
Setting 
Rural 1.01 (0.97,1.05) 0.76 0.99 (0.95,1.02) 0.49 
Urban 1 REF . 1 REF . 
Region 
North Central 1.11 (1.06,1.15) <.0001 1.04 (1,1.08) 0.03 
South 1.01 (0.96,1.05) 0.77 1.01 (0.97,1.06) 0.50 
Unknown 0.67 (0.52,0.87) 0.0022 0.71 (0.56,0.9) 0.0051 
West 1.12 (1.07,1.17) <.0001 1.14 (1.09,1.19) <.0001 




1.11 (1.08,1.15) <.0001 1.08 (1.05,1.11) <.0001 
Older Medicare 
Adult 
1.29 (1.22,1.36) <.0001 1.15 (1.10,1.21) <.0001 
Younger Medicare 
Adult 
1 REF . 1 REF . 
Gender 
Female 1.08 (1.05,1.11) <.0001 0.99 (0.96,1.02) 0.53 
Male 1 REF . 1 REF . 
Health Plan 
CDHP/HDHP 0.76 (0.6,0.96) 0.02 0.79 (0.64,0.98) 0.029 
HMO 1 (0.95,1.06) 0.89 0.95 (0.91,1.00) 0.048 
Missing 1.06 (0.92,1.23) 0.43 1 (0.86,1.15) 0.96 
Other 1.12 (1.08,1.15) <.0001 1.07 (1.04,1.1) <.0001 
POS 0.89 (0.81,0.97) 0.01 0.90 (0.83,0.98) 0.0127 




Fair / Poor / No / 
Missing Coverage 
0.99 (0.91,1.08) 0.77 1.09 (1.01,1.18) 
0.02 




Fair / Poor / No / 
Missing Coverage 
1.02 (0.99,1.05) 0.16 1.03 (1,1.05) 
0.07 
Good Coverage 1 REF . 1 REF . 
Chemotherapy 
Year 
2014 0.98 (0.95,1.01) 0.21 0.98 (0.95,1.01) 0.14 
2015 1 (0.96,1.04) 0.93 0.96 (0.93,1) 0.03 
2013 1 REF . 1 REF . 
Chemotherapy 
Quarter 
2 1 (0.96,1.04) 0.88 0.99 (0.96,1.03) 0.61 
3 0.99 (0.96,1.03) 0.72 0.98 (0.95,1.02) 0.38 
4 0.97 (0.93,1.01) 0.16 0.97 (0.93,1.01) 0.18 
1 1 REF . 1 REF . 
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    Bivariate, Unadjusted Multivariable, Adjusted 




1 1.15 (1.11,1.18) <.0001 1.12 (1.09,1.16) <.0001 




1 0.89 (0.86,0.93) <.0001 1.09 (1.04,1.14) <.0001 
0 1 REF . 1 REF . 
Prior 
Antiemetics 
1 1.08 (1.05,1.12) <.0001 0.99 (0.96,1.02) 0.37 
0 1 REF . 1 REF . 
Chemotherapy 
Type 
Anthracycline Only* 1.40 (1.34,1.45) <.0001 1.29 (1.24,1.35) <.0001 
Carmustine* 1.37 (0.96,1.96) 0.09 1.17 (0.85,1.61) 0.35 
Cyclo Only* 1.43 (1.37,1.48) <.0001 1.41 (1.36,1.46) <.0001 
Cisplatin and Other 0.86 (0.82,0.9) <.0001 0.82 (0.78,0.86) <.0001 
Anthracycline + 
Cyclo 
1 REF . 1 REF . 
Comorbid 
Conditions 







0.99 (0.99,1) 0.02 1.00 (0.99,1.00) 0.65 
*Denotes chemotherapies classified as highly emetogenic based on surface area thresholds 
 
Differences in prescription drug generosity did not have significant effects on under-use at alpha 
= 0.05. However, patients with more than 20% out-of-pocket costs were 1.03 times as likely to under-use 
antiemetics than those with less than 20% out-of-pocket costs (CI: 1.01-1.18, P=0.02). Compared to 2013, 
under-use was the same in 2014, but decreased in 2015 (P=0.03). Concordance did not significantly differ 
in quarters 2, 3, and 4 when compared to quarter 1. 
Patients living in the north central (p=0.03) or western (p<0.0001) United States had a higher risk 
of antiemetic under-use compared to those living in the northeast. There were no significant differences in 
risk of antiemetic under-use between patients living in a rural and urban setting.  
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4.3 Aim 3 Results 
4.3.1 Base Case Results 
The purpose of aim 3 was to evaluate the trade-offs in cost, clinical, and quality-of-life outcomes 
across the guideline-concordant antiemetic strategies in patients initiating highly emetogenic 
chemotherapy.  Specifically, we conducted a cost-utility analysis using a Markov Model.  After ranking 
by cost and applying dominance principles sequentially, we found that from the perspective of the US 
healthcare system, the use of olanzapine + fosaprepitant + 5HT3A + dexamethasone among patients 
initiating highly emetogenic chemotherapy had the lowest total costs ($452) and highest total benefit 
(4.03 QALD) (Figure 4.15,Table 4.7).  As such, this strategy dominated all other strategies.  Olanzapine + 
fosaprepitant + 5HT3A + dexamethasone had the third lowest treatment acquisition costs ($310).  
Aprepitant + 5HT3A + dexamethasone had the highest total costs ($1,073) and rolapitant + 5HT3A + 
dexamethasone had the lowest total benefit (3.58 QALD). Olanzapine + palonosetron + dexamethasone 
had the lowest treatment acquisition cost ($242), and the second lowest total costs ($484) and second 
highest total benefit (3.88 QALD).  Findings were similar from the societal perspective.  
Figure 4.15	Cost Effectiveness Plane Depicting Base Case Results for Antiemetic Strategies Used to 

























Quality Adjusted Life Years Per Patient
Rol+5HT3A+Dex Apr+5HT3A+Dex Fos+5HT3A+Dex
Olanz+Palo+Dex Nepa + Dex Fos+5HT3A+Dex+Olz
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4.3.2 Sensitivity Analyses 
We conducted sensitivity analyses from the perspective of the US healthcare system for the three 
lowest total cost strategies (i.e., olanzapine + fosaprepitant + 5HT3A + dexamethasone, olanzapine + 
palonosetron + dexamethasone, and fosaprepitant + 5HT3A + dexamethasone) because they are closest in 
total costs. The probabilistic sensitivity analyses consisting of 1,000 trials are displayed in the scatter 
plots in (Figure 4.16). Olanzapine + palonosetron + dexamethasone was less effective than fosaprepitant 
+ 5HT3A + dexamethasone + olanzapine in 99.9% of simulations, was dominated in 56.5% of 
simulations, dominates in .1% of simulations, and was cost effective in 37.5% of simulations at a 
willingness to pay threshold of $50,000/QALY (Figure 4.16A). In 79.9% and 50.0% of simulations, 
fosaprepitant + 5HT3A + dexamethasone was dominated by olanzapine + fosaprepitant + 5HT3A + 
dexamethasone (Figure 4.16B) and olanzapine + palonosetron + dexamethasone (Figure 4.16C) 
strategies, respectively. In 7.9% and 0% of simulations, fosaprepitant + 5HT3A + dexamethasone 
dominates olanzapine + fosaprepitant + 5HT3A + dexamethasone (Figure 4.16B) and olanzapine + 
palonosetron + dexamethasone (Figure 4.16C) strategies, respectively.  Compared to olanzapine + 
fosaprepitant + 5HT3A + dexamethasone (Figure 4.16B) and olanzapine + palonosetron + dexamethasone 
(Figure 4.16C) strategies, fosaprepitant + 5HT3A + dexamethasone was cost-effective at a willingness to 
pay threshold of $50,000/QALY in .1% and 19.0% of simulations, respectively.  Figure 4.17 depicts the 
probability of these comparisons being cost effective at willingness to pay thresholds ranging from $0-
$250,000. 
Using one-way sensitivity analysis (Figure 4.18), cost of 5HT3A used, cost of palonosetron, cost 
of fosaprepitant, and cost of CINV event were the inputs to which the ICER was most sensitive when 
comparing olanzapine + palonosetron + dexamethasone with olanzapine + fosaprepitant + 5HT3A + 
dexamethasone (Figure 4.18A). In contrast, when comparing olanzapine + fosaprepitant + 5HT3A + 
dexamethasone to fosaprepitant + 5HT3A + dexamethasone, the analysis was most sensitive to complete 
protection, complete response, and incomplete response utility values as well as CINV event costs (Figure 
4.18B). When comparing olanzapine + palonosetron + dexamethasone with fosaprepitant + 5HT3A + 
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dexamethasone (Figure 4.18C), the 5HT3A costs and effectiveness of fosaprepitant + 5HT3A + 
dexamethasone +olanzapine were the input parameters to which the analysis was most sensitive. 
After conducting a scenario analysis excluding all strategies containing olanzapine in the base 
case, fosaprepitant+5HT3A+dexamethasone had the lowest total costs ($653). Netupitant/palonosetron 
combination + dexamethasone offers an advantage of 0.09 QALDs at an additional cost of $276 over five 
days over fosaprepitant + 5HT3A + dexamethasone resulting in an ICER of $3,064/QALD. To convert 
this ICER to one using QALYs, we multiplied the ICER in QALDs by 365.25.   We found that this ICER 
was not cost-effective at a willingness-to-pay threshold of $50,000/QALY, $100,000/QALY, or 
$200,000/QALY (Table 4.8). Aprepitant + 5HT3A + dexamethasone and rolapitant + 5HT3A + 
dexamethasone were both dominated by the two previous strategies, as they had a higher total cost and 







Table 4.7 Base Case Results Comparing Antiemetic Strategies from the US Healthcare System and Societal Perspectives (2016 US Dollars) 
TREATMENT ACQUISITION COSTS (15, 18) 
Treatment Strategy Costs (USD 2016)       
Olanz+Palo+Dex 242.39       
Fos+5HT3A+Dex 310.09       
Fos+5HT3A+Dex+Olz 320.09       
Rol+5HT3A+Dex 620.59       
Nepa + Dex 635.59       
Apr+5HT3A+Dex 659.09       
Apr+5HT3A+Dex+Olz 669.09       
US HEALTHCARE PERSPECTIVE 
 
1-person (5 Days)     









Fos+5HT3A+Dex+Olz $452  4.03         
Olanz+Palo+Dex $484  3.88 $32  -0.15 Dominated Dominated 
Fos+5HT3A+Dex $653  3.75 $201  -0.28 Dominated Dominated 
Apr+5HT3A+Dex+Olz $801  4.03 $349  0.00 Dominated Dominated 
Nepa + Dex $929  3.84 $477  -0.19 Dominated Dominated 
Rol+5HT3A+Dex $1,044  3.58 $592  -0.45 Dominated Dominated 
Apr+5HT3A+Dex $1,073  3.63 $621  -0.40 Dominated Dominated 
US SOCIETAL PERSPECTIVE 
 
1-person (5 Days)   









Fos+5HT3A+Dex+Olz $477  4.03         
Olanz+Palo+Dex $529  3.88 $52  -0.15 Dominated Dominated 
Fos+5HT3A+Dex $717  3.75 $240  -0.28 Dominated Dominated 
Apr+5HT3A+Dex+Olz $826  4.03 $349  0.00 Dominated Dominated 
Nepa + Dex $984  3.84 $507  -0.19 Dominated Dominated 
Rol+5HT3A+Dex $1,123  3.58 $646  -0.45 Dominated Dominated 




Figure 4.16	Probabilistic Sensitivity Analyses – ICER Scatterplot 
Figure 4.16A Cost Effectiveness Scatterplot of Fos+5HT3A+Dex+Olanz (Ref) vs. Olanz+Palo+Dex 
 
 
Figure 4.16B Cost Effectiveness Scatterplot of Fos+5HT3A+Dex+Olanz (Ref) vs. Fos+5HT3A+Dex 
 
 




Figure 4.17	Cost Effectiveness Acceptability Curves for Olanz + Palo + Dex vs. Fos + 5HT3A+  Dex 




Figure 4.18	One Way Sensitivity ICER (Cost (USD 2016) /QALY) Analysis – Tornado Diagram 
(Top 5 Variables) 
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Table 4.8 Scenario Analysis Excluding Olanzapine Strategies 











Fos+5HT3A+Dex $653  3.75         
Nepa + Dex $929  3.84 $276  0.09 $3,065  $1,119,074  
Rol+5HT3A+Dex $1,044  3.58 $115  -0.26 Dominated Dominated 
Apr+5HT3A+Dex $1,073  3.63 $144  -0.21 Dominated Dominated 
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CHAPTER 5: DISCUSSION 
5.1 Dissertation Objectives Recap 
Patients initiating highly emetogenic chemotherapy are at a 90% risk of chemotherapy-induced 
nausea and vomiting (CINV). Antiemetic drugs are highly effective in preventing CINV, and thus 
improve quality of life and generate cost savings by reducing the need for CINV-related health 
services.(1-4) Despite the fact that guideline-concordant antiemetic prescribing is estimated to prevent 
CINV in as high as 80% of CINV patients, evidence suggests that use of ASCO and NCCN guideline-
concordant antiemetic regimens by patients initiating highly emetogenic chemotherapy are low. 
Furthermore, there are several CINV preventative treatment regimens that are considered guideline-
concordant that are associated with a wide range of costs. However, there is no clearly preferred treatment 
strategy. The purpose of this dissertation was to characterize antiemetic use; identify predictors of 
antiemetic under-use; and evaluate the trade-offs in cost, clinical, and quality of life outcomes across the 
guideline-concordant regimens available for use among patients who initiate highly emetogenic 
chemotherapy. Aim 1 used descriptive statistics to describe antiemetic prescribing patterns, including 
antiemetic under-use, in patients with cancer initiating highly emetogenic chemotherapy using the IBM 
Watson’s/Truven’s MarketScan Commercial Claims and Encounters (CCAE) and Medicare Supplemental 
and Coordination of Benefits data. Aim 2 used a modified Poisson regression to identify predictors (i.e., 
environmental, predisposing, enabling, and need) of antiemetic under-use in these same data. Aim 3 
assessed the health and economic impacts of guideline-concordant antiemetic strategies through a cost-





5.2.1 Summary / Discussion – Aim 1 
The primary purpose of Aim 1 was to describe what types of antiemetic regimens are being used 
and to assess the proportion of antiemetic under-use in patients with cancer who are initiating highly 
emetogenic, intravenous chemotherapy. Our final study population consisted of 31,923 and 8,991 patients 
initiating highly emetogenic chemotherapy between 2013-2015 in the CCAE population and Medicare 
Supplement population, respectively. Antiemetic fills in the Medicare Supplement population were lower 
than the Commercial Claims population with 97% of patients in the Commercial Claims population 
filling at least one antiemetic, compared to 93% in the Medicare Supplement population. This aligns with 
prior US studies in which patients initiating highly emetogenic chemotherapy filled at least one antiemetic 
more than 80% of the time, indicative of provider understanding that patients initiating emetogenic 
chemotherapy should be prescribed an antiemetic strategy to prevent CINV, though the specifics of the 
antiemetic strategy may be lacking.(22, 30) While patients both in the Medicare Supplement and CCAE 
populations had 3 median unique antiemetic fills, the proportion of patients that filled 2 unique 
antiemetics was higher in the Medicare Supplement population and that filled 4 unique antiemetics was 
higher in the CCAE population. Coupling this with the finding that the Medicare Supplement population 
had a lower percentage filling rescue antiemetics in the pre-period suggests that younger patients are 
receiving more aggressive supportive care. This may be because patients under the age of 50 are at a 
higher risk of CINV events as well as younger patients are treated more aggressively in oncology than 
older patients (e.g., receiving more chemotherapy/radiation therapy or adjuvant therapy).(74, 211-213) 
Most preventative antiemetics were intravenously administered with minimal median out-of-pocket costs 
and an interquartile range of less than $6 for filled products. This is likely the result of 1) generous 
coverage of cancer care in these populations and 2) patients having reached out-of-pocket maximums 
given the high cost of cancer care in the CCAE population. Median out-of-pocket costs for filled oral 
antiemetics were generally higher than for intravenously administered antiemetics. It will be important to 
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monitor total cost and out-of-pocket costs of antiemetics as insurance benefits continue to shift toward 
greater use of deductibles and co-insurance. 
More than 80% of CCAE patients and 70% of Medicare Supplement patients filled at least one 
5HT3A and dexamethasone. Additionally, there was minimal uptake of new NK1 products NEPA and 
rolapitant, which is not surprising given the low proportion of patients filling at least one NK1 to begin 
with (58% and 39% in the commercial and Medicare populations, respectively). However, these 
proportions are higher than those in a study conducted between 2006-2008 that found only 11% of 
patients were filled NK1s.(30) Despite olanzapine being recommended for preventative use since 2012 in 
the NCCN guidelines and its low costs, limited olanzapine fills were seen in the pre-period. We 
hypothesize a few reasons for this. First, providers may have concerns about the safety of olanzapine, 
which include significant cardio-metabolic events and a black box warning for death in elderly patients 
with dementia-related psychosis, despite the short duration of use and evidence demonstrating that 
adverse event rates with olanzapine strategies were similar to the comparator arm.(28) Additional high-
quality studies supporting the tolerability of olanzapine for use in this clinical context may alleviate this 
issue. Second, because this indication for olanzapine is not FDA-approved, manufacturers are unable to 
market this indication to providers, so dissemination of evidence of olanzapine’s use for CINV prevention 
is limited compared to that of other antiemetic products, which have an FDA-approved indication.(214) 
Third, there is a limited evidence base for olanzapine use prior to 2016 – early studies had study design 
issues including small sample size and uneven patient characteristic distribution between the 
comparators.(125) Given the new randomized controlled evidence published in 2016, as well as 
olanzapine’s incorporation into the ASCO guidelines in 2017, higher uptake is anticipated in the 
future.(18, 28)  
Under-use of guideline-concordant antiemetic fills is high at 49% and 68% in the commercial 
claims and Medicare supplement populations, respectively. These results align with a prior study that 
found that 56.4% of breast cancer patients on AC therapy were concordant in the commercial claims 
population in 2013.(45) Another US study estimated guideline-concordance to be 91% on day 1 in a 
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practice group in the southeast; however, these providers used an EMR system embedded with a 
standardized antiemetic protocol.(22) We found that the most common reason for discordance is a lack of 
NK1, and under-use of NK1s was higher in the Medicare supplement population (89%) versus the 
commercial claims population (85%). This aligns with prior studies that estimate that a lack of an NK1 
constitutes 51%-80% of the reasons for discordances.(22, 31, 39, 45, 46)  The high under-use of NK1s is 
surprising given that they have been in the guidelines since 2006. This highlights an opportunity for 
further provider education as there is a robust evidence base supporting the superiority of NK1s over 
5HT3As for achieving clinical outcomes and reducing downstream economic impacts.  
One potential reason for low NK1 fills is treatment acquisition cost, as they are the most 
expensive class of antiemetics. While median out-of-pocket costs for NK1s in both populations is 
nominal among those who filled these products, it could still be hypothesized that while providers are 
prescribing NK1s patients did not fill them because of the high out-of-pocket costs. We are unable to 
discern the costs of drugs that were not filled because claims were only filled for filled drugs. Conversely, 
patients in both populations are more likely to fill expensive, second-generation 5HT3A (palonosetron) 
versus cheaper, first-generation 5HT3As (as low as $1.10 / treatment cycle). Intravenous palonosetron 
costs $229 (2016 USD) / treatment cycle, just slightly less expensive than the cheapest NK1, intravenous 
fosaprepitant at $299 (2016 USD) / treatment cycle.(18) Notably, guidelines do not prioritize 5HT3As, 
and palonosetron is more expensive than first-generation 5HT3As (e.g., oral ondansetron costs $1.10 
(2016 USD) / treatment cycle and oral granisetron costs $3.13 (2016 USD) / treatment cycle). This 
suggests that the high costs of NK1s are not the only reason for their limited uptake. Another notable 
finding is that the proportion of patients that used at least one second-generation palonosetron fill was 
more than 20% higher than those who filled at least one first-generation 5HT3A among both populations 
This suggests that patients who are receiving palonosetron have providers who may be more 
knowledgeable of the current antiemetic treatment landscape, which may be the result of manufacturer 
marketing. The lack of NK1 prescribing among palonosetron prescribers may be confusion with 
  
120 
moderately emetogenic chemotherapy recommendations, where palonosetron is the preferred 5HT3A, and 
along with only dexamethasone is considered guideline concordant.  
Concordance increases by about 10% in both populations when assessing anthracycline + 
cyclophosphamide-regimens and non-surface-area based regimens, which are strictly highly emetogenic 
chemotherapy regimens. High under-use in the anthracycline and cyclophosphamide only populations is 
expected given than claims-based data sources (as the ones used in this study) do not provide dosage 
levels for infused products and patients may be receiving doses that are considered moderately 
emetogenic chemotherapy versus highly emetogenic chemotherapy. To the extent that this is the case, we 
would over-estimate antiemetic under-use in these populations. 
5.2.2 Summary / Discussion – Aim 2 
The purpose of Aim 2 was to identify predictors of antiemetic under-use as opposed to guideline-
concordant use in patients with cancer who are initiating highly emetogenic, intravenous chemotherapy. 
Our final study population consisted of 30,275 and 8,565 patients initiating highly emetogenic 
chemotherapy between January 1, 2013-October 1, 2015 in the CCAE population and Medicare 
Supplement population, respectively. While the data sources for this study represent two different 
populations – under age 65 (CCAE) and age 65 and over (Medicare Supplement), there were some 
similarities in the predictors of antiemetic under-use. Compared to receiving chemotherapy in the 
physician office setting, patients receiving chemotherapy in an outpatient hospital setting were at a 28% 
(p<0.0001) and 48% (p<0.0001) higher risk of under-use in the CCAE and Medicare Supplement 
populations, respectively. This might be the result of increased patient-centered care in a community care 
setting compared to that of a hospital-based outpatient clinic, which is not measured in this data.  
Additionally, prior studies have shown that cancer costs are higher in the outpatient hospital setting than 
the physician’s office, which may lead to higher out-of-pocket costs for the patient and prevent patients 
from using antiemetics.(154-156) However, our study found that patients with good medical benefit out-
of-pocket coverage (patients paid less than 20% of medical spending out-of-pocket) were slightly more 
likely fill concordant antiemetics than those without good coverage (RR=1.04 (p<0.05) and RR=1.09 
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(P<0.05) in the CCAE and Medicare Supplement populations, respectively). Good prescription drug 
coverage also improved guideline concordance, but the effect size was small (although statistically 
significant), and smaller than medical benefit coverage in both populations. This suggests that coverage 
generosity has a limited effect on receiving guideline-concordant prescribing, though medical benefit 
generosity plays a bigger role than prescription drug benefit generosity in this particular evaluation. 
Importantly, this is likely due to the fact that commercially insured patients with cancer reach their out-of-
pocket maximums and subsequently have relatively low to no out-of-pocket financial responsibilities 
Type of chemotherapy received was among the greatest predictors of under-use with patients 
receiving anthracycline and cyclophosphamide combination regimens less likely to under-use compared 
to anthracycline-only and cyclophosphamide-only regimens. A limitation of this dataset is that it does not 
include information on surface area-based dosing, which defines whether these two types of regimens are 
considered highly emetogenic or moderately emetic. This is contributing to the high under-use proportion; 
however, it is likely that because of the surface area-based dosing variation under-use may still be more 
likely in this population due to provider confusion as to when surface area-based chemotherapies are 
considered highly emetogenic versus moderately emetogenic. Reasons why patients with prior or 
concomitant chemotherapy or radiation therapy were more likely to under-use antiemetics in both 
populations may include past experience, competing demands, and challenges with coordination of health 
care services. The effects of prior experience are mixed with prior studies finding that patients with prior 
nausea and vomiting are less likely to receive guideline-concordant antiemetic regimens, but patients 
undergoing later cycles of chemotherapy are more likely to receive guideline-concordant antiemetic 
regimens.(34, 36, 43) Finally, under-use tended to slightly decrease over time in our three-year study 
period in both the CCAE and Medicare Supplement populations, potentially highlighting natural provider 
guideline diffusion. This aligns with a prior study by MacGregor-Chavez that found that year of treatment 
was associated with guideline adherence in both of these populations.(45) 
Although there were some similarities between commercially insured and Medicare-insured 
cohorts regarding predictors of antiemetic under-use, there were also several important differences. It is 
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important to identify how under-use factors differ across the two populations to develop targeted 
interventions. Importantly, antiemetic under-use rates were 49.6% and 68.6% during 2012-2015 in the 
CCAE and Medicare Supplement populations, respectively. Differences in under-use may be due to 
younger patients receiving more aggressive supportive care than older patients. Furthermore, we found 
variation within age by payer with younger CCAE patients and Medicare supplement patients having 
significantly lower risks of under-use than older patients in both populations.  While the evidence base is 
mixed, younger patients generally were more likely to receive the guideline-concordant antiemetics 
compared to older patient in prior studies.(4, 32, 34, 39, 43, 74) Because the Medicare supplement 
population is older, it is not surprising that we found that they have higher measured comorbidity (0.50 
vs. 0.22 comorbid conditions, in addition to their cancer diagnoses) and use more medications (3.91 vs. 
3.59). An increase in the number of comorbid conditions increases the risk of under-use among patients in 
the CCAE population, but there is no difference in the Medicare Supplement. This suggests that disease 
burden affects antiemetic use among CCAE patients, but that perhaps because Medicare patients have 
generally higher levels of comorbidity and medication use, they are not affected by these factors. While 
men were more likely to under-use antiemetics in the CCAE population, there were no significant 
differences by gender in the Medicare supplement population. This aligns with prior studies that found 
that women were more likely to receive guideline-concordant antiemetic products and breakthrough 
therapy compared to men across CINV risk as well as in high CINV-risk chemotherapy.(32, 34, 39)  
Additionally, use of prior antiemetics slightly decreased the risk of under-use in the CCAE population, 
but did not have an effect in the supplement population. In contrast to the CCAE population where there 
was no effect, patients using regimens consisting of cisplatin and other types of chemotherapy were less 
likely to under-use antiemetics compared to patients initiating anthracycline and cyclophosphamide 
regimens.   
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5.2.3 Summary / Discussion – Aim 3 
The purpose of aim 3 was to evaluate the trade-offs in cost, clinical, and quality-of-life outcomes 
across the guideline-concordant antiemetic strategies in patients initiating highly emetogenic 
chemotherapy.  Specifically, we conducted a cost-utility analysis using a Markov model to prioritize 
antiemetic strategies, which have a wide range of costs and no clinical preference. From the perspectives 
of both the US healthcare system and society, olanzapine + fosaprepitant + 5HT3A + dexamethasone was 
the most efficient strategy in the base-case cost utility analysis. All other strategies were dominated in the 
base case meaning that they provided lower quality-adjusted life days at higher costs.. Notably, 
olanzapine + palonosetron + dexamethasone had the lowest treatment acquisition cost and second lowest 
total costs.  Compared with olanzapine + fosaprepitant + 5HT3A + dexamethasone, olanzapine + 
palonosetron + dexamethasone  was less effective in 99.9% of simulations, was dominated in 56.5% of 
simulations, and was cost effective in 37.5 % of simulations at a wiliness to pay threshold of 
$50,000/QALY.   
While some strategies offer incremental benefits, the total effectiveness of all strategies is similar 
with the total QALDs for each treatment ranging from 3.63 QALD – 4.03 QALD. This aligns with some 
meta-analyses that have found that products in the NK1 class offer similar effectiveness to each other 
except for rolapitant.(117, 118) As such, it may be appropriate to utilize a cost-minimization approach 
and revert to using the treatment with the lowest acquisition cost, which should be monitored over time as 
drug prices will likely change over time. In this case, olanzapine + palonosetron + dexamethasone is the 
most efficient strategy in our analysis. Furthermore, the cost input variables including 5HT3A, NK1, and 
palonosetron were among the most sensitive inputs when comparing olanzapine + palonosetron + 
dexamethasone with olanzapine + fosaprepitant + 5HT3A + dexamethasone, highlighting the influence of 
cost estimates in this model.  
In addition to treatment acquisition costs, prescribers may consider factors related to medication 
adherence when selecting an antiemetic strategy such as frequency of administration, route of 
administration, and out-of-pocket costs. Aprepitant is not only the most expensive NK1, but also it must 
  
124 
be taken on days 2 and 3 in contrast to the other NK1s, which only have to be taken on day one.(18, 20) 
Additionally, intravenous NK1 (i.e., fosaprepitant) may be given in conjunction with the intravenous 
chemotherapy administration rather than requiring the patient to obtain the oral antiemetic before the 
chemotherapy infusion appointment. This may be more convenient for the patient and may reduce costs 
for patients with less generous prescription drug insurance. Furthermore, Aim 2 results showed medical 
benefit coverage of antiemetics, under which the intravenous NK1 would be covered, is typically more 
generous than prescription drug benefit coverage of antiemetics under which oral NK1s would likely be 
covered. Finally, there is no evidence prioritizing the many 5HT3A options, which range in cost from 
$1.10 to $468.00. While aim 1 results showed that the more expensive, second-generation 5HT3A, 
palonosetron, was filled more frequently than were first-generation 5HT3As, we recommend that unless a 
patient has a contraindication, lower-cost 5HT3As (generic, first-generation intravenous products) should 
be prioritized. 
In scenario analyses, we removed olanzapine-based strategies from considerations for several 
reasons. First, while promising, the evidence base for olanzapine use is limited and there may be some 
hesitation by clinicians to prescribe an antipsychotic for this purpose given the significant side effects of 
this product (albeit a short duration). Furthermore, while NCCN guidelines dictated evidence strong 
enough to support its inclusion, the studies supporting olanzapine + palonosetron + dexamethasone 
remain controversial in the clinical community due to study design issues including small sample size, 
lack of blinding, lack of stratification by CINV risk, and unbalanced patient characteristics.(125) Second, 
relevant cost-effectiveness studies conducted in Italy and the UK did not include olanzapine-based 
strategies in their analyses.(143, 144) Both of these studies found that NEPA dominated aprepitant and 
fosaprepitant-based strategies in patients initiating highly emetogenic chemotherapy. Our scenario 
analysis supported that NEPA dominated rolapitant and aprepitant-based strategies. However, while it 
conferred an additional benefit when compared with fosaprepitant, NEPA was not cost-effective in our 
analysis. Differences observed between this study and those from international settings may be due to 
differing costs both from treatment acquisition as well as care in Italy and the UK versus the US. Notably 
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the treatment acquisition costs of all products were more expensive in the US. For example, the treatment 
acquisition cost of NEPA in the US ($632 (2016 USD)) was several times that in the UK ($223 (2016 
USD)) UK and Italy ($100 (2016 USD)).(18, 143, 144)  
It is important to discuss the generalizability of these results. First, the results of the analysis 
presented here are only applicable to the first highly emetogenic chemotherapy cycle. As guidelines 
dictate, prescribers should use outcomes based on the first cycle to inform future antiemetic use. Second, 
because patients with cancer who are commercially insured often reach their out-of-pockets maximums, 
the results from the US healthcare perspective may be applicable to the US commercial payer perspective. 
This is further supported by the fact that the main difference between the healthcare and commercial 
payer perspectives are the costs of the healthcare resource use associated with each health state, which 
would be modeled by reducing the total costs by a standardized percentage. This would not alter the 
ICER. Third, to the best of our knowledge there is not a commonly accepted willingness to pay threshold 
for QALD. As a result, we converted our primary outcome QALD to QALY to assess cost-effectiveness. 
However, decision-makers should reflect on the implications of extrapolating the QALD in this manner 
when considering their resources and constraints. 
5.3 Limitations 
5.3.1 Aim 1 Limitations 
First, as is inherent with claims database studies, we were only able to capture information on 
healthcare encounters and prescription drug fills that were submitted to insurance for payment, thus 
generating a claim. This neither entirely captures what a provider may have prescribed nor is it indicative 
of what a patient actually took, when precisely they took it, or its intended use. Additionally, antiemetics 
given as samples will not be captured. Second, steroids are an inexpensive component of antiemetic 
regimens and expert opinion suggests that claims may not be filed by providers for these drugs when 
given during a visit in which the chemotherapy infusion is administered, leading to under-reporting of 
steroid use. Third, we did not have access to body mass information or precise drug dosing information. 
We assumed that patients using antiemetics that have varying emetogenic risk based on quantity per body 
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surface area were at high risk for CINV. This could potentially over-estimate guideline discordance if 
these patients were appropriately using antiemetics based on receiving a moderately emetogenic 
chemotherapy does for their size. To address this limitation, we stratified results by regimens that are 
highly emetogenic based on combination or body mass / dose versus always emetogenic. Fourth, the total 
price of the drugs used to calculate total and out-of-pocket costs was based on the transaction price 
between the manufactures and the payer listed in MarketScan, which does not reflect rebates and 
discounts received by payers and thus may overestimate the cost to payers for antiemetics. However, 
because rebates and discount are not typically shared with the patients, we anticipated out-of-pocket 
estimates to be accurate. Fifth, the preventative antiemetic look-back period chosen a priori based on 
expert opinion incorporated a minimum rate of antiemetic use in the measure, which increases the risk of 
capturing antiemetics not intended for CINV prevention. To address this, we limited the look-back period 
calculation to only preventative antiemetic drugs. However, this may still underestimate the proportion of 
patients who underused antiemetics. Similarly, patients with prior non-highly emetogenic chemotherapy 
or radiation therapy may have been using antiemetics captured in the look-back period in conjunction 
with those treatments versus the intravenously administered highly emetogenic chemotherapy treatment. 
Finally, our data had limited overlap following the approval of the netupitant-palonosetron combination in 
late 2014 and rolapitant in late 2015.(1) Additionally, while studies supporting the use of olanzapine as a 
prophylactic antiemetic were published as early as 2011, NCCN included it as a recommendation only in 
2014, ASCO highlighted it as a highly promising therapy in 2015, and the largest trial to date was 
published in 2016, again providing limited overlap with our study period.(27, 52, 84) 
5.3.2 Aim 2 Limitations 
In addition to the limitations outlined in section 5.3.1 regarding retrospective data and antiemetic 
measurement, three other limitations should be noted. First, we were unable to measure prescriber level 
characteristics including physician awareness of current guidelines. This limited our ability to disentangle 
physician-drivers of treatment choice such as lack of knowledge versus provider preference for treatment 
strategy. Second, we did not have data on facility level characteristics such as whether an automated 
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electronic medical record prescribing system existed. Having an automated prescribing system largely 
eliminates the role of physician choice in standard order sets, unless s/he overrode the default antiemetic 
option. Third, we were unable to measure the effect of patient-level engagement or preferences on 
antiemetic use. 
5.3.3 Aim 3 Limitations 
There are several limitations related to uncertainty that our probabilistic sensitivity analysis aimed 
to address by modeling a range of input values. First, there were several challenges with the trial data 
used as clinical inputs. Characteristic of randomized clinical trials, the outcomes did not reflect the real 
world use of the products, as patients may not have adhered to their regimens.(215) We also had to 
compute complete protection rates for olanzapine-based strategies because the trials did not capture this 
outcome. Additionally, because the only trial assessing the effectiveness of olanzapine in the presence of 
NK1 had much lower effectiveness outcomes for the NK1 without an olanzapine arm, we computed base 
case complete response rates based on the relative risk. Second, we assumed that patients either remained 
in the same health state or transitioned to a worse health state by using linear interpolation between the 
acute phase and overall phase to calculate transition probabilities for each day in the delayed phase. While 
this assumption and approach is used in the most recent cost-effectiveness studies modeling antiemetic 
use, in the real world patients may transition into a better health state. In addition, because trials measured 
days 2-5 as a single delayed state, we did not have access to day level health states. Notably, this 
approach is more accurate that older models where days 2-5 were treated as a single period and patients 
would remain in the same health state in all four days of the delayed phase.(56-58) Given that the utilities 
and costs associated with each health state are the same regardless of which day the state is experienced, 
the distribution of days in each health state may not be relevant (e.g., experiencing incomplete response 
consecutively on days 4 and 5 is the same as experiencing incomplete response on days 2 and 5).  
While there are several indirect costs associated with CINV such as transportation costs to access 
the healthcare system and caregiver costs, the only indirect cost information identified in the literature 
was related to productivity. Finally, treatment acquisition costs were based on price information available 
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in the 2017 ASCO antiemetic guideline, which used the following sources: UpToDate.com (dosing 
schedules), Medicare Part B Average Sales Price (ASP) Data (intravenously administered Medicare Part 
D Plan Finder Data (orally administered products). While ASP data incorporate discounts and rebates, the 
Plan Finder Data represent the cost to the consumer, which may not reflect true acquisition costs to plans. 
Additionally, the literature used to identify cost inputs were based on claims studies, which only include 
information on nausea and vomiting events that were severe enough for hospitalizations, so rescue 
medication use on its own was not captured.(8, 9) As such, we used the sum of the median costs for 
olanzapine and ondansetron as a proxy for rescue medication use.  
5.4 Conclusion and Future Research 
In the US, the increased attention on value-based care, including alternative payment models and 
outcomes-based contracting are incentivizing stakeholders to emphasize high-quality, evidence-based 
care, which includes guideline adherence. Oncology especially is an area of interest given the high costs 
associated with cancer care, projected to total $173B in 2020.(60) Prior studies have shown that 
promoting value-based cancer treatment and supportive care is effective in reducing cancer-associated 
spending.(216) This project focuses on antiemetic under-use in patients initiating highly emetogenic 
chemotherapy. Preventing CINV through guideline-concordant antiemetic prescribing has been shown to 
reduce downstream costs and improve quality of life as well as potentially improve future chemotherapy 
adherence.(1, 3, 4, 11-13, 67, 68)   
While there are several antiemetic strategies that have robust evidence supporting their 
effectiveness, their use and the factors that affect use are not well understood in the United States. Studies 
examining antiemetic under-use have largely taken place outside of the United States with the exception 
of two small studies. The first aim of this study contributes to the understanding of antiemetic use by 
examining it in a large claims population reflective of the Commercial Claims and Medicare Supplement 
population. This is the largest study examining under-use in the United States to the best of our 
knowledge. Alarmingly, under-use of guideline-concordant antiemetic fills is high at 49% and 68% in the 
commercial claims and Medicare supplement populations, respectively. While more than 75% of patients 
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are filling 5HT3As and dexamethasone, we found that NK1 product fills were low and olanzapine fills 
were negligible despite NK1s being in guidelines since 2006 and olanzapine being in NCCN guidelines 
since 2014 (and effectiveness data available since 2011). Additionally, more expensive palonosetron was 
more frequently prescribed than low-cost first-generation 5HT3As in both populations, despite having 
similar effectiveness in the presence of NK1s. 
In our second aim, we assessed the effects of environmental, predisposing, enabling, and need 
factors on under-use in the same claims data as Aim 1. Type of chemotherapy received was among the 
strongest predictors of under-use, with patients receiving anthracycline and cyclophosphamide 
combination regimens less likely to under-use compared to anthracycline-only and cyclophosphamide-
only regimens. However, this is expected given anthracycline-only and cyclophosphamide-only regimens 
are considered highly emetogenic only when given at certain doses based on body-surface area 
thresholds. The next greatest predictor of under-use was the setting in which chemotherapy was 
administered. Compared to receiving chemotherapy in the physician office setting, patients receiving 
chemotherapy in an outpatient hospital setting were at 28% and 48% higher risk of under-use in the 
CCAE and Medicare Supplement populations, respectively. As a result, we recommend prioritizing 
interventions targeting under-use in the outpatient hospital setting over the physician outpatient setting.  
Of note, it is hypothesized that out-of-pocket costs may prevent patients from filling guideline-
concordant prescribing treatment strategies, especially given that NK1s are expensive, though this had not 
been previously studied. Our analysis found that medical benefit generosity and prescription drug 
generosity has limited impact on under-use in both populations. Additionally, given the high cost of 
cancer care, patients may be reaching out-of-pocket maximums in the CCAE population, so out-of-pocket 
costs and insurance generosity may be moot. Aim 1 cost results that found patients in both populations 
had a median out-of-pocket costs for $0 for all intravenously administered antiemetic products (covered 
by the medical benefit) support this.  
While not measured in Aim 2 because we did not have the data, the role of the provider in 
antiemetic use is important to consider. Whether guideline discordant prescribing is due to a gap in 
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provider knowledge or provider accountability is unknown. If it is the former, provider education by 
professional societies, patient advocacy groups, payers, and manufacturers is necessary.  If it is the latter, 
one solution is the development of a validated appropriate antiemetic prescribing measure for patients 
initiating highly emetogenic chemotherapy that is implemented into commercial plan quality programs 
and the CMS Merit-Based Incentive Payment System. Notably, ASCO’s Quality Oncology Practice 
Initiative program does include an antiemetic measure for patients initiating highly emetogenic and 
moderately emetogenic chemotherapy under its symptom/toxicity management module.(217) However, it 
requires only that providers prescribe a 5HT3A and dexamethasone for patients initiating highly 
emetogenic chemotherapy, in contradiction with guidelines that also recommend an NK1. It also does not 
allow for olanzapine-based strategies to be considered as a concordant strategy that fulfills the measure, 
which in fact we found to be the most cost-efficient strategy. This highlights the importance of quality 
initiatives correctly incorporating guideline recommendations into their measures as over 8,000 
oncologists are registered for QOPI across the United States.(218) 
Future studies should assess the uptake of newer antiemetic products and regimens in patients 
initiating highly emetogenic chemotherapy with more recent claims data to understand their fill trends. 
Using other data sources such as electronic medical records that include antiemetic prescribing data or 
patient diaries that include data on what antiemetics patients actually took could help triangulate 
occurrences of care failure and address them. Additionally, understanding the real world outcomes (i.e., 
CINV events and their associated healthcare resource) and subsequent activities (e.g., future antiemetic 
prescribing and chemotherapy adherence) associated with antiemetic under-use will support the value of 
appropriate prescribing. Though challenging to conduct in claims data given the lack of specificity in 
identifying chemotherapy-induced nausea and vomiting events, this may be possible in other data sources 
such as electronic health record data or registry data.  
As mentioned earlier, there are several CINV preventative treatment regimens that are considered 
guideline-concordant for patients initiating highly emetogenic chemotherapy, with no clearly preferred 
treatment strategy. Given the wide variability in costs for these regimens, assessing cost effectiveness 
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across the regimens is one way to prioritize products, which we did in Aim 3. Notably, this is the first 
cost-effectiveness analysis to compare all NK1 strategies and olanzapine strategies. Ultimately, we found 
that from the US healthcare system perspective and societal perspective, olanzapine + fosaprepitant + 
5HT3A + dexamethasone dominated all other strategies in the base-case. We also conducted a scenario 
analysis from the US healthcare perspective removing olanzapine strategies given clinical and evidentiary 
concerns and found that that NEPA dominated rolapitant- and aprepitant-based strategies. While it 
conferred an additional benefit when compared with fosaprepitant+5HT3A+dexamethasone, NEPA was 
not cost-effective. Given the limited incremental benefit across strategies (the max difference is .86 
QALD), it may be appropriate to utilize a cost-minimization approach and revert to using the treatment 
with the lowest acquisition cost, which would be, olanzapine + palonosetron + dexamethasone. 
We recommend that guidelines and prescribers consider the cost of antiemetics to prioritize 
strategies. When using an NK1 strategy, especially given that there are no differences in 5HT3A 
effectiveness, there is no reason to prescribe palonosetron over less expensive first-generation 5HT3As 
(both oral and intravenous). Additionally, given that total cost of intravenous antiemetic products is 
generally lower than oral products (in addition to our earlier findings that intravenous products had lower 
out-of-pocket costs to patients), intravenous products should be used over oral products unless the patient 
is contraindicated or unable to tolerate it.  
While we conducted sensitivity analyses, more research on the real world effectiveness of these 
various strategies and indirect cost information is necessary to inform clinical inputs. Future studies 
should also assess this model from the commercial payer, Medicare, and Medicaid perspectives. 
Reimbursement policies and product prices along with patient needs are different across these 
populations. Additionally it is important to assess the effects of these antiemetic products in preventing 
anticipatory or refractory nausea and vomiting in future cycles is critical given the paucity of knowledge 





APPENDIX 1: ANTIEMETIC COST TABLE METHODOLOGY (CHAPTER 2, TABLE 2.4) 
This cost table was leveraged from the 2017 ASCO guidelines.(18)  The following sources of 
data were used to compile this table UpToDate (dosing schedules), pricing for oral products (Medicare 
Part D Plan Finder), pricing for intravenously administered products (Medicare Part B Sales Price Data). 
Please refer to the guidelines for the full methodology.   
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APPENDIX 2: EUROPEAN AND ASIAN STUDIES (CHAPTER 2, SECTION 2.2.2) 
European Studies 
A prospective cohort study in 1996 with approximately 1,200 consecutive Italian cancer patients, 
96.1% received some sort of antiemetic therapy for acute prophylaxis regardless of CINV risk of the 
chemotherapy.(23) All patients on highly emetogenic chemotherapy received some type of antiemetics. 
Nearly all patients received 5HT3A monotherapy or in combination with a corticosteroid. In contrast, 
~36% received antiemetics for delayed CINV, with patients initiating cisplatin-based therapy having the 
highest proportion. While 38.8% of patients were prescribed rescue treatment across CINV-risk, only 
16.8% filled the prescription. While the study cohort included both new and prior initiators of 
chemotherapy (92%), there was no significant difference in the antiemetics used.(23) 
Chinese Studies 
 
Zong 2016 published the largest study examining antiemetic prescribing using the China Health 
Insurance Research Association (CHIRA) Database consisting of over 14,000 patients initiating 
moderately or highly emetogenic chemotherapy between 2008-2012, when NK1s were not approved in 
China.(32) This study found that 89.5% of patients received antiemetics for prevention of acute CINV, 
71.5% for delayed CINV, and 9.0% for breakthrough CINV. Among patients using antiemetics to prevent 
acute CINV, 6.3%, 93.3%, and 0.4% used single, multiple, and herbal/alternative regimens, respectively.  
Product use for preventing CINV in the delayed phase was similar. Nearly 60% of patients initiating 
highly emetogenic chemotherapy received three-class regimens in both the acute and delayed phases, with 
the most common three-class regimen consisting of a 5HT3A+corticosteroid, and either antihistamine or 
benzoylamide. (32) Additionally, 26.5% and 25.5% of patient initiating highly emetogenic chemotherapy 
initiated four-class regimen in the acute phase and delayed phase respectively. Notably, 5HT3As (97.4% 
and 97.5%) were prescribed to a higher proportion of patients initiating highly emetogenic chemotherapy 
than corticosteroids (85.5% and 84.2%) in the acute and delayed phases, respectively.(32) Another large 
retrospective study that took place between 2005-2011 consisting of more than 2,500 Japanese patients 
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found that antiemetic use increased over time, up 95% in 2011 among highly emetogenic chemotherapy 
users.(33) Additionally, NK1 use increased to 60% in 2011 use in highly emetogenic chemotherapy users 
after 37.0% use after its approval in 2009. (33) A retrospective, distributed research network study in 
Japan also found that the 96% of patients initiating highly emetogenic chemotherapy received at least one 
antiemetic in the acute phase but overall compliance was only 9.4%.(34) Also, while the NK1 use in the 
delayed phase was increasing, the corticosteroid use was low. (34)  
A pan-Asia and Australia prospective study using a combination of electronic medical record data 
and self-reported data from 2011-2012 found that all patients but 1 out of 318 initiated highly emetogenic 
chemotherapy received an antiemetic for preventing acute CINV with 96% receiving a 5HT3A and 85% 
receiving a corticosteroid.(35) On average, patients in the highly emetogenic group were prescribed 3.2 
(1.1) and 1.9 (1.1) unique antiemetic drugs in the acute and delayed phases. (35) Another prospective 
observational study in Singapore using data from 2006-2011found that 90% of patients initiating highly 
emetogenic chemotherapy (N=361) were prescribed 5HT3A + corticosteroid regimen in the delayed 
phase versus an aprepitant + dexamethasone regimen, though adherence was only 58%.(36) Additionally 
they found the rate of dexamethasone prescribing was low. (36) A third prospective observational study 
found that over 70% of Japanese patients initiating highly emetogenic chemotherapy were using a three-
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